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EVALUATION OF THE PHYSICOCHEMICAL PROPERTIES AND STABILITY OF 
SOLID LIPID NANOPARTICLES DESIGNED FOR THE DELIVERY OF 
DEXAMETHASONE TO TUMORS 
 
 Pre-clinical and clinical trials suggest that pre-treatment with dexamethasone 
(Dex) may facilitate enhanced uptake of subsequently administered chemotherapeutic 
agents. To reduce the side effects associated with systemic administration of Dex, solid 
lipid nanoparticles (SLNs) containing dexamethasone palmitate (Dex-P) were prepared as 
a means of achieving tumor-targeted drug delivery. These studies were aimed at 
evaluating the physicochemical properties and both the physiological and storage stability 
of the SLNs.  
  
SLNs were prepared using nanotemplate engineering technology. Stearyl alcohol 
(SA) was used as the lipid phase with Brij
®
 78 and Polysorbate 60 as surfactants and 
PEG6000 monostearate as a long-chain PEGylating agent. Both formulations exhibited a 
small particle size, ellipsoidal shape, and low polydispersity.
 1
H-NMR spectroscopy 
confirmed that SLNs have the expected solid core and PEGylated surface. Analysis of the 
bulk materials indicated that a number of complex interactions are present among the 
SLN components, including a eutectic between SA and Brij
®
 78.  
 
Dex-P could be incorporated in SLNs at 10-30% w/w SA with encapsulation 
efficiencies >85%.  A preferential interaction with the SA-Brij
®
 78 eutectic was 
identified, indicating a possible interfacial localization. For comparison, SLNs were also 
prepared with ascorbyl palmitate (AP) and curcumin.  Higher drug loads were achieved 
with both palmitate-containing prodrugs than curcumin, though all appeared to align 
differently within the SLNs.  
  
SLNs undergo a concentration-dependent particle size growth when incubated at 
physiological temperature. However, they appear to remain intact with over 85% of the 
added Dex-P retained at 24 h in conditions mimicking human plasma. In the presence of 
carboxylesterase, SLNs became turbid and showed a reduction in particle size as 
compared to controls. This instability was shown to be a result of the hydrolysis of 
PEG6000 monostearate and Polysorbate 60.  
To enhance storage stability, a lyophilization protocol designed to minimize 
changes in the physicochemical properties of SLNs was developed. During a 3 month 
period, lyophilized SLNs stored at 4°C demonstrated the greatest stability, showing a 
consistent particle size and an encapsulation efficiency >80%. Overall, these results 
indicate that Dex-P loaded SLNs possess the physicochemical properties and stability 
desirable for development as a tumor-targeted drug delivery system.  
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 Chapter 1 
Introduction and Statement of Problem 
 
In spite of the development of an arsenal of highly potent chemotherapeutic agents, 
clinical success in treating cancer remains a challenge. Tumors are characterized by a 
number of properties (e.g., high interstitial fluid pressure (IFP), irregular vasculature, 
efflux pumps) that may act as barriers to drug delivery [1, 2]. As a result, many drugs fail 
to perform in vivo as well as would be predicted from in vitro studies due to a failure to 
reach the target site in adequate quantities. Correspondingly, a high amount of the 
administered drug is left to act on healthy tissues, often to the point of generating dose-
limiting side effects. 
 
Pre-treatment with Dexamethasone (Dex) is one possible technique for improving the in 
vivo success of chemotherapeutic agents. Dex is a synthetic gluococorticoid well known 
for its anti-inflammatory properties [3, 4]. However, recent pre-clinical and clinical trials 
have indicated that it may also have use as a chemotherapeutic adjuvant. Pre-
administration of Dex was shown to reduce the toxicity and, in some cases, increase the 
efficacy of chemotherapeutic agents. For instance, Dex pre-treatment was shown to 
significantly increase the efficacy of carboplatin (DNA alkylating agent), gemcitabine 
(antimetabolite), or a combination of both drugs by 2-4 fold in six xenograft models 
tested (2 colon, 2 breast, 1 lung, and 1 glioma cancers) [5]. Dex pre-treatment also 
reduced the significant decrease in granulocyte counts seen with carboplatin treatment in 
CD-1 mice [6]. In clinical trials, Dex pre-treatment has resulted in a reduction in 
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hematopoietic toxicity and an improvement in absolute granulocyte count and platelet 
count recovery times [7, 8].  
 
The complete mechanism behind Dex‟s beneficial effects remains elusive but is likely a 
result of its inhibition of the nuclear factor kappa B (NF-κB) signaling pathway [9, 10]. 
Disruption of this signaling pathway is thought to be associated with a change in the 
tumor cytokine profile [11] that results in decreased IFP [12, 13] and a normalization of 
the tumor vasculature [11, 14]. In turn, it is suspected that these effects allow for the 
enhanced uptake of chemotherapeutic agents into tumors [5, 11], improving their efficacy 
and limiting their toxic side effects [6]. However, there may be some limitations to this 
therapy. First, the results do appear to be schedule, dose, and possibly chemotherapeutic 
agent-dependent with some literature indicating that Dex may result in a decrease in the 
efficacy of chemotherapeutic agents [15-18]. Additionally, there are a number of side 
effects associated with systemic administration of Dex that may be undesirable for 
patients undergoing chemotherapy, most notably immunosuppression through T-cell 
depletion and inhibition [3, 19].   
 
In order to maximize the potential of Dex to serve as a chemotherapeutic adjuvant while 
minimizing its toxicities, a localized delivery system would be preferable. Nanoparticles 
are one potential means of achieving this goal. Though a number of advantages, 
including enhanced solubilization [20], controlled/bioresponsive release capacity [21-24], 
evasion of multidrug resistance (MDR) mechanisms [25, 26], and limited drug 
degradation [27] have been claimed for these systems over their solution counterparts, the 
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most notable is their targeting ability. Due to the enhanced permeability and retention 
(EPR) effect of tumors [28, 29], nanoparticles of the appropriate size are able to passively 
target tumors [30, 31]. This can enhance drug uptake into the tumor while limiting its 
presence throughout the rest of the body.  
 
While a number of nanoparticle drug delivery systems are available, solid lipid 
nanoparticles (SLNs) have received considerable attention due to their low toxicity [32-
34] and amenability to large-scale production methods [33, 34]. Early work from this 
laboratory resulted in two SLN formulations encapsulating dexamethasone palmitate 
(Dex-P), an ester prodrug of Dex [35]. This prodrug was chosen because the palmitate 
moiety was expected to associate with the hydrophobic core of the SLNs and enhance the 
drug loading. Additionally, Dex-P has previously been used in humans with a good safety 
profile [36]. Interestingly, drug release from the nanoparticles appeared to be dependent 
on the carboxylesterase (CE) activity of the surrounding environment [37].  
 
This dissertation will focus on gaining a thorough understanding of the physicochemical 
properties of the Dex-P loaded SLN formulations as well as evaluating them for both 
physiological and storage stability. Initially, SLNs will be assessed for their size, shape, 
core-shell structure, and crystallinity. The extent and mechanism of drug loading will be 
evaluated, and comparisons will be made with other drugs of similar structure and 
lipophilicity. Secondly, the stability of SLNs will be evaluated under physiological 
conditions, both in the absence and presence of CE enzymes. Finally, a lyophilization 
protocol designed to minimize changes in the physicochemical properties of the SLNs 
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will be developed, and the long-term storage stability of lyophilized SLNs and SLN 
suspensions will be compared. These studies may provide valuable information regarding 
the structure and stability of not only the drug delivery system under consideration, but 
also nanoparticles in general.  
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Chapter 2 
Plan of Research 
 
Pre-clinical and clinical trials suggest that delivery of Dex to tumors can lower the IFP 
[13], thereby reducing this physiological barrier to the uptake of administered 
chemotherapeutic agents.  However, Dex exhibits toxicities such as immunosuppression 
that can adversely affect patients undergoing chemotherapy.  Targeting the delivery of 
Dex specifically to tumors would minimize the undesirable side effects associated with 
systemic administration of the drug. Nanotemplate engineered SLNs containing Dex-P 
were prepared as a means of achieving tumor-targeted drug delivery. The overall 
hypothesis of this dissertation is that the interactions among the components of SLNs 
decrease the crystallinity of nanoparticle lipids resulting in enhanced drug loading and 
limited stability of the nanoparticles under both physiological and storage conditions. The 
following specific aims will be pursued in order to test this hypothesis: 
 
Specific Aim 1: To fully characterize the physicochemical properties of nanotemplate 
engineered SLNs, including particle size, shape, structure, and changes 
in the extent or type of crystallinity from the starting materials due to 
interactions among the nanoparticle components. 
Specific Aim 2:  To assess the degree of loading of Dex-P into nanotemplate engineered 
SLNs as compared to other compounds of similar structure or 
lipophilicity. 
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Specific Aim 3:  To evaluate the stability of nanotemplate engineered SLNs in 
conditions mimicking those of human plasma as a function of time. 
Specific Aim 4: To determine if the PEGylating agents incorporated into SLNs are 
affected by the CE activity of the surrounding environment. 
Specific Aim 5: To determine if the storage stability of drug loaded SLNs is enhanced 
when using lyophilization protocols that minimize changes in the 
physicochemical properties of the nanoparticles. 
 
To achieve these Specific Aims, the research plan described in sections 2.1 through 2.5 
was carried out.  
 
2.1. Preparation and Characterization of Blank SLNs  
The objective of this section was to compare the physicochemical properties of two SLN 
formulations previously developed for Dex-P loading. SLNs were prepared using 
nanotemplate engineering technology (NET). Stearyl alcohol (SA) was used as the lipid 
phase with Brij
®
 78 and Polysorbate 60 (PS60) as surfactants in both formulations; the 
second formulation differed by the inclusion of a long-chain PEGylating agent, PEG6000 
monostearate (PEG6000MS).  Nanoparticle size and shape were assessed using a 
combination of dynamic light scattering (DLS) and transmission electron microscopy 
(TEM) techniques. SLN structure was determined through a comparison of the 
1
H-NMR 
spectra of solubilized and intact SLNs accompanied by relaxation time measurements. 
Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) were used 
to analyze the crystallinity of the SLNs.   
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2.2. Preparation and Characterization of Drug Loaded SLNs 
The use of Dex-P has been shown to enhance drug loading in the SLNs. The goals of this 
section were 1) to prepare and characterize SLNs loaded with Dex-P and 2) to make 
comparisons with other drugs of similar structure or lipophilicity. In addition to the 
properties described above (size, shape, structure, and crystallinity), SLNs will be 
assessed for the extent of drug loading and encapsulation efficiency. Ultrafiltration will 
be used for separation of free and encapsulated drug; quantification will be performed 
using an HPLC-UV assay. Curcumin and ascorbyl palmitate (AP) will be used for the 
comparison studies. Both drugs are lipophilic, but curcumin lacks the palmitate moiety 
that may align with the SLN lipids.  
 
2.3. Stability of Drug Loaded SLNs in Human Plasma-mimicking Conditions 
Release of Dex from the SLNs appeared to be dependent on the presence of CE activity. 
The aims of this section were 1) to confirm the stability of SLNs and 2) to confirm the 
retention of Dex-P with the SLNs under conditions mimicking those found in human 
plasma (specifically the absence of CE activity). Initial studies were focused on 
monitoring the size and shape of SLNs incubated at 37°C. To further elucidate the 
mechanism of particle size growth, the effect of SLN concentration on particle size 
growth was evaluated, and SLNs returned to 4°C following incubation at 37°C were 
tested for size recovery. SLNs were then exposed to human serum albumin (HSA) as a 
representative protein and monitored for size and turbidity changes. Size exclusion 
chromatography (SEC) was used as a secondary technique to confirm the intact state of 
the SLNs in the presence of HSA. To determine the retention of Dex-P with the SLNs in 
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the presence of human plasma, a multi-step filtration process was employed, consisting of 
an initial filtration through a 0.2 μm membrane followed by ultrafiltration. By accounting 
for the known protein binding, the amount of drug retained with the SLNs was calculated.   
 
2.4. Stability of PEGylating Agents in the Presence of CE Activity 
The objective of this section was to determine if the accelerated drug release observed in 
the presence of CE enzymes may be partially attributable to hydrolysis of the ester-
containing materials, PS60 and PEG6000MS, leading to increased accessibility of the 
prodrug to enzymes. Hydrolysis of PEG6000MS was monitored using SEC, and 
hydrolysis of PS60 was monitored using a pH-stat assay. Comparisons were made 
between the materials in SLNs and in micelles, and controls were run using bis(4-
nitrophenyl) phosphate (BNPP) as a CE inhibitor. In parallel, the effects of hydrolysis on 
the stability of SLNs were evaluated through monitoring changes in turbidity, particle 
size, and particle shape.  
 
2.5. Storage Stability of Drug Loaded SLNs  
The goals of this section were 1) to optimize a protocol for lyophilizing SLNs and 2) to 
compare the long-term stability of aqueous and lyophilized SLNs. In optimizing the 
lyophilization protocol, the following aspects were considered: lyoprotectant (LP) type 
and concentration, SLN concentration, freezing temperature, rate of freezing, and drying 
time. SLNs were assessed for changes in the particle size, shape, monodispersity, and 
drug loading. For the long-term stability study, lyophilized SLNs and SLN suspensions 
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were stored at 4°C and 25°C/60% RH. Samples were removed at days 0, 1, 3, 7, 14, and 
months 1, 2, and 3 for measurement of the particle size and drug loading. 
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Chapter 3 
 
Background and Significance 
 
3.1. CANCER AND CHEMOTHERAPY 
Cancer can be defined as the uncontrolled growth and spreading of abnormal cells [38]. 
As of 2010, it remained one of the leading causes of death in the United States of 
America, second only to cardiovascular disease [39]. Although the final numbers are not 
in, it is estimated that nearly 600,000 Americans died from cancer in 2010 and another 
1.5 million people were diagnosed with new cases [39]. Due to the staggering numbers 
associated with this disease, a variety of treatment options are currently being utilized, 
and a number of others are under development [38, 40, 41].  
 
Surgical resection is typically employed with early-stage disease [38, 41]. Unfortunately, 
it cannot be utilized in all cases, such as when the cancer is undetectable, has 
metastasized, or is not confined to a solid tumor (e.g., leukemia). Further, it may be 
difficult to completely remove the affected cells, and surgery may trigger a faster 
metastatic process for any remaining cells [38]. For this reason, chemotherapy, radiation 
therapy, hormone therapy, immunotherapy, or a combination of these may be employed, 
either in lieu of or following surgery [38]. Of these, chemotherapy is the most 
mainstream.  
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3.2. BARRIERS TO CHEMOTHERAPY 
Chemotherapy refers to the use of drugs directed at killing or controlling the growth of 
cancer cells. Despite extensive research on the development of highly potent 
chemotherapeutic agents, clinical success in treating cancer remains limited. Although 
many of these drugs demonstrate in vitro potency, they are often less successful than 
anticipated in vivo because of drug delivery limitations. Following injection, a drug must 
be distributed throughout the vascular space, transported across the vascular wall, 
transported through the interstitial space, and finally transported across the cell 
membrane [42].  Unfortunately, many obstacles exist on this path that may prevent drug 
from reaching the site of action in sufficient quantity. As a result, drug distributes into 
healthy tissues, potentially inducing dose-limiting toxicities [38].   
 
The irregular vasculature of tumors is the first barrier to tumor drug delivery (Figure 3.1) 
[1]. Tumor vasculature consists of blood vessels co-opted from the host vasculature as 
well as vessels that result from the angiogenic response of host vessels to cancer cells [1, 
43]. As a result, tumor vasculature may display different fractal dimensions and 
minimum path lengths from normal blood vessels. Some regions of a tumor may be well-
vascularized, while others may be necrotic regions based on a lack of blood flow. This 
may prohibit drug from reaching all regions of the tumor. Unfortunately, this issue is 
further complicated by the fact that the characteristics of the vasculature may be 
dependent on the tumor type, growth rate, location, and disease stage.  
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Figure 3.1. Differences in the stroma of normal tissue (a) and tumo(u)r tissue (b). 
Adapted from [44]. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Cancer, 4(10), 806-813 (2004), copyright © 2004. 
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High IFP is a second barrier that may be encountered during the extravasation step [1, 
44]. The IFP of tumors is controlled by a combination of the hydrostatic pressure 
(pressure exerted by a fluid due to the force of gravity) and colloid osmotic pressure 
(pressure built up by the tendency of water to diffuse through a semipermeable 
membrane into a compartment with higher concentration of high molecular weight 
molecules, such as proteins that are unable to pass through the membrane) (Figure 3.2).   
While normal blood vessels display a net outward pressure of 1-3 mm Hg, tumor blood 
vessels may exhibit a net inward pressure of up to 18 mm Hg. This may limit the 
transport of molecules out of the vasculature into the interstitial space. 
 
Figure 3.2. Schematic showing the hydrostatic and colloid osmotic pressures in 
capillaries (PCAP and COPCAP, respectively) and the surrounding interstitium (PIF 
and COPIF, respectively) in normal tissues (a) and tumo(u)r tissues (b). It should be 
noted that values are approximate. Adapted from [44]. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Cancer, 4(10), 806-813 (2004), 
copyright © 2004. 
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It is thought that there may be several contributors to this high IFP (Figure 3.1) [44]. 
First, as mentioned above, tumor vasculature is highly irregular with numerous 
convolutions and defects. It is also characterized by enhanced “leakiness” as a result of 
larger inter-endothelial pores than are present in healthy blood vessels. This may lead to 
larger numbers of proteins exiting the vasculature. Secondly, tumor lymphatic vessels 
may be underdeveloped or defective, preventing adequate drainage of fluid and proteins 
from the tumor tissue. Finally, the interstitial matrix may be contracted based on the work 
of tumor fibroblasts. While higher concentrations of proteins in the tumor interstitium 
may result in higher colloid osmotic pressures, increased fluid may lead to elevated 
hydrostatic pressures. Depending on their balance, the net pressure may oppose flow of 
molecules into the interstitial space.  
 
If molecules successfully extravasate from the blood vessels into the tumor interstitium, 
they must then traverse the interstitial space in order to reach tumor cells. Unfortunately, 
numerous impediments may again exist. First, tumors are characterized by a large 
interstitial space [42], and drug transport by diffusion may be slow [1]. This can be 
exacerbated by non-specific binding of the drug to various proteins. Secondly, the IFP is 
higher in the center of the tumors than it is in the periphery, forcing materials to 
overcome this outward convection to diffuse into the tumor center [1]. Thirdly, the tumor 
stroma itself may be prohibitive of drug transport (Figure 3.1). Tumors are characterized 
by elevated collagen concentrations, resulting in a dense network that may impede drug 
movement [42]. Macrophages and other inflammatory cells are also known to infiltrate 
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tumors, releasing cytokines and growth factors that may act on cells of the blood vessels 
and stroma fibroblasts to further increase interstitial fluid pressure [45]. 
 
Finally, drugs may face obstacles in achieving high intracellular drug concentrations. In 
order to protect themselves, many cancer cells overexpress transporters that serve to 
pump drugs out; these are also known as efflux pumps [2, 46]. The most well-known 
efflux pump is P-glycoprotein (P-gp/MDR1), an ATP-dependent transporter encoded for 
by the ABCB1 gene. Others that have received attention include the multidrug resistance 
associated proteins (MRP1, MRP2, and probably MRP3, MRP4, and MRP5) and the 
ABCG2 protein. Thus, although the drugs may pass readily through the cellular 
membrane, they are rapidly effluxed from the cell and are unable to achieve therapeutic 
efficacy. This is termed MDR and can be apparent from an initial treatment (intrinsic 
MDR) or can be developed following treatment (acquired MDR).  
 
3.3. DEXAMETHASONE (Dex) 
In order to reduce or eliminate these barriers to chemotherapy, additional drugs may be 
administered either prior to or concurrently with the chemotherapeutic agents. These 
drugs may or may not have therapeutic properties of their own but are primarily used as 
adjuvants in order to improve the efficacy and/or decrease the toxicity of the 
chemotherapeutic agents. One example of such a drug is Dex (Figure 3.3). Dex is a 
synthetic glucocorticoid most well known for its anti-inflammatory and 
immunosuppressive properties [3, 4]. It has shown effectiveness against certain types of 
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cancers, such as leukemia [47, 48], and it has been extensively used in conjunction with 
chemotherapeutic agents as an anti-emetic [49, 50].  
 
 
 
 
 
Figure 3.3. Structures of Dexamethasone (Dex, top) and Dexamethasone palmitate 
(Dex-P, bottom) 
 
 
 
However, recent pre-clinical and clinical trials have focused on its use as a 
chemotherapeutic adjuvant. Studies have shown that Dex pre-treatment can reduce the 
toxicity and, in some cases, increase the efficacy of chemotherapeutic agents. For 
instance, both prednisolone and Dex effectively protected progenitor cells in four strains 
of mice against 5-fluorouracil, a cell-cycle-specific antimetabolic chemotherapeutic agent 
[51]. Bone marrow progenitors and blood cell numbers were shown to return to normal 
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from 3-5 days and from 1-2 days earlier, respectively, than without glucocorticoid 
treatment. The same level of efficacy could be achieved with Dex at an approximately 
16.5-fold lower dose than with prednisolone. A synergistic growth inhibition was also 
observed in six B-cell non-Hodgkin lymphoma cell lines when tumor cells were pre-
treated with Dex prior to treatment with rituximab, a chimeric human immunoglobulin 
G1 (IgG1) anti-CD20 monoclonal antibody known to induce cytotoxicity in malignant B 
cells [52]. Wang et al demonstrated that pre-administration of Dex was able to 
significantly increase the efficacy of carboplatin, a DNA alkylating agent; gemcitabine, 
an antimetabolite; or a combination of both drugs by 2-4 fold in six xenograft models 
tested (2 colon, 2 breast, 1 lung, and 1 glioma cancers) [5]. Correspondingly, Dex pre-
treatment was effective in reducing the decrease in granulocyte counts shown to occur 
with carboplatin treatment in CD-1 mice [6]. The same group also examined the effects 
of Dex on adriamycin (an anthracycline antibiotic capable of intercalating DNA, also 
known as doxorubicin) therapy with similar results. Pre-administration of Dex resulted in 
almost complete inhibition of tumor growth in a syngeneic model of breast cancer [11]. 
In clinical trials, Dex pre-treatment has resulted in a reduction in hematopoietic toxicity 
and an improvement in absolute granulocyte count and platelet count recovery times [7, 
8].  
 
The complete mechanism (Figure 3.4) behind Dex‟s beneficial effects remains elusive, 
but it is assumed to be rooted in Dex‟s inhibition of the NF-κB signaling pathway [9, 10]. 
Dex administration induces production of the inhibitory protein IκBα, which can bind to 
activated NF-κB and prevent its entrance into the nucleus [9, 10]. As the NF-κB signaling 
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pathway is known for its role in the production of a number of pro-inflammatory 
cytokines [53, 54], its inhibition would be expected to have major repercussions. This is 
in alignment with the significant change in the tumor cytokine expression profile that has 
been reported upon administration of Dex [11]. For example, Dex treatment was shown 
to upregulate tumor necrosis factor-α (TNF-α), a cytokine known to enhance tumor 
development and metastasis at low concentrations but to induce necrosis and apoptosis of 
tumor cells at high concentrations. Administration of Dex also resulted in the 
downregulation of vascular endothelial growth factor (VEGF), a marker for angiogenesis, 
and interleukin 1β (IL-1β), a pro-inflammatory cytokine. It is thought that this change in 
cytokine expression plays a role in the reported ability of Dex to decrease the interstitial 
fluid pressure of tumors [12, 13] and normalize the vasculature [11, 14]. With these 
barriers to drug delivery reduced, subsequently administered chemotherapeutic agents 
may be taken up into tumors to a greater extent [5, 11], improving their efficacy. Also, as 
more drug is delivered to tumors, less is delivered to healthy tissues, and side effects may 
be reduced or eliminated [6].  
 
Figure 3.4. Proposed mechanism of action for Dex’s chemotherapeutic adjuvant 
properties 
Inhibition of NF-κB 
signaling pathway
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Yet, despite the potential for this therapy, there may be some limitations. Some studies 
have shown antagonistic results with pre- or co-administration of Dex actually resulting 
in a decrease in the therapeutic efficacy of chemotherapeutic agents. For example, Herr at 
al demonstrated that co-administration of Dex negated some of the effects of cisplatin. 
This was traced to a down-regulation of some pro-apoptotic elements of the death 
receptor and mitochondrial apoptosis pathways resulting in decreased activity of various 
caspases [55]. Meyer et al also found a reduction in the therapeutic efficacy of cisplatin 
with pre-administration of Dex [18]. Through an upregulation of the survival factor Akt 
and an attenuation of the activation of the mitochondrial apoptotic pathway, Dex reduced 
the high dose cisplatin induced apoptosis by 10-25% in human osteosarcoma cells.  
Studies by Sui et al showed that pre-treatment with Dex reduced the therapeutic efficacy 
of paclitaxel against human breast and ovarian xenografts tumors by 20-25% [17]. These 
results, however, are in contrast with clinical observations [8].  
 
A second potential limitation of this therapy is that Dex is capable of inducing a number 
of side effects when administered systemically [56]. The most notable of these is 
immunosuppression through T-cell depletion and inhibition [3, 19].  For patients 
undergoing chemotherapy with already weakened immune systems, this can be a limiting 
factor. In order to maximize the therapeutic potential of Dex while minimizing its side 
effects, a localized delivery system is desirable.  
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3.4. NANOPARTICLES 
3.4.1. Definition and Advantages 
Nanoparticles are increasingly being used as drug delivery systems. In strictest terms, the 
word nanoparticle refers to a structure in the 1-100 nm size range in at least one 
dimension [57]. However, more commonly the term is applied to any particle within the 
nanometer size range. Possibly of more importance is the fact that materials at this scale 
frequently display different properties than those of the bulk material.  
 
A number of nanoparticle drug delivery systems have been developed, including solid 
lipid nanoparticles (SLNs, dispersions of solid lipids), liposomes (self-assembled lipid 
bilayers), micelles (self-assembled amphiphilic molecules) and dendrimers (repeatedly 
branched spherical polymers) (Figure 3.5). These systems display a number of 
advantages over conventional drug delivery systems. First, nanoparticles are capable of 
achieving enhanced solubility [20]. This is critical in an age of increasingly hydrophobic 
drugs, where new methods are continually required for solubility enhancement. 
Depending on the type and composition, nanoparticles may also be able to provide this 
enhancement with considerably decreased toxicity as compared to earlier methods (e.g., 
Cremophor) [58]. Secondly, nanoparticles have the capacity for controlled and/or 
bioresponsive drug release. Systems can be designed so that drug is released slowly over 
an extended period of time, generally by a diffusion process [59, 60]. Alternatively, 
systems can be developed that achieve a rapid release of drug upon the addition of a 
biological stimulus, such as a change in pH, redox potential, temperature or the presence 
of a relevant enzyme [21-24]. Thirdly, nanoparticles have been reported to evade MDR 
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mechanisms. This can be a result of their cellular internalization pathway [61, 62] or P-gp 
inhibition [26]. Fourthly, nanoparticles have been shown to protect loaded molecules 
from enzymatic degradation [27]. This advantage is particularly relevant for proteins and 
other enzymatically-labile compounds that would quickly become inactivated in the 
absence of a protective drug carrier.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Representative nanoparticle drug delivery systems: solid lipid 
nanoparticles (top left), dendrimers (top right), micelles (bottom left), and liposomes 
(bottom right). Adapted from [63]* 
 
 
 
However, of the most relevance in terms of drug delivery for chemotherapeutic purposes 
is the ability of nanoparticles to target drug to tumors. As described above for Dex as 
well as for many chemotherapeutic agents, there is a desire to localize drug delivery to 
tumors as much as possible in an attempt to maximize the efficacy of the drug while 
22 
 
minimizing its toxic side effects. Nanoparticles have two potential means of achieving 
this. 
 
The first and most widely-applied targeting approach is passive targeting, which is based 
on the well-known EPR effect [29, 64]. The permeability portion of the EPR effect 
results from the fact that tumor vasculature is irregular and “leaky”, or characterized by 
larger inter-endothelial junctions than are present in healthy tissue, as mentioned above 
(Figure 3.6). Therefore, by incorporating a drug into a nanoparticle of an appropriate size, 
the drug should be targeted to the tumor simply based on the size effect. Studies have 
shown that tumors have a characteristic pore size of 200 nm to 1.2 μm [29]. However, the 
average size varies based on the type of tumor and its location within the body. 
Therefore, the generally recommended size limit for nanoparticles designed for tumor-
targeted drug delivery is <200 nm. Coupled with the leaky vasculature, the poorly 
developed lymphatic system of tumors may lead to enhanced retention of materials 
within the tumor tissue. Notably, based on similar conditions found at sites of 
inflammation, nanoparticles may also be used to provide targeted drug delivery for 
diseases such as arthritis [65-67].  
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Figure 3.6. Schematic depicting nanoparticle extravasation into tumor tissue via the 
enhanced permeability and retention (EPR) effect 
 
 
 
Active targeting is the second targeting approach that can be employed [57]. Using this 
technique, ligands that can interact with cell surface receptors are attached to the 
nanoparticle surface. Receptors upregulated on either tumor cells or on tumor-associated 
endothelial cells can be chosen for targeting. Because tumor cell receptors are 
inaccessible from the blood, extravasation into the tumor tissues remains primarily a 
product of the EPR effect. However, following extravasation, higher intracellular drug 
concentrations can be obtained through receptor-mediated endocytosis of the 
nanoparticles [68]. Because endothelial cell receptors are accessible from the vasculature 
and transport mechanisms are available that ferry materials across the endothelial cell 
barrier, vascular targeting may potentially be used to increase extravasation into the 
tumor tissue [69]. Vascular targeting may also be used for therapies targeted at 
endothelial cells (e.g., anti-angiogenic drugs).  
 
 
Normal Vasculature Leaky Tumor Vasculature 
Particles>Pore Cutoff size Particles<Pore Cutoff size 
24 
 
3.4.2. Nanoparticle PEGylation* 
3.4.2.1. Theory 
In order for nanoparticles to serve as successful tumor-targeted drug delivery systems, 
they must first remain in circulation long enough to reach the tumor site. Before this can 
happen, many colloidal carriers are cleared from the circulation as a result of 
opsonization of the particles and subsequent uptake by cells of the reticuloendothelial 
system (RES) [70-72]. Though some studies have shown an opsonin-independent uptake 
of liposomes by macrophages in mice [73-76], the macrophage uptake of nanocarriers in 
most species appears to be dependent on interaction with proteins adsorbed on the 
nanoparticle surface [77-80]. Opsonin proteins, such as the complement protein C3b, 
immunoglobulins G and M, fibronectin, C-reactive protein, β2-glycoprotein, and 
apolipoproteins [71, 76, 81, 82] may recognize nanoparticles based on their size, charge, 
rigidity, or hydrophobicity, instigating removal of the foreign particles by the RES. 
Complement proteins, immunoglobulins, and fibronectin were found to be the major 
opsonin proteins, but which protein serves as the dominant opsonin appears to depend on 
the specific characteristics of the nanocarrier with most showing high levels of adsorption 
of at least several different proteins [81, 82]. Thus, in order for nanoparticles to become 
viable alternatives to traditional delivery systems, they must be made less susceptible to 
recognition by these opsonins.   
 
The neutrality, hydrophilicity, molecular flexibility, and non-immunogenicity of 
poly(ethylene glycol) (PEG) made it a natural initial choice for surface modification of 
nanoparticles, and today, PEGylation (the coating of a surface with PEG via adsorption, 
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grafting, or entrapment methods) is considered the means of choice for decreasing protein 
adsorption and imparting „stealthiness‟ (the ability of avoid RES uptake) to nanocarriers. 
Several theories have been proposed to explain why PEG increases the stealthiness of 
nanocarriers (Figure 3.7). Simple explanations include the reduction in surface charge 
[71] and/or hydrophobicity [83, 84] and, hence, a decrease in the attractive forces 
between the nanoparticle and opsonin proteins. However, numerous other hydrophilic 
molecules have been used as coatings and failed to produce similar results [85].  Nagaoka 
et al discuss the possibility that the high mobility of the longer PEG chains simply 
prevents proteins from interacting with a surface for a time sufficiently long enough to 
bind [86]. Coupled with the hydrophilicity and mobility of PEG is its wettability [87]. 
Highly flexible PEG chains are able to squeeze water molecules out of the polymer layer, 
creating a large water cloud impermeable to proteins [88, 89]. Others have posited that 
PEG creates a minimum interfacial free energy and decreases the necessity of protein 
binding in order to reduce the interfacial energy.  However, based on protein adsorption 
studies performed by Jansen et al, this theory appears to hold only in limited situations 
[90]. In fact, in several other cases, it has been shown that minimizing interfacial free 
energy results in additional protein binding [90, 91]. The most widely accepted 
explanation, put forth by Jeon et al, relies on a description of the interactions between 
proteins and PEGylated surfaces [70, 92].  PEG chains are hydrophilic and flexible, 
leading to an extended conformation when free in solution. When proteins encroach on 
the nanoparticle surface, the PEG chains are compressed. This change to a higher energy 
conformation in turn creates a repulsive force that can inhibit protein binding. 
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Figure 3.7. Mechanisms by which PEG prevents opsonin adsorption when grafted in 
an optimal configuration. Adapted from [63]* 
 
 
 
As an alternative theory, some investigators have proposed that long-circulating 
characteristics are not a matter of avoiding protein adsorption, but of attracting the 
appropriate proteins. While it is thought that PEG causes a nonspecific decrease in 
protein adsorption [81], some have proposed that it instead alters the profile of adsorbed 
proteins. Moghimi and Patel have performed several studies that support the idea of the 
existence of liver- and spleen-specific opsonins [93-96], which may cause an altered 
distribution profile. Additionally, there appear to be some proteins that behave as 
dysopsonins, suppressing phagocytic uptake [72, 97] (Figure 3.7).  Early studies 
identified two serum components, one with a molecular weight < 30,000 Da and one with 
a molecular weight > 100,000 Da, that remained bound to poloxamine 908 (four PEG 
polymers attached to four poly(propylene glycol) (PPG) polymers all connected by an 
ethylene diamine moiety, MW ~ 25,000 Da) coated polystyrene particles and decreased 
uptake by liver cells beyond that seen with poloxamine 908 alone [98, 99]. More recent 
O-Opsonin 
D-Dysopsonin 
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studies by Dunn et al and Mosqueira et al also support the concept of dysopsonic activity 
but fail to show such promising results with their covalently PEGylated nanostructures 
[100, 101]. Dunn et al utilized similar polystyrene particles and saw decreased uptake by 
liver non-parenchymal cells for both polystyrene particles and poloxamine 908 coated 
polystyrene particles. Additionally, those particles with a low surface coating of 
covalently attached 2,000 Da PEG (PEG2000) showed a significant decrease in uptake 
after incubation with serum. However, as the PEG2000 surface concentration was 
increased from a PS:PEG2000 ratio of 1:0.025 (~15% C-O surface coverage) to a ratio of 
1:1.053 (~41% C-O surface coverage), the significant reduction in liver uptake was no 
longer observed, possibly because the PEG coating was too dense to allow dysopsonin 
binding.  
 
3.4.2.2. Optimization of Surface Coverage 
Despite the apparent value of PEGylation, guidelines remain elusive for achieving 
optimum surface coverage. If one accepts the Jeon theory, adequate surface coverage of 
the particle with PEG must be achieved in order to block adsorption of proteins. The ideal 
coverage has been described as intermediate between the “mushroom” and “brush” 
configurations [70, 102]. The “mushroom” configuration is characterized by very low 
surface coverage, leading to large areas available for protein binding. The “brush” 
configuration is characterized by a very high surface coverage, which could theoretically 
lead to a restriction of PEG flexibility and a potential decrease in its steric repulsion 
properties. However, most experimental data indicate that a predominantly brush 
configuration provides the most effective opsonin repulsion [103, 104]. This might be 
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attributable to an inability to attain a sufficiently high density such that PEG flexibility is 
restricted.   
 
Coverage of the surface can be controlled through chain molecular weight, surface chain 
density, and chain conformation. Although each individual system requires optimization, 
several trends in surface coverage have emerged: (i) the surface density is more important 
than the molecular weight of the PEG chain [92, 100, 105], (ii) there is a threshold 
molecular weight for PEG chains to be effective because of a loss of flexibility and 
hydration with shorter PEG chains [70, 106, 107], (iii) linear PEG chains of molecular 
weight greater than 5,000 Da rarely provide improved results and may show an increase 
in protein adsorption because of an inability to obtain high surface density [82, 108, 109], 
and (iv) branched PEG chains are less effective at preventing adsorption than linear PEG 
chains [106, 110].  Generally, linear PEG chains of molecular weight 1,500-5,000 Da 
have been shown to provide efficient stealthiness [82, 106, 111]. The exact length 
necessary likely depends on the curvature of the surface and other attractive forces. As an 
overarching rule, it has been recommended that a minimum effective hydrodynamic layer 
thickness of approximately 5-10% of the particle‟s diameter should be sought for 
sufficient coverage [102, 112].   
 
This list is by no means exhaustive, and there have been several exceptions noted. For 
example, Mosqueira et al found that when PEG chains of 20,000 Da and 5,000 Da were 
both grafted at a distance of 4.5 nm between PEG chains, PEG20000 was better able to 
prevent cell uptake of nanocapsules. A grafting distance of only 2.2 nm was required for 
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PEG5000 to achieve the same results as PEG20000 at a distance of 7.8 nm, and 
PEG20000 continued to decrease cell uptake at higher grafting densities. They proposed 
that the PEG chains could have different conformations at the surface resulting in 
different efficiencies in preventing interaction between the nanocapsule and a cell, or that 
since there is a low surface coverage, the chain length became the limiting factor [101]. 
Gref et al also found improved circulation times as well as reduced liver uptake with 
PEG20000 over PEG with 0, 5, and 12 kDa chains [113].  
 
3.4.2.3. Attachment Methods 
One common method for attaching PEG to the surface of nanoparticles is surface 
adsorption. This can be done through the use of linear PEG polymers or through the use 
of poloxamers (nonionic block copolymers composed of a central hydrophobic chain of 
poly(propylene glycol) (PPG) flanked by two hydrophilic chains of PEG) and 
poloxamines  where the hydrophobic PPG chains insert into the hydrophobic particle and 
the PEG chains orient themselves toward the aqueous environment [102]. Alternatively, 
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-PEG (DSPE-PEG) is commonly used 
in the preparation of liposomes. These methods have been used since the early 1980s and 
are thoroughly reviewed elsewhere [102, 107]. Though many particles exhibited 
improved stealth capacities, some results were less than satisfactory. 
 
The major hypothesis to explain these less than optimal results was the desorption of 
PEG or displacement by proteins when in the bloodstream [114, 115]. Thus, there was a 
move towards ensuring more stable linkages. Harper et al was one of the first groups to 
30 
 
attach PEG via a covalent linkage. They showed an average reduction in macrophage 
uptake of approximately 40% by preparing polystyrene-poly(ethylene glycol) (PS-PEG) 
particles as opposed to adsorbing PEG onto the surface of PS particles. An even greater 
decrease was seen when poloxamer 238 was adsorbed onto the surface of the PS-PEG 
particles [116]. Bazile et al found improved results with polymeric nanoparticles made 
from poly(d,l-lactic acid)-poly(ethylene glycol) (PLA-PEG) diblock copolymers. The in 
vivo plasma half-life of the PLA-PEG nanoparticles was increased by a factor of 180 as 
compared to the poloxamer-stabilized PLA nanoparticles [117]. Later, in vitro assays 
revealed that, in the presence of serum, PLA nanocapsules coated with a poloxamer 
showed higher levels of protein adsorption [109] and cell uptake [101] than nanocapsules 
with covalently attached PEG.  
 
Today, many polymeric micelles and nanoparticles are made from PEG-based diblock 
copolymers, which ensure a stable coating.  Liposomes are also being further developed 
into polymersomes, composed entirely of PEG-based block copolymer amphiphiles. 
Those systems not composed of block copolymers rely on the inclusion of a certain 
percentage of pre-formed PEG-lipids or PEG-phospholipids in addition to their non-
PEGylated counterpart. By using a compound already integral to the particle, a stable 
linkage may be obtained. What follows is a sampling of recent reports. Nanoparticles 
prepared with PEG-lipids were capable of delivering 70-80% of injected siRNA to 
tumors by four hours [118]. SLNs prepared with dipalmitoylphosphatidylethanolamine-
PEG2000 or stearic acid-PEG2000 showed 30-40% less uptake by murine macrophages 
than non-stealth SLNs [119]. Doxorubicin-loaded SLNs containing stearic acid-PEG2000 
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exhibited reduced clearance as well as an improved biodistribution over non-stealth SLNs 
[120]. Lidocaine-loaded poly(lactic-co-glycolic acid)(80kD)-PEG(20kD) nanoparticles 
showed less than 30% uptake by the liver Küpffer cells at five hours compared to 66% 
uptake in five minutes for uncoated particles [113]. Doxorubicin-loaded poly(β-benzyl-L-
aspartate)-PEG copolymer micelles showed a sustained drug release and increased 
antitumor activity over free drug [60]. Sustained release of salvicine over 28 days was 
obtained with poly(n-hexadecyl cyanoacrylate)-poly(ethylene glycol) (PHDCA-PEG) 
nanoparticles [121]. Phagocytosis of poly(hydroxyethylaspartamide methacrylated)-
PEGylated nanoparticles was reduced based on the degree of PEGylation [122]. 
Poly(methoxy-polyethyleneglycol5000 cyanoacrylate-co-n-hexadecyl cyanoacrylate) 
(PHDCA-PEG5000) niosomes were prepared that exhibited a half-life of 11.46 hours and 
that reduced tumor weight by 89.3% at half the dose given via a normal injection of 
solution [108]. Camptothecin-loaded nanocapsules prepared with PLA-PEG showed an 
increase of approximately 30% in the reduction of metastatic nodules over uncoated 
nanocapsules [123].  
 
3.4.2.4. Current State of the Art 
Currently, there are several PEGylated nanocarriers approved for therapeutic use or 
undergoing testing  [124]. Of these, Doxil is probably the most well-known as it was the 
first liposomal drug formulation approved by the Food and Drug Administration (FDA). 
In this formulation, doxorubicin HCl is encapsulated (>90%) in a liposome composed of 
cholesterol, hydrogenated soy phosphatidylcholine (HSPC), and DSPE-mPEG. Doxil was 
originally approved for the treatment of AIDS associated with Kaposi‟s sarcoma in 1995 
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[125] but is now also used for the treatment of metastatic breast and ovarian cancers and 
multiple myeloma. Compared to the non-liposomal drug, Doxil achieves up to 10-fold 
higher levels in tumors. It is also noted for its long-circulating characteristics and 
reduction in toxicity, especially cardiotoxicity. Beyond these PEGylated nanocarriers, 
there are a variety of PEGylated protein products on the market, including PEGylated 
arginine deaminase, PEGylated interferon, and PEGylated L-asparaginase. As evidenced 
by these products and the wide variety of other products in which PEG is used as an 
excipient, PEG has repeatedly been deemed safe by the FDA.   
 
3.5.  SOLID LIPID NANOPARTICLES 
3.5.1.  Definition and Advantages 
Several reports exist of Dex being loaded into nanoparticle systems, including polymeric 
nanoparticles [59, 126, 127], polymer-drug conjugates [67], and liposomes [128, 129]. 
Unfortunately, these systems may be limited by a number of disadvantages, including 
toxicity, low drug encapsulation efficiency, unknown or unproven safety of some of the 
materials used in their preparation, and rigorous or high-cost production methods [130, 
131]. For this reason, solid lipid nanoparticles (SLNs) were proposed as an alternative 
nanoparticle system.  
 
SLNs are characterized by a solid lipid core with stabilizing surfactants and/or polymers 
on the particle surface [132]. They have gained increasing attention since their 
development in the early 1990s based on their reported ability to combine the advantages 
of several nanoparticle systems while negating some of their disadvantages [33, 34].  
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First, they can be prepared from inexpensive, readily available materials. A wide variety 
of both lipids (e.g., triglycerides, partial glycerides, waxes, PEGylated lipids, fatty 
acids/alcohols, steroids) and surfactants/polymers (e.g., polysorbates, brijs
®
, lecithin, bile 
acids) have been used in their preparation. Secondly, because the lipid matrix can be 
prepared from biocompatible lipids and the surfactants and/or polymers used can be 
chosen based on FDA approval status, these drug delivery systems typically exhibit very 
low toxicity. Coupled with the low toxicity of the materials used in SLN preparation is 
the fact that most SLN preparation methods do not rely on the use of organic solvents, 
eliminating that as a possible toxicity concern. Thirdly, and possibly of most importance, 
is the fact that SLNs can be prepared using simple, scalable production methods, a 
requirement for translation from academic labs to industrial labs.  
 
3.5.2.  Production Methods 
The two most commonly used SLN production methods are the high pressure 
homogenization (HPH) and microemulsion techniques [34]. HPH was the earliest method 
used for SLN preparation. This technique arose from its use in the preparation of o/w 
emulsions for parenteral nutrition. Although a liquid lipid is replaced with a solid lipid 
for SLN preparation, a similar procedure can be employed if conducted at temperatures 
above the melting point of the lipid. This is referred to as hot homogenization. Basically, 
the drug is added to the lipid at 5-10°C above the lipid melting point, and then the melt is 
dispersed with stirring in an aqueous surfactant solution at the same temperature. The 
pre-emulsion is then homogenized, and the resulting hot o/w microemulsion is cooled to 
room temperature (or lower). SLNs are produced as the lipid solidifies.  
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The cold homogenization technique can be applied when 1) drugs exhibit temperature 
sensitivity, 2) hydrophilic compounds partition into the aqueous phase at elevated 
temperatures, and 3) lipid crystallization is complex leading to multiple polymorphic 
forms of the lipid and/or supercooled melts [33, 34]. The first step of this process is the 
same as that in the hot homogenization. Drug is added to the melted lipid. However, 
following this step, the melt is cooled, and the solid lipid is ground to lipid 
microparticles. The lipid microparticles are then dispersed in a cold surfactant solution. 
Homogenization is conducted at room temperature or below, producing SLNs.  
 
SLNs can also be produced from o/w microemulsions using scalable methods [34, 131]. 
Microemulsions can be defined as stable biphasic mixtures of two immiscible liquids 
stabilized by a surfactant and usually a co-surfactant [131]. It may be necessary to add the 
co-surfactant in order to generate the low interfacial surface tensions (γ) between the 
dispersed and continuous phases required for the preparation of stable microemulsions. 
Because microemulsions are characterized by a large surface area, the interfacial surface 
tension must be low enough so that the positive interfacial energy (γA, where A is the 
interfacial area) can be balanced by the negative free energy of mixing (ΔGm). 
 
Microemulsions can be prepared using solid lipids by employing a preparation 
temperature above their melting point. The lipid will solidify upon cooling, generating 
SLNs. Initially, the cooling procedure was performed through dilution in cold water 
[133]. More recently, a process known as nanotemplate engineering technology (NET) 
was developed in which “direct cooling” is utilized [131, 134]. A schematic of the 
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preparation procedure is shown in Figure 3.8. Basically, the process consists of three 
steps: 1) melting a pharmaceutically acceptable matrix comprised of lipid(s), 
surfactant(s), polymer(s), and drug at 55-70°C, 2) adding pre-heated water with stirring to 
form the o/w microemulsion, and 3) cooling to room temperature with stirring to generate 
the SLNs.  
 
Figure 3.8. Nanotemplate engineering technology (NET) 
 
In comparison to the dilution method, NET has the advantage of being a single vessel 
preparation method. By utilizing a direct cooling approach, it becomes unnecessary to 
optimize the rate and ratio of mixing, which have been reported to have a significant 
impact on the properties of the resulting SLNs [34]. Further, much higher concentrations 
may be obtainable using NET than using the dilution method as microemulsion:water 
dilution ratios of 1:10 v/v up to 1:100 v/v have been reported in the literature [131]. This 
represents a major improvement in microemulsion technology as low concentrations were 
previously considered a significant disadvantage of the microemulsion technique as 
compared to the HPH technique [34].  
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3.5.3. Limitations 
As described above, SLNs have the potential to overcome many of the disadvantages 
associated with other nanoparticle drug delivery systems. However, they too may have 
limitations, most of which are associated with the lipid crystallinity of the particles. On 
one end of the spectrum, SLNs that exhibit high crystallinity may be limited by low drug 
loading [135]. There may simply be little room for the drug to be inserted among the 
tightly packed lipid molecules. On the other end of the spectrum, working with less 
crystalline lipids (or reducing the crystallinity of the lipid through the addition of other 
lipids and/or surfactants) may lead to stability issues. If the lipid crystallizes over time, it 
may lead to drug expulsion [136-138], particle size growth [138, 139], or gelation [140-
143]. However, by characterizing the physicochemical properties of the SLNs, these 
issues may be anticipated and avoided through changes to the composition (e.g., lipids, 
surfactants) [144, 145], preparation procedure [33], or storage conditions [146].  
 
3.6. PRELIMINARY WORK** 
3.6.1. Formulation Optimization 
In preliminary work from this laboratory designed to develop Dex loaded SLNs using 
NET, approximately 160 formulations containing various combinations of cetyl alcohol, 
stearyl alcohol, polysorbates (20, 40, 60 or 80), and Brij
®
 78 were prepared. Cremophor, 
lecithin, and various PEGylating agents were added to some formulations. An optimized 
formulation that yielded clear nanoparticle suspensions and a small particle size 
distribution was obtained. The formulation was comprised of SA (1.6 mg/mL), PS60 (0.4 
mg/mL), and Brij
®
 78 (3.5 mg/mL) (structures are shown in figure 3.9). To potentially 
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improve the stealthiness of the nanocarriers, the formulation was adjusted for the 
inclusion of a long-chain PEGylating agent, PEG6000MS. This is essentially a 
PEGylated analog of a stearyl (C16) function and is expected to be more compatible with 
the primary component of the lipid matrix, SA, than other commonly used PEGylating 
agents, such as DSPE-PEG. Because the PEGylating agent is able to function as a 
surfactant, the Brij
®
 78 concentration could be reduced to 2.8 mg/mL when PEG6000MS 
was included. 
 
 
Stearyl alcohol (SA) 
 
 
Polysorbate 60 (PS60) 
 
38 
 
 
Brij
® 
78 
 
 
PEG6000 monostearate (PEG6000MS) 
 
Figure 3.9. Structures of SLN components 
 
3.6.2.  Drug Loading 
Dex could be loaded into SLNs (without PEG6000MS) at a drug load of 3.5% w/w SA 
(e.g., 0.056 mg/mL Dex in comparison to 1.6 mg/mL SA) while maintaining a small 
particle size (~70 nm). Following incubation in PBS at 37°C, a burst release of drug was 
observed, accounting for 45–55% of the original amount of Dex loaded into the SLNs. In 
considering the time required for SLNs to distribute throughout the circulation and 
extravasate into tumors, it was decided that these SLNs would not deliver Dex to tumors 
in sufficient quantities.  
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For this reason, Dex-P (Figure 3.3) was chosen as an alternative drug for loading. Dex-P 
is a lipophilic ester of Dex that has been used in marketed products, such as Limethason
®
, 
an intravenously administered lipid emulsion [36]. A liposome formulation containing 
Dex-P has also been described, and a conformational analysis showed that the palmitate 
chain was aligned with the acyl chains of the phospholipids while Dex was oriented 
towards the aqueous phase [129]. It was expected that Dex-P would align similarly when 
incorporated into SA-based SLNs. Early studies indicated that Dex-P could be loaded in 
SLNs with or without PEG6000MS at 10-30% w/w SA with high encapsulation 
efficiencies. This was confirmed at a later time; results are discussed in chapter 5.  
 
3.6.3.  Evaluation of Stealth Properties 
The stealth properties of the nanoparticles were evaluated by determining the adsorption 
of a model opsonin, 
125
I-IgG. 10% Dex-P loaded SLNs with and without 2.5 mg/mL 
PEG6000MS were compared. Latex particles (90 nm) were used as a positive control 
because they are hydrophobic and readily adsorb IgG.  Nanoparticle-adsorbed IgG was 
separated from free IgG by SEC using a Sepharose CL-4B column. Representative 
elution profiles are shown in Figure 3.10. Expressed in quantitative terms as the mean ± 
standard deviation (SD) of 3 measurements, this equates to an adsorption of the following 
(all values in μg IgG/mg nanoparticle): latex, 185.0±9.5; non-PEGylated SLNs, 20.8±1.6; 
PEGylated SLNs, 6.7±0.7. Both SLNs with and without PEG6000MS exhibited 
considerably lower protein adsorption as compared to latex particles. In the absence of 
PEG6000MS, this could be attributed to the presence of the polyether portion of Brij
®
 78 
and PS60. Although not as long as suggested based on most PEG research as described 
40 
 
above, these surfactants apparently exhibit some protective capacity.  However, the SLNs 
containing PEG6000MS exhibited a statistically lower amount of protein adsorption as 
compared to SLNs without PEG6000MS (P<0.05).  
 
 
Figure 3.10. Adsorption of IgG (as measured by radioactive CPM) on SLNs. 
Nanoparticle-adsorbed protein was separated from free protein using a Sepharose 
CL-4B column; nanoparticles eluted in fractions 5-7.  Adapted from [35]** 
 
 
 
As a second test of the stealth properties, SLNs that had been radiolabeled with 
14
C-SA 
were evaluated for uptake by murine macrophages. The initial study was conducted using 
SLN prepared with 2.5 mg/mL PEG6000MS as in the IgG adsorption studies. While 
there was a difference in the SLNs taken up by these cells after a 90 min incubation as 
compared to SLNs without PEG6000MS, the difference at earlier time points was 
minimal. Additional studies were performed to evaluate the effect of including higher 
concentrations of PEG6000MS in the SLN formulation. The results are shown in Figure 
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3.11. Two-way ANOVA revealed that the effect of different formulations depends on 
what time uptake was evaluated. There was a statistically significant interaction between 
formulation and time (P<0.001). Multiple comparisons versus control group (SLNs with 
0 mg/mL PEG6000MS) were done using the Holm–Sidak method. The addition of 
PEG6000MS significantly decreased the macrophage uptake at the 30, 60, and 90 min 
time points as compared to the control group (P<0.05). At the 90 min time point, each of 
the two groups was significantly different (P<0.05). As more PEG6000MS was used in 
the preparation of SLNs, the macrophage uptake decreased. The uptake of SLNs with 0 
mg/mL PEG6000MS was 36.6%/mg cell protein. As the amount of PEG6000MS in the 
formulation increased, the uptake of the 
14
C-labeled nanoparticles was observed to 
decrease, reaching a low of 14.7%/mg cell protein for SLNs formulated with 4 mg/mL of 
PEG6000MS. These results indicated that as the concentration of PEG6000MS was 
increased, there was a corresponding increase in the stealth properties.  
 
Figure 3.11. Uptake of 
14
C-labeled Dex-P loaded SLNs with varying amounts of 
PEG6000MS by murine macrophages as a function of time. All data represents the 
mean ± SD of 5 measurements.  Adapted from [35]** 
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Based on the above studies, two formulations were chosen for evaluation in this project 
(Table 3.1). Formulation 1 did not include PEG6000MS. Although the addition of the 
molecule appeared to increase the stealthiness of the nanoparticles, it was considered 
worthwhile to compare formulations with and without this molecule to determine if the 
increased complexity was warranted.  PEG6000MS was included in formulation 2 at a 
concentration of 3 mg/mL. This was considered to provide the optimal combination of 
particle size, drug loading, and stealth capacity. 
 
Table 3.1. SLN formulations 
 Formulation 1 Formulation 2 
Stearyl alcohol (SA) 1.6 mg/mL 1.6 mg/mL 
Polysorbate 60 (PS60) 0.4 mg/mL 0.4 mg/mL 
Brij
®
 78 3.5 mg/mL 2.8 mg/mL 
PEG6000 monostearate (PEG6000MS) 0.0 mg/mL 3.0 mg/mL 
Dexamethasone Palmitate (Dex-P) 0.16-0.48 mg/mL 0.16-0.48 mg/mL 
 
 
*The text from the Nanoparticle PEGylation section as well as Figures 3.5 and 3.7 were 
previously published in [63]. Reproduced with minor modifications from American 
Scientific Publishers: Journal of Biomedical Nanotechnology, PEGylation of Nanocarrier 
Drug Delivery Systems: State of the Art, 4, 2008, 133-148, M.D. Howard, M. Jay, T.D. 
Dziubla, X. Lu. Copyright © American Scientific Publishers 2008. 
**Portions of the text from the preliminary work section, Figure 3.10 (originally 
presented in table format), and Figure 3.11 were previously published in [35]. 
Reproduced with kind permission from Springer Science+Business Media: The AAPS 
Journal, Nanoparticles containing Anti-inflammatory Agents as Chemotherapy 
Adjuvants: Optimization and In Vitro Characterization, 10(1), 2008, 133-140, X. Lu, 
M.D. Howard, M. Mazik, J. Eldridge, J. Rinehart, M. Jay, M. Leggas. Copyright © 
Springer Science+Business Media 2008. 
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Chapter 4 
 
Physicochemical Characterization of Nanotemplate Engineered Solid Lipid 
Nanoparticles* 
 
 
4.1.  INTRODUCTION 
Due to their simplicity of formulation and basic biocompatibility of the constituent 
materials, SLNs have become an exciting area for nanomedicine research. As with other 
systems, they have the potential for targeted drug delivery [147, 148], controlled or 
triggered drug release [149-151], enhanced drug solubility [152, 153], and improved drug 
stability [154, 155]. Yet, SLNs also possess low inherent toxicity due to the use of 
physiological lipids and non-organic solvents during preparation
 
[33, 34, 130] and are 
amenable to large-scale production methods [33, 34]. Of course, SLNs possess some 
limitations, including low drug loading [135], drug expulsion [136-138], particle size 
growth [138, 139], and a tendency to form gels [140-143]. These issues are linked to the 
fundamental physicochemical properties that are predominately controlled by the 
material of composition (e.g., lipids, surfactants) and preparation procedure [33]. For 
example, SLNs prepared from highly crystalline triglycerides have lower drug loading 
capacity than SLNs prepared from complex glycerides [138]. Lipids with multiple 
polymorphic forms can lead to drug expulsion upon form transitions [138], which are 
kinetically modulated by surfactant choice [145, 156]. The choice of lipid(s) and 
surfactant(s) and their concentrations have been found to affect SLN aggregation and 
gelation [139, 157]. Even the choice of formulation parameters has been shown to affect 
drug loading, release profiles, and long-term physical stability [158, 159].   
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The SLNs under consideration in this study are prepared using NET.  While in vitro and 
in vivo results have been promising [160, 161], there exists relatively little 
physicochemical characterization of nanotemplate engineered SLNs beyond particle size 
and zeta potential measurements [162, 163].  Indeed, the complex interplay of the 
multicomponent systems used in SLN preparations make a priori predictions of the 
overall stability and phase behavior of the SLN difficult, necessitating a more thorough 
understanding of the SLN physiochemical properties. As such, the objective of this study 
was to perform a thorough characterization of the two SLN formulations being 
considered for development as a Dex-P delivery system, providing comparisons and 
possible advantages/disadvantages of the two.  
 
4.2.  MATERIALS AND METHODS 
4.2.1.  Materials. PS60 and Brij
®
 78 were obtained from Uniqema (Chicago, IL). 
PEG6000MS was a gift from Stepan (Northfield, IL). SA was purchased from Spectrum 
Chemicals and Laboratory Products (Gardena, CA). Water was obtained from a Milli-Q 
Synthesis ultrapure water system (Millipore; Billerica, MA). Chloroform-d (CDCl3) and 
deuterium oxide (D2O) were products of Acros Organics; the deuteration of both NMR 
solvents was at least 99.8%.  
 
4.2.2.  SLN Preparation. SLNs were prepared using NET as previously described [131]. 
Briefly, the process consists of three steps: 1) melting an appropriate mixture of lipids, 
surfactants, and (optionally) long-chain PEGylating agents; 2) adding pre-heated water 
with stirring to generate an o/w microemulsion; and 3) cooling the microemulsion to 
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form a suspension of SLNs. For this study, microemulsions were prepared at 70°C in 
order to facilitate the melting of all components. SLNs were cooled in a room 
temperature water bath. Formulation 1 composition was 1.6 mg/mL SA, 0.4 mg/mL 
PS60, and 3.5 mg/mL Brij
®
 78. Formulation 2 composition was 1.6 mg/mL SA, 0.4 
mg/mL PS60, 2.8 mg/mL Brij
®
 78, and 3.0 mg/ml PEG6000MS. Batch size ranged from 
2-10 mL. SLNs were filtered using a 0.2 μm polyethersulfone membrane prior to 
analysis. SLNs for DSC and PXRD analysis were freeze-dried using a Virtis Advantage 
benchtop freeze-dryer following freezing at -40°C. Freeze-dried SLNs were tested for 
water content using a Karl Fischer coulometric assay.  
 
4.2.3. DLS and TEM. DLS particle size measurements were performed in triplicate at 
25°C on a Delsa™ Nano Zeta Potential and Submicron Particle Size Analyzer (Beckman 
Coulter Inc., Brea, CA) following a 1:30 dilution with Milli-Q water. TEM images were 
obtained using a Philips Tecnai Biotwin 12 equipped with a Gatan ES 1000W CCD 
digital camera (FEI, Hillsboro, OR). A drop of sample (7 µl) was incubated for 1.5 min 
on a carbon coated TEM grid. The grid was then dried and stained (0.2 μm filtered 2% 
uranyl acetate) for an additional 1.5 min. For each formulation, three samples were 
analyzed with a minimum of five images taken per sample at different locations on the 
grid. Analysis of the images was performed using ImageJ [164]. The lengths of both the 
major and minor axes were obtained using the manual analytical tools. Assuming a 
prolate spheroid shape for the ellipsoid where the minor axis is the same in the x and y 
directions, the volume of an ellipsoid with these dimensions was calculated according to 
the following:  
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where r is the radius of the relevant axis. Using this value as the volume of an equivalent 
sphere allowed for the calculation of an approximate particle diameter according to the 
following equation:  
          
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
In order to apply a quantitative measurement to the particle shape analysis, the aspect 
ratio for the particles was calculated by dividing the length of the major axis by that of 
the minor axis. These calculations were performed for 20 particles per image, giving a 
total of 100 measurements per sample. The average measurement for each sample was 
used in calculating the average and standard deviation for particles in each formulation.  
As a measurement of the homogeneity of the size distribution (comparable to the PI 
values obtained by DLS), a pooled standard deviation (PSD) was also calculated using 
the following equation: 
        
          
      
       
 
   
 
where si represents the standard deviations obtained from each individual sample of 100 
particles, ni represents the sample size (i.e., 100 for all 3 samples), and k represents the 
number of samples (i.e., 3). This differs from the standard deviation calculated above 
which represents the variability in the average size obtained from the three samples.  
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4.2.4. NMR Spectroscopy. NMR experiments were performed on a Varian 500 MHz 
NMR (Varian Inc., Palo Alto, CA). 
1
H-NMR spectra were obtained for the individual 
SLN components and SLNs dissolved in CDCl3 and for intact SLNs in D2O. Peaks were 
assigned to their associated structures based on available NMR tables. Benzenesulfonic 
acid sodium salt was added in a known concentration to the D2O samples as an internal 
standard. Molecular relaxation times were calculated for the three main signals (0.9, 1.3, 
and 3.6 ppm) in the intact SLN spectra and in spectra obtained from the surfactant 
micelles in D2O. Spin-lattice (T1) relaxation times were analyzed using an inversion 
recovery experiment, and spin-spin (T2) relaxation times were analyzed using a Carr 
Purcell Meiboom Gill (CPMG) sequence.  
 
4.2.5. DSC. DSC analysis was performed on a TA Instruments DSC 2920 (TA 
Instruments, New Castle, DE) using a 1°C/min heating rate from 25°C-75°C in triplicate. 
The corresponding TA Instruments Universal Analysis software was used to identify 
peak maxima temperatures and peak enthalpies; in the case of mixtures, the enthalpy 
associated with a peak was corrected for the proportion of its associated material in the 
mixture. Where appropriate, samples were cooled to 0°C at a 5°C/min rate and subjected 
to a second heating cycle. SA, Brij
®
 78, and PEG6000MS were analyzed initially in their 
original state; PS60 exhibited no thermal events in this range. These components were 
then analyzed following exposure to the thermal treatments used in the preparation 
method described above but without forming an aqueous dispersion (referred to as 
“processed”). Basically, samples were melted at 70°C with stirring followed by cooling 
in a room temperature water bath. This same technique was used to evaluate mixtures of 
48 
 
the SLN components (prepared in the same ratios found in SLNs). All combinations are 
denoted as Component X-Component Y. These are differentiated from SLNs, which are 
prepared using the NET method and freeze-dried prior to DSC analysis.  Phase diagrams 
covering the full range of molar ratios were prepared for SA-Brij
® 
78, SA-PEG6000MS, 
and Brij
® 
78-PEG6000MS. Following preparation, all samples were stored at room 
temperature for 24 hours prior to analysis. Hermetically sealed aluminum pans were used 
with loadings of 5-6 mg for all single component and mixture samples and 1-2 mg for 
freeze-dried SLNs.  
 
4.2.6.  PXRD. A MultiFlex X-ray powder diffractometer (Rigaku, The Woodlands, TX) 
and Jade XRD pattern processing software (Materials Data Inc., Livermore, CA) were 
used to obtain the x-ray diffraction patterns of SA, Brij
® 
78, PEG6000MS, and freeze-
dried SLNs. The scan parameters were set at a range of 5-60° 2θ, step size of 0.02° 2θ, 
and scan speed of 2° 2θ.  
 
4.2.7.  SLN Temperature-Dependent Stability Study. Particle size measurements 
were performed on SLNs as described above at temperatures ranging from 20-65°C for 
formulation 1 SLNs and from 25-70°C for formulation 2 SLNs, both in 5°C intervals. 
Samples were incubated in the DLS chamber, and measurements were automatically 
recorded every 30 min for 6 h.  In determining particle size, the solution viscosity was 
adjusted as a function of temperature. As the change in particle size was observed to be 
linear for the duration of the experiments, growth rates were obtained through a linear 
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least squares fit.  Growth rate was then plotted as a function of temperature, and a double 
tangent approach was applied to determine a critical point. 
 
4.2.8. Statistical Analysis. All data is presented as the mean ± SD of three independent 
measurements unless otherwise noted. Comparisons were made using a t-test (paired two 
sample for means). Results are considered statistically significant at a level of p<0.05.  
 
4.3.  RESULTS 
4.3.1. DLS and TEM Analysis. Particle size measurements were taken by DLS. Both 
formulations produced nanoparticles of a small size (<100 nm) and low polydispersity 
(Table 4.1). No differences were observed for particles before and after filtration (Table 
4.2) or among batches ranging from 2-10 mL (Table 4.3). SLNs were also analyzed by 
TEM (Figure 4.1). As the particles appeared to have a slightly ellipsoidal shape, particle 
size was calculated by determining the volume of the ellipsoid and back-calculating the 
particle size of a sphere with the equivalent volume. For purposes of analysis, it was 
assumed that the particles were prolate spheroids and not oblate spheroids. The data from 
these two techniques is in reasonable agreement. The size obtained for formulation 1 
SLNs by TEM was larger than that obtained by DLS, whereas no significant difference 
(P>0.05) was found for the particle size of formulation 2 SLNs determined by the two 
techniques. The aspect ratio of the particles was also calculated as a quantifiable marker 
for particle shape differences. Formulation 1 appeared slightly more spherical than 
formulation 2. 
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Table 4.1. Particle size and shape data (n=3) 
Formulation 
DLS TEM 
Particle size 
(nm) 
PI 
Particle size 
(nm) 
PSD 
(nm) 
Aspect 
Ratio 
1 53.2±1.4 0.119±0.041 69.8±5.3 15.2 1.24±0.02 
2 89.4±1.9 0.111±0.023 92.9±3.7 16.4 1.30±0.02 
 
 
 
Table 4.2. Effect of filtration (0.2 μm polyethersulfone membrane) on SLN 
properties (n=2) 
 
Property 
Formulation 1 Formulation 2 
Unfiltered Filtered Unfiltered Filtered 
Particle size (nm) 56.4±1.4 56.7±0.6 91.4±0.8 90.7±0.7 
PI 0.094±0.021 0.048±0.001 0.058±0.020 0.048±0.011 
Intensity 11468±223 10575±723 11416±136 11995±761 
Density (mg/mL) 1015.8±4.2 1017.9±2.7 1012.7±0.6 1013.9±2.5 
 
 
 
Table 4.3. Effect of batch volume on SLN properties (n=3) 
 
Batch 
Volume 
Formulation 1 Formulation 2 
Size (nm) PI Size (nm) PI 
2 ml 54.9±1.0 0.094±0.011 89.6±3.4 0.114±0.033 
5 ml 55.1±2.3 0.097±0.016 90.1±2.3 0.085±0.049 
10 ml 55.1±1.3 0.114±0.052 87.7±0.8 0.051±0.033 
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Figure 4.1. TEM images of formulation 1 (left) and 2 (right) SLNs. Images were 
taken at a magnification of 98000x (formulation 1) and 68000x (formulation 2).  
 
 
 
4.3.2. NMR Analysis. SLN components were dissolved in CDCl3, and 
1
H-NMR spectra 
were obtained for each. The following 
1
H-NMR signals were detected - 0.9 ppm (R-
CH3): SA, PS60, Brij
®
 78, PEG6000MS; 1.3 ppm (R-CH2CH3): SA, PS60, Brij
®
 78, 
PEG6000MS; 1.6 ppm (R-CH2-CH2-OR): SA, PS60, Brij
®
 78, PEG6000MS; 2.3 ppm 
(R-CH2-COOR): PS60, PEG6000MS; 3.6 ppm (R-CH2-OR): SA, PS60, Brij
®
 78, 
PEG6000MS; 4.2 ppm (CH2-COO-CH2CH2OR): PS60. Of these signals, the most 
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important to consider are the ether signal at 3.6 ppm generated from the PEG portions of 
PS60, Brij
®
 78, and in formulation 2, PEG6000MS, as well as the prominent aliphatic 
signal seen at 1.3 ppm in all four components.  
 
1
H-NMR spectroscopy was further applied to SLNs to gain structural information on the 
nanoparticles. There is a significant reduction in the size and number of aliphatic peaks 
present in the intact SLNs in D2O as compared to solubilized SLNs in CDCl3 (Figure 
4.2). This is likely attributable to the peak broadening that occurs due to solid phase 
intermolecular interactions, rendering the peaks associated with the solid lipid core 
undetectable. To quantify the reduction, benzenesulfonic acid sodium salt was added to 
the D2O samples as a reference standard. There was essentially no loss in the PEG peak 
at 3.6 ppm moving from the solubilized to intact SLNs. Approximately 100% (97.8% in 
formulation 1 and 106.7% in formulation 2) of the added PEG (from Brij
®
 78, PS60, and 
PEG6000MS) remained in a detectable liquid state in the intact SLN sample, presumably 
on the surface of SLNs but also potentially in micellar form. This allowed us to use the 
3.6 ppm peak as a reference to determine the reduction in size of the aliphatic peaks in 
the intact SLNs as compared to the solubilized SLNs. The signal at 1.3 ppm was reduced 
by 79.4% in formulation 1 and 90.5% in formulation 2. 
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Figure 4.2. 
1
H-NMR spectra of formulation 1 (left) and formulation 2 (right) 
solubilized SLNs in CDCl3 (top) and intact SLNs in D2O (bottom). Integrations are 
given for the PEG peak (3.6 ppm) and the main aliphatic peak (1.3 ppm). 
Percentages are calculated using the CDCl3 spectra as the control.  
 
 
Additional complementary information on the structure of SLNs was gained by 
determining the relaxation times for the remaining signals
 
[165]. Similar spin-lattice (T1) 
and spin-spin (T2) relaxation times are indicative of a group with high molecular 
mobility, whereas a T1 value significantly larger than the corresponding T2 value is 
indicative of a group with limited molecular mobility. Table 4.4 shows the data obtained 
for the three major peaks seen in all D2O samples. It can be seen that the T1/T2 ratios for 
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the 3.6 ppm PEG peak are in the range of 1.1-1.3 for the SLNs, indicating a high degree 
of molecular mobility. This corresponds well with the expected localization of PEG on 
the surface of the particles. Alternatively, the T1/T2 ratios for the aliphatic peaks at 0.9 
ppm and 1.3 ppm are significantly larger, indicating that the remaining lipid molecules 
(not in the solid state) have limited molecular mobility. These signals may be attributed 
to the aliphatic chains of the surfactants that adsorb to the surface and form a loose shell 
around the solid core, or to the presence of micelles. In order to investigate these 
possibilities, the individual micellar suspensions were also analyzed (Table 4.4). At the 
concentrations used in this study (the same as in SLNs), less than 10% of each 
component would be expected to exist free in solution based on previously determined 
CMC values (appendix C). Thus, the T1/T2 ratios for the micellar suspensions should 
primarily reflect the signals of the molecules in micelle form. The T1/T2 ratio for the SLN 
1.3 ppm peaks is approximately 7.5-9.0 whereas that for the micelles is only in the range 
of 1.2-3.4, indicating that the aliphatic chains of micelles are not the primary contributors 
to the aliphatic peak signals in the SLN samples. Interestingly, the 0.9 ppm peaks showed 
similar T1/T2 ratios across both SLN and micelle samples. As this peak arises from the –
CH3 portion of the aliphatic chains, it is likely that this signal is reflective of a very small 
proportion of molecules in the loose shell orientation or in micelles. 
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Table 4.4. T1 and T2 relaxation times determined for SLNs and SLN components  
prepared using SLN preparation conditions  
 
 
 
ppm T1(s) T2 (s) T1/T2 
  Formulation 1 
0.9 0.9229 0.2876 3.2085 
1.3 0.6045 0.0796 7.5976 
3.6 0.6662 0.5749 1.1589 
Formulation 2 
0.9 0.8967 0.2745 3.2667 
1.3 0.6391 0.0720 8.8764 
3.6 0.7401 0.6046 1.2241 
PS60 
0.9 0.9343 0.4371 2.1375 
1.3 0.4454 0.3669 1.2140 
3.6 0.6990 0.6099 1.1460 
Brij
®
 78 
0.9 0.9822 0.3097 3.1711 
1.3 0.5865 0.1752 3.3484 
3.6 0.6888 0.5219 1.3199 
PEG6000MS 
0.9 0.8770 0.1969 4.4540 
1.3 0.5687 0.2291 2.4820 
3.6 0.6936 0.5782 1.1996 
 
 
4.3.3.  DSC and PXRD Analysis. DSC was used to evaluate a series of samples, 
including the SLN starting materials, mixtures of the SLN components, and the SLNs 
themselves, for melting point and enthalpy changes. Samples were stored at room 
temperature for 24 hours prior to analysis, but no differences were observed for samples 
run immediately following preparation versus those stored for up to one month at room 
temperature. Freeze-dried SLNs were shown to have low water content (1.17±0.91% H2O 
for Formulation 1 and 0.69±0.22% H2O for Formulation 2). The observed melting point 
reductions of the SLNs were primarily attributable to interactions among the SLN 
components with the SLN preparation procedure having a minimal effect, as evidenced 
by the data obtained with the “processed” materials (Table 4.5). Phase diagrams were 
constructed for three of the analyzed mixtures: SA-Brij
®
 78 and SA-PEG6000MS 
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because of the large reductions in the SA melting point and Brij
®
 78-PEG6000MS 
because of the development of an intermediate peak (Figures 4.3-4.5). 
 
Table 4.5. Melting points (Tfus) determined from DSC peak maxima temperatures 
(Data is represented as the mean ± SD of 3 independent measurements of the Tfus 
value)  
 
Sample
1
 
SA:PS60:Brij 
78:PEG6000MS 
weight ratio 
Tfus (°C) 
Brij
®
 78
2
 SA PEG6000MS 
SA - - 58.16±0.46 - 
Brij
®
 78 - 44.39±0.14 - - 
PEG6000MS - - - 63.09±0.78 
SA (processed) - - 57.98±0.32 - 
Brij
®
 78 (processed) - 42.93±0.27 - - 
PEG6000MS (processed) - - - 61.20±0.70 
SA-PS60 1.6 : 0.4 : 0.0 : 0.0 - 56.30±0.22 - 
SA-Brij
®
 78 1.6 : 0.0 : 2.8 : 0.0 41.61±0.56 51.48±0.25 - 
SA-PEG6000MS
3
 1.6 : 0.0 : 0.0 : 3.0 - 47.09±0.66 58.79±0.25 
PS60-Brij
® 
78 0.0 : 0.4 : 2.8 : 0.0 42.55±0.39 - - 
Brij
® 
78-PEG6000MS
4
 0.0 : 0.0 : 2.8 : 3.0 41.50±0.29 - 59.15±0.20 
SA-Brij
®
 78-PS60 1.6 : 0.4 : 3.5 : 0.0 40.42±0.22 50.13±0.35 - 
SA-Brij
®
 78-PS60-
PEG6000MS 
1.6 : 0.4 : 2.8 : 3.0 38.70±0.09 51.20±0.11 58.01±0.14 
Formulation 1 SLNs 1.6 : 0.4 : 3.5 : 0.0 40.24±0.33 48.50±0.23 - 
Formulation 2 SLNs 1.6 : 0.4 : 2.8 : 3.0 
36.40±0.18/ 
39.87±0.59 
49.86±0.35 57.73±0.11 
 
 
                                                          
1
 Combinations prepared by subjecting materials to the NET procedure but without the 
addition of water are represented as component X-component Y. SLNs were freeze-dried 
prior to analysis.   
 
2
 Brij
®
 78 or SA-Brij
®
 78 eutectic   
3
 An additional small peak was present at 50.40±0.26°C. 
4
 An additional small peak was present at 50.38±0.21°C. 
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The SA-Brij
®
 78 phase diagram (Figure 4.3) revealed that at low SA concentrations (<15 
mole %), a solid solution with SA dissolved in Brij
®
 78 was apparent. At the 
concentrations of interest (Formulation 1, 66.06 mole % SA; Formulation 2, 70.97 mole 
% SA), the sample was characterized by the presence of both an SA phase and a eutectic 
phase. The eutectic composition was observed at approximately 30-40 mole %. The 
solid-liquid equilibrium line was modeled with good agreement using the van‟t Hoff 
freezing point relationship [166] as follows:  
       
     
 
 
 
    
 
 
 
  
where x is the mole fraction of the major component at the temperature T, R is the gas 
constant, ΔHfus is the molar enthalpy of fusion of the pure component, and Tfus is the 
melting temperature of the pure component. Residuals [experimental value (y) – model 
value (m)] were calculated and used in the determination of the sum of squares due to 
error [                ], giving a low value of SSE = 10.26. Goodness of fit 
[     
   
   
, where SST = y – yavg] was calculated to be 0.9997. 
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Figure 4.3. Top: SA-Brij
®
 78 phase diagram obtained from DSC peak maxima 
temperatures. Samples of different molar proportions were heated from 25-75°C; 
each symbol represents a peak seen in the thermograms. SA appears to dissolve in 
Brij
®
 78 up to 15 mole %. A eutectic appears at 30-40 mole % SA. Data is modeled 
using the van’t Hoff freezing point relationship equation with good agreement (solid 
line). Dashed lines indicate assumed phase boundaries. α = Brij® 78-rich solid phase; 
β = SA-rich solid phase; L = liquid phase. Bottom: Representative SA-Brij® 78 
thermogram at the ratio of interest (70.87 mole % SA, formulation 2) 
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The second mixture chosen for study was SA-PEG6000MS (92.21 mole % SA). The 
thermogram of the original mixture showed two peaks with melting temperatures 
significantly reduced below that of SA, and a major endotherm associated with 
PEG6000MS. Throughout the entire range of compositions, the same major endotherm 
was observed with the shoulder becoming more prominent at higher and lower 
concentrations (Figure 4.4). The cause for the shoulder is unknown, giving rise to the 
label, γ, for the intermediate region of the phase diagram. Correction of the enthalpy 
associated with this peak for the proportion of PEG6000MS present in the mixture (SLN 
concentration) produced a larger value than was seen with PEG6000MS alone (234.8±1.9 
J/g>170.9±13.0 J/g), indicating that this peak was likely not attributable to a single phase. 
This agrees with the region of the phase diagram below this endotherm being bound by 
two solid forms, indicating the possible presence of both a PEG6000MS and an SA-
PEG6000MS mixed phase. 
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Figure 4.4. Top: SA-PEG6000MS phase diagram obtained from DSC peak maxima 
temperatures. Samples of different molar proportions were heated from 25-75°C; 
each symbol represents a peak seen in the thermograms. Dashed lines indicate 
assumed phase boundaries.  A shoulder was observed on the PEG6000MS peak, 
becoming more apparent at higher and lower mole percentages (intermediate region 
labeled γ). The area below this region is bounded by two solid phases, indicating the 
likely presence of both PEG6000MS and SA-PEG6000MS phases. Assumed phases 
are labeled as an aide. A more complete analysis is required to verify their exact 
nature.  S, S’= Solid phase of unknown structure; L= Liquid phase; γ = unknown. 
Bottom: Representative SA-PEG6000MS thermogram at the ratio of interest (92.21 
mole % SA) 
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Brij
®
 78-PEG6000MS (16.44 mole % PEG6000MS) was the final mixture chosen for 
further analysis. The original sample displayed three endotherms: one each from Brij 78 
and PEG6000MS and a smaller peak intermediate between these two. The phase diagram 
(Figure 4.5) showed that below 30 mole %, no crystalline Brij
®
 78 was detectable, 
indicating possible dispersion in PEG6000MS. A separate Brij
®
 78 phase is present 
above 30 mole % that upon melting leaves a PEG6000MS-rich solid phase and a liquid. 
At PEG6000MS mole percentages of 10-30%, the small intermediate peak was present 
but disappeared above these levels. Above the melting temperatures associated with this 
peak, a modified PEG6000MS-rich solid phase is present along with a liquid phase. The 
PEG6000MS peak was again characterized by a left-hand shoulder (intermediate region 
labeled γ in the phase diagram). 
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Figure 4.5. Top: Brij
®
 78-PEG6000MS phase diagram obtained from DSC peak 
maxima temperatures. Samples of different molar proportions were heated from 25-
75°C; each symbol represents a peak seen in the thermograms. Dashed lines indicate 
assumed phase boundaries.  A shoulder was again observed on the PEG6000MS 
peak. Brij
®
 78 appears to dissolve in PEG6000MS up to approximately 30 mole %. 
A small intermediate peak was seen at low PEG6000MS mole percentages. Overall, 
the materials remain as two separate phases with minimal interaction. Assumed 
phases are labeled as an aide. A more complete analysis is required to verify their 
exact nature.  S, S’, S’’= Solid phase of unknown structure; L= Liquid phase; γ = 
unknown. Bottom: Representative Brij
®
 78-PEG6000MS thermogram at the ratio of 
interest (16.44 mole % PEG6000MS) 
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DSC and PXRD were used to evaluate the crystalline polymorph(s) present in SLNs. 
Since it is known that rapid cooling of melted SA can induce the formation of the 
metastable β-form [167], a DSC assay including a cooling cycle and a second heating 
cycle was developed. The generation of the β-form was confirmed with pure SA. 
Thermograms were then obtained for the mixtures (SA-PS60-Brij
®
 78 and SA-PS60-
Brij
®
 78-PEG6000MS) using this protocol to determine where the β- and γ-forms would 
appear if present. These were compared to the SLN thermograms (Figure 4.6). The major 
SLN peaks were shown to overlap with the known γ-peaks in the mixtures. Overlayed 
powder X-ray diffractograms of the SLNs and their starting components are shown in 
Figure 4.7. Although SA peak intensity was significantly reduced in the SLNs as 
compared to the pure component materials, no obvious transition to the metastable form 
was observed. The SA peak in the SLNs was shifted slightly to the left as would be 
expected with the β-form [167], but as only one peak is visible, it is likely that this can be 
attributed to the γ-form.  Neither technique was sensitive enough to conclude that the β-
form was absent.  
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Figure 4.6. DSC thermograms comparing formulation 1 (left) and formulation 2 
(right) SLNs with a second heating of their respective mixtures (SA-PS60-Brij
®
 78 
and SA-PS60-Brij
®
 78-PEG6000MS) *SA β-form 
 
 
 
Figure 4.7. Powder X-ray diffractograms of freeze-dried SLNs in comparison to the 
starting materials. Formulation 1 in comparison with SA and Brij
®
 78 (left); 
Formulation 2 in comparison with SA, Brij
®
 78, and PEG6000MS (right).  
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4.3.4.  SLN Temperature-Dependent Stability Study. The growth rate of SLNs 
increased with increasing temperature (Figure 4.8). Formulation 1 SLNs were observed 
to become fully destabilized at temperatures exceeding 65°C, preventing analysis at 
higher temperatures. The same phenomenon was not apparent in formulation 2 SLNs 
until 70°C. When the growth rates were plotted against temperature, a break point was 
observed for each formulation: 35.2°C and 43.0°C for formulation 1 and formulation 2, 
respectively.  
 
 
Figure 4.8. Particle size growth rates of SLNs at different temperatures. Application 
of the double tangent method indicated a critical temperature of 35.2°C for 
formulation 1 SLNs (left) and 43.0°C for formulation 2 SLNs (right).  
 
 
 
4.4. DISCUSSION 
In order to ensure the utility of SLNs as a clinically applicable drug delivery system, it is 
important to have a thorough understanding of their physicochemical characteristics. 
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These properties have been shown to have a significant effect on particle stability, 
including size growth [138, 139], gelation tendency [140-143], and drug retention [136-
138].  
 
DLS and TEM indicated that both NET formulations studied had a particle size of less 
than 100 nm, similar to SLNs produced using other methods [168-170]. Data from the 
two measurement techniques were in reasonable agreement though the particle sizes 
observed from TEM images were slightly larger than those obtained from DLS 
measurements. As the two techniques are based on different principles, this was an 
unexpected result. Measurements obtained from light scattering are based on the 
hydrodynamic diameter of the particle and provide an intensity-weighted average particle 
size, whereas measurements obtained using microscopic techniques are based on the 
diameter of the dry particle and give a number-weighted average particle size. As a result, 
particle sizes from DLS tend to be larger than those obtained by TEM [171]. The 
different result seen here may be attributed to the assumption of spherical particles 
inherent in the DLS calculations. However, the possibility of particle size and shape 
changes due to TEM grid preparation cannot be excluded. Non-spherical shapes have 
been reported for a number of SLN systems [172-174]. Anisometric particles may be a 
result of a crystal modification present [140] or a result of crystallization occurring non-
uniformly in three dimensions [173]. Overall, it was determined that particles were within 
a size range appropriate to take advantage of the enhanced permeability and retention 
effect for tumor targeting [29]. The effect of morphology is unclear but may be expected 
to play a role in drug release, transport, and internalization [175].  
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Other groups have reported the existence of supercooled melts within a SLN formulation 
[136, 137]. To determine if this was present in the NET SLNs, 
1
H-NMR spectroscopy 
was performed.  Although supercooling of 5-10°C was observed in the two formulations 
under study, it was not significant enough to prohibit the formation of SLNs. Only a 
small proportion of the lipid remained in solution, which high T1/T2 ratios indicated was 
likely attributed to the aliphatic chains adsorbed to the particle surface.  
 
Further structural information on the SLNs was obtained by evaluating the PEG signal 
arising from PS60, Brij
®
 78, and for formulation 2, PEG6000MS. PEG surface coverage 
is critical for the prevention of particle aggregation and gelation [139] and inhibiting 
protein adsorption [63]. Although it is presumed that PEG is present on the surface of 
nanoparticles in a flexible conformation, it is important to confirm this as other structures 
are feasible. Reverse micelles have been detected in SLNs [176], although not those 
possessing PEGylated surfactants. The addition of an internal standard confirmed that 
~100% of the added PEG remains in solution in intact SLNs, and the low T1/T2 ratio 
found for the 3.6 ppm NMR peak indicated that it had high molecular mobility, 
correlating well with the expected surface localization of PEG.  
 
To determine the physical state (e.g., crystalline vs. amorphous) of the solid phase, DSC 
and PXRD were performed. Changes in the crystalline nature of the SLNs were analyzed 
by DSC by monitoring for shifts in melting point and enthalpy from the raw materials. 
The crystallinity index can be determined by dividing the peak enthalpy of a processed 
material by that of the raw material in order to quantify the extent of crystallinity. 
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However, this calculation is not appropriate if the material forms a new phase not seen in 
the pure components (i.e., if it has formed a eutectic with another material or if it has 
undergone a polymorphic conversion).   
 
DSC indicated that SLNs had reduced melting points as compared to the starting 
materials. A series of samples were used to evaluate the effects of the preparation 
procedure and the interactions among the SLN components in the bulk state.  While the 
preparation procedure was shown to play some role in reducing the SLN melting points, 
the interactions among the formulation components appeared to be the primary 
contributors. The three samples showing the most complex thermograms (SA-Brij
®
 78, 
SA-PEG6000MS, and Brij
®
 78-PEG6000MS) were chosen for further study to confirm 
that no changes were occurring that would prohibit calculation of the crystallinity index. 
Specifically, phase diagrams covering the entire range of molar combinations were 
constructed for each mixture. It should be noted that the phase diagrams were obtained by 
observing phase transitions with measurable enthalpy changes, and are unlikely to 
identify all phase transitions that may exist in these mixtures.   
 
The Brij
®
 78-PEG6000MS mixture was chosen for further study because of the additional 
peak observed intermediate between those of the individual components. This was 
assumed to be attributable to a new phase developed based on the interactions between 
the two materials. Based on their similar structures, it might be expected that these 
interactions would be significant. However, the peak was relatively small in comparison 
to the other two peaks (10-20% of the enthalpy of the Brij
®
 peak), and it was of interest 
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to see how this would change with other proportions. The phase diagram indicated that 
this peak remains small and is only present at 10-30 mole % PEG6000MS. At most 
concentrations, the materials exist as two separate phases. The lack of interaction may be 
of some concern if it leads to the presence of multiple nanoparticle populations. Based on 
the above DLS and TEM data, this does not appear to be the case, but the possibility 
cannot be eliminated.  
 
The other two mixtures chosen for study were those of SA with Brij
®
 78 and SA with 
PEG6000MS. The SA-Brij
®
 78 mixture was chosen because of the large reduction in the 
SA melting point observed as compared to the starting material. The phase diagram for 
this mixture revealed that a eutectic was formed at 30-40 mole % SA. This prevents the 
calculation of crystallinity indices from the peak enthalpies because the peaks no longer 
represent a single component that can be compared to the starting materials. The SA-
PEG6000MS (92.21 mole% SA) mixture was chosen because of the presence of multiple 
peaks and the large reduction in the SA melting point. The phase diagram indicated that 
at most temperature and concentration combinations, both PEG6000MS and an SA-
PEG6000MS mixed phase exist. Thus, while the initial analysis indicated that SA 
crystallinity was reduced in the SLNs, the in-depth study revealed that SA is actually 
present in several different forms within the SLNs.  
 
An additional drop in the melting point was observed on going from the complete 
mixtures to the SLNs (50.13°C to 48.50°C for formulation 1 and 51.20°C to 49.86°C for 
formulation 2). Three possible explanations were considered for this. The first was the 
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presence of water in the freeze-dried SLNs. The water content was shown to be ~1% 
based on a Karl Fischer titration. Using this value, it was calculated that there could be up 
to 1 molecule of water per 6 molecules of SA if the water was present in the lipid core of 
the particles. This would potentially decrease the lipid melting temperature. However, it 
seems more likely that most of the remaining water would be associated with the 
hydrophilic PEG shell of the particles and would only minimally impact the lipid melting.   
 
The second possible explanation was the Kelvin Effect, which describes why smaller 
particle sizes result in lower melting temperatures [177]. Numerous studies exist that 
have demonstrated this to play a role in the melting of SLNs
 
[178-180]. This effect can be 
approximated using the Gibbs-Thomson equation [177]: 
  
 
  
    
      
      
 
Assuming an interfacial surface tension, γsl, in the range of 10
-2
 – 10-3 mN/m (common 
for microemulsions, [131]), a specific volume, Vs, of the solid of 1.23 cm
3
/g, a radius, r, 
of 45 nm (for formulation 2 SLNs), and a ΔHfus of 210 J/g (bulk SA value from DSC), a 
T/T0 ratio of ~0.999 was calculated. Multiplying this by the SA melting temperature 
found in the SA-Brij
®
 78-PS60-PEG6000MS combination, a reduced temperature of 
51.15°C would be expected, which is higher than the experimental value obtained.  
However, as this is only an approximation, the actual effect may be larger. 
 
The presence of a different polymorph represented a third possible explanation for the 
observed results. The β-form of SA is known to have a lower melting point than the γ-
form [167]. In order to elucidate whether the third explanation was a possibility, two 
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additional studies were performed. SLNs were compared to DSC thermograms of the 
mixtures that had undergone a cooling phase designed to introduce the metastable β-form 
of SA. Additionally, powder X-ray diffractograms of the freeze-dried SLNs were 
compared to those of the starting materials. Although it was difficult to conclude that the 
β-form of SA was absent, it did not appear to be the primary crystalline polymorph of SA 
present. As such, it seems likely that the small particle size of SA in the SLNs and the 
presence of water in the samples are the main contributors to the reduction in the SLN 
melting point. 
 
Based on these results, it appeared that the SLNs under consideration have promise as a 
drug delivery system. The interactions among the components may lead to the decreased 
crystallinity desirable for high drug loading capacities [35], a goal of SLN research. For 
instance, liquid lipids have been added to solid lipids to generate lipid matrices with 
multiple defects. These so-called nanostructured lipid carriers have shown enhanced drug 
loading [143, 181, 182]. Nanotemplate engineered SLNs with an appropriate formulation 
may be able to attain a similar result. On the other hand, there may be cause for concern 
in terms of the stability of the SLNs.   The proximity of the low melting point of the SA-
Brij
®
 78 eutectic (38-40°C) to physiological temperatures may lead to a disruption of the 
particle structure under in vivo conditions. Enhanced mobility of the SLN components 
may allow for crystallization, causing changes in particle size or drug release profiles. 
Alternatively, it may decrease protection for biologically sensitive compounds (e.g., by 
making them susceptible to enzymatic attack). This was of particular concern with 
formulation 1 SLNs in which there is a higher concentration of Brij
®
 78 than in 
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formulation 2, possibly leading to a higher proportion of SA present in this low melting 
form. Analysis of the SLN DSC thermograms (Figure 4.6) furthered this concern, as the 
SA-Brij
®
 78 eutectic peak was considerably more prominent in the formulation 1 SLNs 
than in the formulation 2 SLNs. 
 
However, the question remained as to whether the bulk properties adequately represent 
the situation observed in nanoparticles. In order to determine this, growth curves were 
constructed for the SLNs at a variety of temperatures. At the temperature where the SLNs 
melt or partially melt, it might be expected that there would be a transition in their growth 
curves if growth is due to Ostwald ripening as has been proposed [34]. Particle size 
increased with time at all temperatures; higher temperatures led to higher growth rates. At 
65°C and 70°C, formulation 1 and formulation 2 SLNs, respectively, became completely 
destabilized, preventing determination of a growth curve. In plotting the growth rates for 
the formulation 1 SLNs at lower temperatures, a break point was observed at the critical 
temperature of 35.2°C. If figure 4.6 is referenced, it can be observed that this corresponds 
approximately with the onset of melting of the SA-Brij
®
 78 eutectic, indicating that a 
portion of SA is present in this form even if the composition is different from that 
observed in the bulk state. While the low critical temperature (below 37°C) observed with 
these SLNs confirms that physiological stability may, in fact, be a problem for these 
particles, it also provides an important result in that it validates the assessment of the bulk 
properties of materials used in SLN preparation as a means of anticipating and/or 
understanding the interactions occurring within nanoparticles.  
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The critical temperature for the formulation 2 SLNs was higher, at 43.0°C. This 
corresponds approximately with the onset of melting of SA alone, indicating that little to 
no SA is present in the low melting eutectic form in these SLNs. As such, these SLNs are 
expected to exhibit considerably higher stability than formulation 1 SLNs under 
physiological conditions.  
 
4.5. CONCLUSIONS 
Nanotemplate engineered SLNs were shown to exhibit desirable properties for a drug 
delivery system. Both formulations were of a small particle size (<100 nm), ellipsoidal 
shape, and low polydispersity.
 1
H-NMR spectroscopy confirmed that the SLNs have the 
expected solid core structure and PEGylated surface. Analysis of the bulk materials 
indicated that a number of complex interactions are present among the SLN components, 
including the formation of a SA-Brij
®
 78 eutectic and a mixed SA-PEG6000MS phase. 
The decreased crystallinity resulting from these interactions may allow for enhanced drug 
loading. However, physiological stability was identified and confirmed as a potential 
problem due to the low melting point of the eutectic. For this reason, formulation 2, in 
which PEG6000MS is present and the amount of Brij
®
 78 in the formulation is reduced, 
was chosen as the primary formulation for future studies.  
 
 
*Reprinted with permission from Howard, M. D.; Lu, X.; Rinehart, J. J.; Jay, M.; 
Dziubla, T. D., Physicochemical Characterization of Nanotemplate Engineered Solid 
Lipid Nanoparticles. Langmuir 2011, 27, (5), 1964-1971. Copyright © 2011 American 
Chemical Society.  
 
Copyright © Melissa Howard 2011  
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Chapter 5 
A Comparative Study of the Extent and Mechanism of Drug Loading in Solid Lipid 
Nanoparticles 
 
5.1. INTRODUCTION 
SLNs are a versatile drug delivery system capable of carrying both hydrophobic and 
hydrophilic small molecule drugs [131] as well as proteins [183], DNA [184], and 
contrast agents [185, 186]. Of these, hydrophobic small molecules have been studied 
most extensively.  Numerous drugs, including doxorubicin [161], cyclosporine [187], and 
coenzyme Q10 [163, 188] have been successfully loaded into SLNs. Three main models 
are typically used to describe drug incorporation: 1) a solid solution model, 2) a core-
shell model with a drug-enriched shell, and 3) a core-shell model with a drug-enriched 
core [34]. While these are useful for explaining obtained results (e.g., drug release), it can 
be difficult to predict and/or optimize how drug will be incorporated into the particles and 
to what extent. 
 
Systematic studies considering the effects of lipid and surfactant composition have shed 
some light on how these parameters affect drug loading. For instance, the use of complex 
glycerides in lieu of pure glycerides can allow for higher drug loading due to their lower 
crystallinity [138]. An increase in the monoglyceride content of the lipid phase was 
shown to accelerate drug release; this was attributed to the ability of the monoglycerides 
to act as a surfactant and allow more drug to reside at the particle surface [153, 189]. 
High surfactant concentrations have also led to a burst release of drugs for a similar 
reason [190]. Our current understanding of how the physicochemical properties of the 
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drug itself influence drug loading is more limited. Most reports on drug loading into 
SLNs have focused on the optimization of a system for a specific drug [149, 168]. 
Although a number of drugs have been reported to be loaded into SLNs, it can be 
difficult to compare them across different formulations and preparation methods.   
 
Only recently has SLN research been directed toward gaining a better understanding of 
how the physicochemical properties of drugs are a determinant of how and to what extent 
they are loaded into nanoparticles. Advancements in technologies like electron 
paramagnetic resonance (EPR) [191] and paraelectric spectroscopy [192] have allowed 
for the determination of the location of probe structures within SLNs. Other studies have 
attempted to systematically vary drug lipophilicity and determine the effect on drug 
loading [153, 193]. In general, drug loading has been shown to increase with 
lipophilicity. Further, enhanced lipophilicity tends to slow drug release as a result of 
better incorporation in the lipid matrix of the nanoparticles. However, as the lipophilicity 
is typically increased through the addition of hydrophobic side chains that may align with 
SLN lipids, it may be difficult to discern whether changes are primarily associated with 
the change in drug lipophilicity or structure.  
 
In our own studies, we found that the use of Dex-P , a lipophilic ester prodrug of Dex, in 
SLNs was able to enhance drug loading and slow drug release as compared to Dex itself 
[35]. As with other nanoparticle systems, it was difficult to discern whether this was 
primarily associated with the increased lipophilicity of the compound or whether it was 
due to the palmitate side chain aligning with the SLN lipids. A conformational analysis of 
76 
 
the packing of Dex-P into liposomes showed that Dex was likely oriented toward the 
aqueous phase, interacting with the phospholipid head groups, while the palmitate chain 
was aligned with the acyl chains of phospholipids [194]. It was expected that Dex-P may 
align similarly in SLNs composed of a SA lipid phase and stabilized by PS60, Brij
®
 78, 
and PEG6000MS. This theory was supported by the apparent cleavage of Dex from the 
SLNs by the action of CE enzymes [37]. 
 
This section was focused on further evaluating the extent and mechanism of loading of 
Dex-P into the SLNs as well as on determining how drug loading affects the 
physicochemical properties of the SLNs. For comparison, two additional drugs, AP and 
curcumin, were chosen for study. Structures and relevant physicochemical properties of 
these compounds are given in Figure 5.1. Both have previously been loaded into SLNs by 
other groups [195, 196]. AP was chosen because it is a prodrug with the same palmitate 
side chain present in Dex-P. However, as ascorbic acid (AA) is considerably more 
hydrophilic than Dex, loading of AP should be primarily dependent on the palmitate 
moiety. Curcumin was chosen for study because it is lipophilic but characterized by a 
different structure with no hydrophobic side chains. SLNs were prepared with the three 
drugs of interest at loadings of 10-30% w/w SA (0.16-0.48 mg/ml drug in comparison to 
1.6 mg/ml SA). Encapsulation efficiency (amount of drug associated with particles/added 
drug) was determined, and drug loaded particles were assessed for their size, shape, and 
core-shell structure. Interactions between the drugs and the nanoparticle components 
were analyzed in order to better understand how the drugs were loaded into the SLNs. 
Finally, drug release from the SLNs was monitored.  
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Figure 5.1. Structures of Dex-P, AP, and curcumin. MW was calculated by 
ChemDraw. LogP and aqueous solubility values were taken from the literature 
(References: Dex-P [197], AP [198-201], Curcumin [202-205]). Melting temperatures 
(Tfus) were determined by DSC.  
 
 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials. SA and polysorbate 80 were obtained from Spectrum Chemicals and 
Laboratory Products (Gardena, CA). PS60 and Brij
®
 78 were purchased from Uniqema 
(Chicago, IL). PEG6000MS was a gift from Stepan (Northfield, IL). AP, curcumin, 
deuterium oxide (D2O), acetonitrile (ACN), methanol (MeOH), and D-Salt 
Polyacrylamide 6000 desalting columns were purchased from Fisher Scientific 
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(Pittsburgh, PA). Dex (USP) was a gift from Pfizer (Kalamazoo, MI). Palmitoyl chloride 
and Float-A-Lyzer G2 dialysis tubes (1 mL, 100 kD) were from Sigma-Aldrich (St. 
Louis, MO). Phosphate buffered saline (PBS) was purchased from Invitrogen (San Diego, 
CA). Water was from a Milli-Q Synthesis ultrapure water system (Millipore; Billerica, 
MA). Centrifugal filter devices (Microcon YM-10) were purchased from Millipore.  
 
5.2.2. Synthesis of Dex-P. The procedure to prepare Dex-P has previously been 
reported [35]. In brief, 300 mg Dex was dissolved in 12 mL pyridine followed by a 
dropwise addition of 578 mg palmitoyl chloride. The mixture was stirred in the dark 
under nitrogen for 24 h. Nitrogen was used to evaporate the solvent, and the product was 
dissolved in dichloromethane prior to loading onto a 30 mL silica gel column. Elution of 
the column with a dichloromethane to dichloromethane:ethyl acetate (6:4 v/v) gradient 
was used to isolate the purified product. The reaction progress was monitored using silica 
gel thin layer chromatography (TLC) with a chloroform:ethyl acetate (7:3) mobile phase. 
Retention factor values were 0.10 and 0.69, for Dex and Dex-P, respectively. 
 
5.2.3. SLN Preparation. SLNs were prepared using the nanotemplate engineering 
method [131]. The process used in this study consisted of 1) melting an appropriate 
mixture of lipids, surfactants, and drug at 70°C, 2) adding an aqueous phase to generate 
an oil-in-water microemulsion, and 3) cooling the microemulsion to room temperature to 
form a suspension of SLNs.  PBS was used as the aqueous phase of the microemulsion 
for all studies except the NMR studies, in which D2O was substituted. Blank SLNs (with 
no added drug) consisted of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij
®
 78, and 
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3.0 mg/mL PEG6000MS. For drug loaded SLNs, Dex-P and curcumin were added to the 
original mixture at 10, 20, or 30% w/w SA. As AP was degraded in a concentration-
dependent manner during the preparation process, presumably largely as a result of 
oxidative reactions [206], the amount added initially was adjusted in order to give final 
drug loads of 10, 20, or 30% w/w SA (correction equation: actual load = 1.18*expected 
load - 10.4).  
 
5.2.4. Drug Loading and Encapsulation Efficiency. HPLC was used to determine the 
concentration of drug loaded in the SLNs.  The following conditions were used for Dex-P 
analysis: Alltech C18 column (5 μm, 250 mm×4.6 mm), 95:5 ACN:H2O mobile phase 
run at 2 ml/min, and UV detection at λ=240 nm. AP was analyzed using the following 
parameters: Alltech Nucleosil C18 column (5 μm, 150 mm×4.6 mm), 75:10:15:0.1 
MeOH:ACN:20 mM PBS:TFA  mobile phase run at 1 ml/min, and UV detection at 
λ=254 nm. Analysis conditions for curcumin were as follows: Supelco Discovery C18 
column (5 μm, 250 mm×4.6 mm), 50:50 ACN:H20 mobile phase run at 1 ml/min, and 
UV detection at λ=420 nm. Standard curves for each drug were developed. Samples were 
prepared at 1 mg/ml and diluted with the respective mobile phase to concentrations in the 
range of 10-200 μg/ml. Five concentrations were chosen for each drug, and three separate 
samples were analyzed at each concentration.  
 
Following preparation, each SLN suspension was passed through a 0.2 μm filter: Dex-P 
and AP through nylon membranes and curcumin through polytetrafluoroethylene (PTFE) 
membranes due to its extensive adsorption to nylon membranes. For analysis of the drug 
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concentration in these initial and filtered SLN suspensions, 100 μl of each sample was 
diluted 5x with methanol, and 10 μl were injected on the HPLC column. Filtered Dex-P 
and AP SLNs (300 μL) were then ultrafiltered (Microcon YM-10, 10K MWCO) to 
remove free drug followed by three washes with PBS. Filtrates were directly injected to 
the HPLC column. The amount of free drug present in the filtrates was subtracted from 
the amount present in the filtered SLN suspension; this was compared to the initial 
preparation in order to calculate the encapsulation efficiency.  
 
Due to binding of curcumin to the ultrafiltration membrane, free drug was instead 
removed from these SLNs using a D-salt polyacrylamide 6000 desalting column. Three 
hundred microliters of the filtered curcumin SLN suspensions were loaded to the column; 
PBS was used as the eluent. A strong yellow band was observed to travel through the 
column, allowing for easy collection. This band came off in the void volume of the 
column (as confirmed by blue dextran), providing evidence that it was associated with 
SLNs and not free drug. Further, particle size of the collected sample was analyzed and 
shown to coincide with intact SLNs. Drug concentration of the collected sample was 
determined following a 5x dilution with methanol. After correction for the sample 
dilution that occurs with running the sample through the column, the encapsulation 
efficiency was calculated by comparing this concentration with the concentration present 
in the initial preparation.  
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5.2.5. DLS and TEM. DLS was used to measure particle size.  Samples were diluted 
1:30 with Milli-Q water and analyzed in triplicate at 25°C on a Delsa™ Nano Zeta 
Potential and Submicrometer Particle Size Analyzer (Beckman Coulter Inc., Brea, CA). 
TEM images were used to provide information on the shape of SLNs. One drop (~7 μL) 
of a SLN suspension was incubated for 1.5 min on a carbon-coated TEM grid. The grid 
was then dried and stained (0.2 μm filtered 2% uranyl acetate) for an additional 1.5 min. 
Following 5 min of drying, the grid was imaged using a Philips Tecnai Biotwin 12 
equipped with a Gatan ES 1000W CCD digital camera (FEI, Hillsboro, OR).  
 
5.2.6. NMR Spectroscopy. 
1
H-NMR spectra were obtained for drug loaded SLNs in 
D2O using a Varian 500 MHz NMR (Varian Inc., Palo Alto, CA). Comparisons were 
made with images of blank SLNs previously analyzed [207]. To provide a quantifiable 
means of comparing the different samples, the ratios between the integrals of the main 
aliphatic peak at 1.3 ppm and the PEG peak at 3.6 ppm were calculated.  
 
5.2.7. DSC. DSC analysis was performed on a TA Instruments DSC 2920 (TA 
Instruments, New Castle, DE).  The corresponding TA Instruments Universal Analysis 
software was used to identify peak maxima temperatures. Mixtures of the drugs with the 
SLN components were prepared at the ratios found in SLNs. Dex-P and AP were used at 
10, 20, or 30% w/w SA; curcumin was used at either 10 or 20% w/w SA. Materials were 
melted and mixed at 70°C as in the SLN preparation but without forming an aqueous 
dispersion and then cooled to room temperature. Following preparation, samples were 
allowed to sit for 24 h prior to loading of 5-7 mg in hermetically sealed aluminum pans. 
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Dex-P containing mixtures were run from 25-75°C at a 1°C/min heating rate. AP and 
curcumin containing mixtures were run using the same protocol followed by a 10°C/min 
ramp to 150°C and 250°C, respectively. Comparisons were made with drugs analyzed 
individually as well as with blank mixtures previously analyzed [207]. All measurements 
were performed in triplicate.  
 
5.2.8. Drug Release. SLNs were prepared in PBS with 0.02% Polysorbate 80; the drug 
loading was 10% for all drugs. Following filtration using an appropriate 0.2 μm 
membrane, 1 mL SLNs were loaded into 100 kD Float-A-Lyzer G2 dialysis tubes 
preconditioned in Milli-Q water for 15 min and in PBS with 0.02% Polysorbate 80 for 30 
min and dialyzed against 1 L of the same buffer at 37°C with shaking at 50 rpm.  At 
various time points (0, 1, 3, 6, 24, and 48 h), 100 μL were withdrawn from inside the 
dialysis tube and immediately diluted 5x with MeOH. HPLC assay conditions were as 
described above. To determine if diffusion of the drug across the dialysis membrane was 
a rate-limiting factor, studies were repeated with free drug. Excess drug was added to 
solutions of PBS with 0.02% Polysorbate 80 and allowed to shake for 1 h. Following 
filtration (0.2 μm), samples were loaded into dialysis tubes, and the experiment was 
conducted in the same manner as that used for analyzing release of drug from SLNs. 
GraphPad Prism was used for fitting of the data; single or double phase exponential 
decay profiles were chosen as appropriate. The initial value was fixed at 100% drug 
remaining, and complete drug release was required.  
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5.3. RESULTS 
5.3.1. Drug Loading and Encapsulation Efficiency. Linear calibration curves were 
obtained for all three drugs in the range of 10-200 μg/mL (Figure 5.2). Comparison with 
these showed that SLNs could be loaded with Dex-P or AP at 10-30% w/w SA with 
encapsulation efficiencies >85% (Tables 5.1-5.3). Higher drug concentrations did not 
result in decreased encapsulation efficiencies. Drug loss was predominantly associated 
with removal during the 0.2 μm filtration step. In general, only 1-2% of the drug was 
removed during the ultrafiltration step. In contrast, the encapsulation efficiency for SLNs 
containing 10% curcumin was reduced to approximately 75%, with around 10% being 
removed during the 0.2 μm filtration step and the other 15% removed during the column 
filtration step. Column filtration was required due to adsorption of curcumin to the 
ultrafiltration membrane. 
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Figure 5.2. Calibration curves developed for Dex-P, AP, and curcumin using the 
appropriate HPLC assay (n=3) 
 
Table 5.1. Particle size and encapsulation efficiency data for SLNs loaded with Dex-
P at 10-30% w/w SA. Blank information is taken from [207]. 
 
Drug 
Loading 
Dex-P 
EE (%) Size (nm) PI 
Blank - 89.4±1.9 0.111±0.023 
10% 91.56±4.48 97.7±0.1 0.069±0.027 
20% 86.63±7.54 114.4±10.4 0.096±0.010 
30% 91.77±6.02 132.1±3.1 0.096±0.003 
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Table 5.2. Particle size and encapsulation efficiency data for SLNs loaded with AP 
at 10-30% w/w SA. Blank information is taken from [207]. 
 
Drug 
Loading 
AP 
EE (%) Size (nm) PI 
Blank - 89.4±1.9 0.111±0.023 
10% 91.84±3.86 88.5±3.0 0.069±0.013 
20% 94.28±0.78 84.4±2.8 0.071±.029 
30% 85.88±8.25 84.8±1.2 0.032±0.23 
 
 
Table 5.3. Particle size and encapsulation efficiency data for SLNs loaded with 
curcumin at 10-30% w/w SA. Blank information is taken from [207]. 
 
 Curcumin 
Drug 
Loading 
EE (%) Size (nm) PI 
Blank - 89.4±1.9 0.111±0.023 
10% 74.62±5.05 79.4±0.5 0.078±0.051 
20% 
SLNs not formed 
30% 
 
 
5.3.2. DLS and TEM. The particle size of Dex-P loaded SLNs was shown to increase 
with higher drug loads as determined by DLS (Table 5.1). Analysis of the particle shape 
by TEM indicated that, at 10 and 20% loadings, SLNs retained a similar ellipsoidal shape 
to that observed with blank SLNs (Figure 5.3). However, both rod- and ellipsoidal- 
shaped particles were apparent in the SLNs with 30% Dex-P. The number and length of 
the rod-shaped particles differed from sample to sample.  
 
SLNs loaded with 10% AP were similar in particle size to blank SLNs where loadings of 
20 or 30% AP led to a slight reduction in particle size (Table 5.2). All drug loaded 
particles appeared similar in shape to blank SLNs (Figure 5.3). Inclusion of 10% 
curcumin led to a reduction in the particle size of SLNs by approximately 10 nm (Table 
5.3). Particles also appeared slightly more spherical than blank SLNs (Figure 5.3).  
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Figure 5.3. TEM images of SLNs loaded with Dex-P, AP, or curcumin in 
comparison with blank SLNs 
 
 
 
5.3.3. NMR Spectroscopy. 
1
H-NMR spectroscopy was previously used to confirm the 
core-shell structure of blank SLNs [207]. Comparison of the spectra of solubilized SLNs 
in CDCl3 and intact SLNs in D2O indicated that approximately 90.5% of the aliphatic 
chains of SLNs exist in the solid state with the remaining tightly adsorbed to the 
nanoparticle surface. Further, it was shown that essentially 100% of the added PEG is on 
the surface of SLNs in a flexible conformation. The 
1
H-NMR spectra of all drug loaded 
SLNs in D2O appeared similar; spectra for the Dex-P loaded SLNs are shown in Figure 
5.4. For a quantifiable comparison, the ratio between the integral of the major aliphatic 
peak at 1.3 ppm and the PEG peak at 3.6 ppm was calculated for all samples. Results are 
shown in Table 5.4. Changes were minimal in comparison to blank SLNs. A slight 
increase was observed in AP
20% Dex-P also resulted in an increase, but 30% Dex
PEG peak is expected to remain the same as blank SLNs, the ratio differences are likely a 
result of changes in the 1.3 ppm aliphat
spectra, but this was primarily attributable to the 
 
 
Figure  5.4. 1H-NMR spectra of Dex
of blank SLNs. Spectra for AP and
 
 
 
Table 5.4. Comparison of the 
SLNs in D2O. The 1.3 ppm aliphatic signal and 3.6 ppm PEG signal were integrated, 
and the 1.3 ppm/3.6 ppm ratio was
 
 
Blank 
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 loaded SLNs with increasing drug loading. Loading of 10 or 
-P resulted in a decrease. 
ic peak. Drug-associated peaks were absent in all 
low drug concentrations present.
-P loaded SLNs in D2O in comparison with that 
 curcumin-loaded SLNs appeared similar.
1H-NMR spectra of drug loaded SLNs with blank 
 calculated. 
Sample 1.3 ppm/3.6 ppm 
Blank 0.0868 
 
10% Dex-P 0.1038 
20% Dex-P 0.1012 
30% Dex-P 0.0832 
10% AP 0.0917 
20% AP 0.1034 
30% AP 0.1102 
10% Curcumin 0.0823 
10% 20% 
Since the 
 
 
 
30% 
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5.3.4. DSC. In order to better understand the interactions occurring between the drugs 
and the SLN components, mixtures of each drug with the SLN matrix were prepared and 
thermal analysis was conducted using DSC.  The blank SLN mixture exhibits three peaks 
in the DSC thermogram which were previously shown to be attributable to an SA-Brij
®
 
78 eutectic (38.70±0.09°C), a separate SA phase (51.20±0.11°C), and a SA-PEG6000MS 
mixed phase (58.01±0.14°C) [207]. The thermograms for the mixtures containing drug 
were characterized by similar profiles, although transition temperatures were shifted in 
some cases (Figure 5.5). All three drugs caused a downward shift of the SA-Brij
®
 78 
eutectic peak. However, whereas higher Dex-P and curcumin concentrations resulted in 
greater reductions in the melting temperature, the peak shift was relatively insensitive to 
AP concentration. The SA peak was shown to shift to lower temperatures with increasing 
Dex-P or AP concentrations; the change resulting from the addition of AP was larger than 
that of Dex-P. The addition of curcumin led to an increase in the melting temperature. 
The SA-PEG6000MS peak also showed a downward shift with all three drugs. The 
change was concentration-dependent with AP and curcumin but concentration-
independent with Dex-P. A small left-hand shoulder was also present on the SA peak in 
all cases that was not present in the blank mixtures. This was likely a result of a certain 
proportion of the SA existing in the metastable β-form. Drug-associated peaks were 
difficult to discern in the Dex-P and AP samples. A very broad peak around 200°C was 
present in the mixtures containing curcumin.  
89 
 
 
 
 
 
34.50
35.00
35.50
36.00
36.50
37.00
37.50
38.00
38.50
39.00
10% 20% 30%
T
fu
s,
 S
A
-B
ri
j®
7
8
 e
u
te
ct
ic
Drug Loading
Dex-P
AP
Curcumin
46.00
47.00
48.00
49.00
50.00
51.00
52.00
53.00
10% 20% 30%
T
fu
s,
 S
A
Drug Loading
Dex-P
AP
Curcumin
90 
 
Figure 5.5. Analysis of drug containing mixtures by DSC. Results are separated by 
the three main peaks observed in the thermograms: SA-Brij
®
 78 eutectic, SA, and 
SA-PEG6000MS mixed phase. The peak maxima are given as the melting 
temperatures (Tfus), and the value associated with the blank mixtures is indicated by 
the dotted line.  
 
 
 
5.3.5. Drug Release. Drug release profiles for Dex-P and curcumin loaded SLNs are 
shown in Figure 5.6. AP was shown to be unstable under the conditions of the study, and 
as such, drug release profiles for AP loaded SLNS could not be obtained. In both cases, 
release was characterized by a rapid initial phase followed by a slower secondary phase. 
The data could be fit using two-phase exponential decay curves: Dex-P, y=0.1838e
-0.3793x 
+ 0.8162e
-0.003024x
 ; Curcumin, y=0.3918e
-0.5349x 
+ 0.6082e
-0.0234x
 . However, the release of 
curcumin was considerably faster than that of Dex-P in both phases. At 48 h, drug release 
of Dex-P was <30%, whereas with curcumin it was approximately 80%.  
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To determine the role diffusion of the drug across the dialysis membrane plays in limiting 
the analysis of drug release, studies were conducted using free drug. With both Dex-P 
and curcumin, drug was completely eliminated from within the dialysis tube by the 6 h 
time point. Single exponential decay curves could be used for fitting the data with the 
following results: Dex-P, y=e
-0.7832x
; curcumin, y=e
-0.9510x
 (Figure 5.6).  
 
 
Figure 5.6. Drug release profiles for SLNs loaded with either 10% Dex-P or 
curcumin in comparison with diffusion of free drug across the dialysis membrane. 
The dotted lines represent the fit obtained using either one- or two-phase 
exponential decay equations: SLN-encapsulated Dex-P, y=0.1838e
-0.3793x 
+ 0.8162e
-
0.003024x
 ; SLN-encapsulated Curcumin, y=0.3918e
-0.5349x 
+ 0.6082e
-0.0234x
; free Dex-P, 
y=e
-0.7832x
; free curcumin, y=e
-0.9510x
. 
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5.4. DISCUSSION 
As SLNs have gained popularity as drug delivery systems, there has been increasing 
interest in understanding the parameters that control drug loading. While systematic 
studies have provided information on how the choice of lipids and surfactants as well as 
their concentrations may play a role in determining the extent and localization of drug 
loading, information on how the properties of the drug itself may affect loading remain 
limited. In this study, loading of Dex-P, the drug of interest, was compared with AP and 
curcumin. AP has a structure similar to Dex-P, but the ascorbate functionality is more 
hydrophilic than Dex. Curcumin is lipophilic but has no aliphatic chains that might be 
expected to align with the SLN lipids. In order to better understand how the drugs were 
loaded, the physicochemical properties of drug loaded SLNs (size, shape, and structure) 
and the interactions between the drugs and the SLN components were studied. Drug 
release from the SLNs was also monitored. 
 
Dex-P could be loaded at 10-30% w/w SA with encapsulation efficiencies of >85%; 
precipitation was observed above this concentration. AP could be loaded at even higher 
concentrations; however, for comparative purposes, only the 10-30% drug loading data is 
presented. Encapsulation efficiencies for AP were also >85%. SLNs could not be 
prepared with curcumin loadings greater than 10%. The encapsulation efficiency was also 
lower (~75%) at this concentration.  
 
Interestingly, though both Dex-P and AP exhibit high encapsulation efficiencies, SLNs 
loaded with these two drugs exhibit different properties. While AP loaded SLNs exhibit a 
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particle size similar to or just smaller than blank SLNs, Dex-P loaded SLNs exhibit a 
concentration dependent increase in the particle size, though remaining in the size range 
appropriate for taking advantage of the EPR effect [29]. Particle shape appears similar to 
blank SLNs at all AP concentrations and at low Dex-P concentrations, but at the highest 
Dex-P loading (30%), a transition from ellipsoidal- to rod-shaped particles was observed. 
Based on the NMR studies, the overall solid core and PEGylated surface structure of the 
SLNs appeared to be maintained upon loading of either drug. Increases in the 1.3 
ppm/3.6 ppm ratio are likely indicative of the drug inhibiting recrystallization of the lipid 
to the same extent as observed with blank SLNs and are to be expected.  However, 
whereas this ratio increases in a concentration-dependent manner across the entire range 
of AP loadings, the addition of Dex-P increases the ratio only up to the 20% loading. 
Above this, the ratio is actually shifted lower than that observed with blank SLNs, 
echoing the transition in particle shape.  
 
It was assumed that these differences may be attributable to how the drugs pack within 
the SLNs. By studying how the loading of drug affects the melting temperature of SLN 
component mixtures, information can be gained on drug-matrix interactions. Based on 
the previous modeling studies with Dex-P [129], it seems likely that this drug along with 
AP may reside at the interface of the solid core and PEG shell with the hydrophobic 
palmitate moiety anchoring the drug within the lipid phase. Evidence for this was 
provided in the DSC studies where the addition of Dex-P or AP was shown to decrease 
not only the melting temperature of the SA phase but also one of the SA-surfactant 
phases. 
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On the other hand, the fact that the two drugs predominantly impact the melting of 
different SA-surfactant phases may explain why the drug loaded SLNs exhibit such 
different properties. In the case of AP, there is a concentration-dependent decrease in the 
melting temperature of the SA-PEG6000MS mixed phase with little effect on the melting 
temperature of the SA-Brij
®
 78 eutectic. In contrast, the addition of Dex-P results in a 
concentration-dependent decrease in the melting temperature of the SA-Brij
®
 78 eutectic 
while only minimally affecting the SA-PEG6000MS phase. It is unknown why the drugs 
associate with the SLNs in such distinctly different manners but is likely attributable to 
the hydrophilicity and/or size of the parent drugs.  
 
In contrast to both Dex-P and AP, SLNs could not be formed with curcumin loadings 
>10%, and encapsulation efficiency was lower at this concentration. Though 
1
H-NMR 
spectroscopy indicated that the core-shell structure was maintained, the particle size was 
reduced by approximately 10 nm as compared to blank SLNs. Further, the particles took 
on a more spherical shape than blank SLNs, indicating a possible third drug packing 
mechanism. 
 
In analyzing the DSC results, it appears that curcumin‟s interactions with SA are 
negligible. There was actually a slight increase in the SA melting point instead of the 
decrease observed with Dex-P and AP. Instead, large downward shifts in the melting 
temperatures of both SA-surfactant phases were observed. Based on the apparent 
interactions with both SA-surfactant phases, it may be tempting to conclude that 
curcumin resides within the PEG shell. However, caution must be used in making this 
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conclusion. It is possible that curcumin resides within the interfacial region similarly to 
the Dex and ascorbic acid functionalities but lacks the aliphatic chain that extends into 
the lipid core of the particle. 
 
As a final comparison, drug release from the Dex-P and curcumin loaded SLNs was 
evaluated; AP was unstable under the conditions of the study. Both drug release profiles 
appeared biphasic, demonstrating a burst release within the first 3-6 h of the study 
followed by a slower release over the remaining time period. The burst release may be 
due to an initial rapid diffusion of surface-associated drug from the SLNs, while the 
sustained release may be attributable to drug lost through a particle erosion mechanism. 
This corresponds with the assumed growth due to Ostwald ripening, which relies on the 
exchange of nanoparticle components. Yet, notably, release of curcumin was faster than 
Dex-P in both phases. Whereas nearly 80% of the encapsulated Dex-P remains associated 
with the nanoparticles following the 48 h time period, approximately 80% of the 
curcumin was found to be released. This difference was not associated with the time 
necessary for the drug to diffuse out of the dialysis membrane, as both drugs were 
eliminated from the internal compartment within 6 h. This data is in line with curcumin 
residing within the PEG interfacial region but not being anchored within the solid particle 
core as is assumed to be the case with Dex-P (and AP).  
 
5.5. CONCLUSIONS 
Overall, it appears that Dex-P loaded SLNs can be prepared with high drug loading and 
encapsulation efficiency while maintaining a suitable particle size, shape, and structure. 
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However, due to the presence of multiple particle populations with higher drug 
concentrations, a loading of 10% w/w SA will be used for further studies. Interestingly, 
comparison with AP and curcumin indicated that all three drugs showed different loading 
capacities and mechanisms. Release of Dex-P was shown to be slower than that of 
curcumin, and higher encapsulation efficiencies were achieved for both palmitate 
prodrugs than curcumin despite the fact that all three drugs likely reside at the core-shell 
interface. This was attributed to the ability of the hydrophobic side chains of Dex-P and 
AP to anchor the drugs within solid lipid core of the particles. Yet, even with Dex-P and 
AP, differences in the mechanism of drug packing were observed with corresponding 
changes in the properties of the SLNs.  
 
 
 
 
 
 
 
 
 
 
Copyright © Melissa Howard 2011 
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Chapter 6 
Solid Lipid Nanoparticle Stability in Human Plasma 
 
6.1. INTRODUCTION* 
Preliminary results with Dex-P loaded SLNs indicated a dependence of drug release on 
the CE activity of the surrounding media (Figure 6.1) [37]. In this study, nanoparticles 
were diluted 1:14 with 10% media in PBS and incubated at 37°C.  At certain time points, 
samples were subjected to ultrafiltration, and filtrates were assayed for drug 
concentration (in the form of either Dex-P or Dex). In mouse plasma with high CE 
activity [208],  drug release was rapid, reaching nearly 100% within 24 h. All drug 
assayed in the filtrates was found to be in the form of Dex, indicating that cleavage had 
occurred. Alternatively, in media with negligible CE activity (human plasma [208], 
denatured mouse plasma, mouse plasma treated with BNPP), nearly all drug was retained 
in the retentate and found to be in the form of Dex-P. Drug release was intermediate 
between these two in rat plasma, corresponding well with reported values for CE activity 
in rat plasma as compared to mouse or human plasma [208]. 
98 
 
 
Figure 6.1. Dependence of drug release on CE activity of the surrounding 
environment over a 24 h incubation at 37°C (n=3). Adapted from [37]* 
 
 
If drug release was in fact triggered by CE, it presented both some interesting challenges 
and possibilities. Because of the difference in CE activity between human plasma and 
plasma of typical small animal models (mice and rats), testing this drug delivery system 
in vivo may be problematic as results obtained would likely not be representative of what 
would be observed in humans. Carboxylesterase-deficient Es1e(-/-)/SCID mice were 
considered as a potential alternative. Although drug release remained higher than that 
seen with human plasma (Figure 6.1), it was closer than that observed with mice or rats, 
indicating that these animals may serve as a model more closely representative of the 
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human situation. On the other hand, this enzymatically-triggered drug release may 
provide a mechanism for controlling drug release at the tumor site based on the higher 
CE activity levels found in human tumors than in human plasma [209, 210]. Drug may 
remain stably entrapped in SLNs while in circulation and then be triggered to rapidly 
release upon extravasation into tumors. To test this, drug release was tested in A549 
human tumor xenografts that were removed from mice and homogenized (Figure 6.1). 
Approximately 78% of the drug was released within 24 h, and again, nearly all was in the 
form of Dex. To determine if any of this release was attributable to mouse plasma 
remaining in the homogenate, an additional study was performed using an A549 cell 
lysate. Release was similar at 24 h (Figure 6.2), confirming that drug release may be 
accelerated in human tumors over human plasma. 
 
Figure 6.2. Accelerated drug release from SLNs incubated at 37°C for 24 h in 
homogenized  human tumor xenografts or human tumor cell lysates as compared to 
human plasma  (n=3). Adapted from [37]* 
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However, the caveat to this study was that it was difficult to differentiate between drug 
retained in SLNs and drug associated with plasma proteins. It was considered possible 
that Dex-P was “released” from the SLNs (either due to partitioning out of the SLNs or to 
general SLN instability) but remained associated with plasma proteins that would prevent 
its filtration. Enzymatic cleavage may then take place at the protein surface, generating 
free Dex that may be filtered. This is shown schematically in Figure 6.3. As such, it was 
important to show 1) that the SLNs remained intact and 2) that Dex-P remained stably 
associated with the SLNs in conditions mimicking human plasma in order to confirm the 
CE-dependent drug release.  
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Figure 6.3. Potential mechanisms of drug release from SLNs. Top: Dex is 
enzymatically cleaved from surface of SLNs. Middle: Dex-P partitions out of intact 
SLNs onto plasma proteins prior to enzymatic cleavage. Bottom: SLNs are unstable 
in the presence of plasma proteins, leading to adsorption of Dex-P onto the surface 
of plasma proteins prior to enzymatic cleavage.  
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6.2. MATERIALS AND METHODS 
6.2.1. Materials. SA was from Spectrum Chemicals and Laboratory Products (Gardena, 
CA). PS and Brij
®
 78 were products of Uniqema (Chicago, IL). PEG6000MS was a gift 
from Stepan (Northfield, IL). Tritiated dexamethasone [6,7-
3
H(N)] (specific activity = 
35-50 Ci/mmol) was purchased from American Radiolabeled Chemicals (Saint Louis, 
MO). PBS was obtained from Invitrogen (San Diego, CA). Centrifugal filter devices 
(Microcon YM-10) were purchased from Millipore (Billerica, MA). Human plasma 
containing sodium heparin as the anticoagulant was purchased from Innovative Research, 
Inc. (Novi, MI). HSA (96-99%) was a product of Sigma-Aldrich (St. Louis, MO). Liquid 
scintillation cocktail (Optiphase HiSafe3) was purchased from PerkinElmer (Waltham, 
MA). 
 
6.2.2. Synthesis of Dex-P. Dex-P was prepared as previously described [35]. Briefly, 
300 mg Dex was dissolved in 12 mL pyridine. Palmitoyl chloride (578 mg) was added 
dropwise to this solution. The mixture was stirred in the dark under nitrogen for 24 h. The 
solvent was removed by nitrogen, and the product was dissolved in dichloromethane for 
loading onto a 30 mL silica gel column. A dichloromethane to dichloromethane:ethyl 
acetate (6:4 v/v) gradient was used to elute the purified product. The reaction progress 
was monitored using silica gel TLC with a chloroform:ethyl acetate (7:3) mobile phase. 
Retention factor values were 0.10 and 0.69, for Dex and Dex-P, respectively. For the 
preparation of radiolabeled Dex-P, 
3
H-Dex was used in place of Dex. 
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6.2.3. SLN Preparation. SLNs were prepared using the nanotemplate engineering 
technique as reported previously [131]. Basically, the process consisted of three steps: 1) 
melting an appropriate mixture of lipids and surfactants (and drug in the case of drug-
loaded SLNs), 2) adding PBS to generate an oil-in-water microemulsion, and 3) cooling 
the microemulsion to room temperature in order to generate the SLNs. Blank SLNs with 
a formulation of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij
®
 78, and 3.0 mg/mL 
PEG6000MS were used for particle size, shape, and turbidity analyses. A second 
formulation (2.0 mg/mL SA, 0.5 mg/mL PS60, 3.5 mg/mL Brij
®
 78, 3.5 mg/mL 
PEG6000MS, and 0.2 mg/mL Dex-P/
3
H-Dex-P) was used for the SEC studies and for the 
evaluation of the stability of the Dex-P association with SLNs.  
 
6.2.4. SLN Stability – Physiological Temperature and pH  
6.2.4.1. Temperature Effect. Samples were incubated at either 4°C or 37°C. At each 
time point (0, 1, 3, 6, and 24 h), 30 μL were removed and diluted to 1 mL with 0.2 μm 
filtered water. Particle size analysis was performed in triplicate at 25°C on a Delsa™ 
Nano Zeta Potential and Submicrometer Particle Size Analyzer (Beckman Coulter Inc., 
Brea, CA). Following the final time point, samples were collected for TEM imaging. One 
drop (~7 μL) of a SLN suspension was incubated for 1.5 min on a carbon-coated TEM 
grid. The grid was then dried and stained (0.2 μm filtered 2% uranyl acetate) for an 
additional 1.5 min. Excess stain was removed, and the grid was allowed to dry for 5 min. 
Images were obtained using a Philips Tecnai Biotwin 12 equipped with a Gatan ES 
1000W CCD digital camera (FEI, Hillsboro, OR).  
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Three samples were analyzed per temperature, and a minimum of five images were taken 
per sample at different locations on the grid. Images were analyzed using ImageJ
 
[164]. 
The lengths of both the major and minor axes were obtained using the manual analytical 
tools. Assuming a prolate spheroid shape for the ellipsoid where the minor axis is the 
same in the x and y directions, the volume of an ellipsoid with these dimensions was 
calculated using the following equation:  
       
 
 
             
  
where r is the radius of the relevant axis. Using this value as the volume of an equivalent 
sphere, the approximate particle diameter was calculated: 
          
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
In order to apply a quantitative measurement to the particle shape analysis, the aspect 
ratio for the particles was calculated by dividing the length of the major axis by that of 
the minor axis. These calculations were performed for 20 particles per image, giving a 
total of 100 measurements per sample. The average measurement for each sample was 
used in calculating the average and standard deviation for particles stored at each 
temperature. The PSD was also calculated using the following equation: 
        
          
      
       
 
   
 
where si represents the standard deviations obtained from each individual sample of 100 
particles, ni represents the sample size (i.e., 100 for all 3 samples), and k represents the 
number of samples (i.e., 3). This differs from the standard deviation calculated above 
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which represents the variability in the average size obtained from the three samples and is 
used primarily as a measurement of the homogeneity of the size distribution (comparable 
to the PI values obtained by DLS).  
 
6.2.4.2. Size Recovery. SLNs were incubated at 37°C for 24 h. Following a return to 
refrigerated (4°C) conditions, samples were removed for measurement of the particle size 
at 0, 1, 3, 6, 25, 50, and 168 h. DLS analysis was performed as described above (n=3). 
 
6.2.4.3. Concentration Effect. SLNs were diluted 10-fold or 30-fold with PBS. These 
SLNs along with SLNs at the original prepared concentration were incubated at 37°C for 
24 h. DLS particle size measurements were performed at 0, 1, 3, 6, and 24 h (n=3). For 
consistency among the samples, all samples were diluted with PBS as necessary to 
achieve a 30-fold dilution from the original concentration prior to analysis.  
 
6.2.5. SLN Stability – Human Plasma Proteins 
6.2.5.1. Size and Shape of SLNs in Human Plasma. SLNs were diluted 1:14 (v/v) with 
a 10% human plasma solution in PBS. Following incubation at 37°C, 30 μL were 
removed and diluted to 1 mL with 0.2 μm filtered water for particle size analysis by DLS. 
TEM images were obtained after a 24 h incubation, using similar methods to those 
described above with the exception of an additional 5-fold dilution with water prior to 
grid preparation.  
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6.2.5.2. Size and Turbidity of SLNs with HSA. To replicate a 10% human plasma 
solution, HSA was dissolved in PBS at a concentration of 5 mg/mL. SLNs with and 
without HSA were incubated at 37°C with shaking at 100 rpm. At each time point (0, 1, 
3, 6, and 24 h), 500 μL aliquots were removed. Four hundred and seventy microliters 
were used in assessing the turbidity [determined by the absorbance of the suspensions at 
350 nm as measured by a Beckman DU 7500i Spectrophotometer (Beckman Coulter Inc., 
Brea, CA)] (n=3). The remaining 30 μL were diluted to 1 mL using 0.2 μm filtered water, 
and DLS particle size measurements were obtained as described above (n=3).  
 
6.2.5.3. SEC of SLNs with HSA. A Shimadzu Prominence Ultra Fast Liquid 
Chromatography (UFLC) system equipped with a gel filtration-HPLC column, TSK-GEL 
G 3000 SW (7.5 mm i.d. x 30 cm) and coupled to a diode array detector was employed to 
separate SLNs from HSA. SLNs were mixed 1:1 with a 10 mg/mL HSA solution in PBS 
and incubated at 37°C for 2 h. The mixture at time 0 and 2 h, HSA solution (2x diluted 
with PBS), and SLNs (2x diluted with PBS) were injected onto the column with an 
injection volume of 20 μL. The elution was monitored at 280 nm (HSA λmax). 
 
6.2.6. Stability of Dex-P Association with SLNs. All radioactivity measurements were 
performed using a Tri-Carb liquid scintillation counter (LSC; PerkinElmer). For the 
determination of the protein binding of Dex-P in human plasma, 0.5 mg Dex-P/
3
H-Dex-P 
were mixed with 2 mL of human plasma and incubated at 37°C for 24 h (n=2). The 
mixture was filtered through a 0.2 μm filter (referred to as MF filtrate), and 100 μL of 
each MF filtrate was measured for radioactivity. An additional 300 μL of each MF filtrate 
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were ultrafiltered, and 50 μL of the UF filtrate measured for radioactivity. Using this 
data, the percentage of free drug in human plasma was calculated; this is referred to as 
the protein unbound ratio. Binding of Dex-P to the ultrafiltration membrane under these 
conditions was determined by collecting 200 μL of the UF filtrate and refiltering it 
through a new membrane. One hundred microliters of the second filtrate were assayed for 
radioactivity. The loss of radioactivity in the second UF filtrate as compared to the first 
was considered due to the binding of the drug to the membrane.  
 
3
H-Dex-P labeled SLNs were mixed with 50% human plasma (1:14 dilution, v/v) and 
filtered through a 0.2 μm filter. The loss of radioactivity at this stage was assumed to be 
due to the precipitation of any drug aggregates. Two hundred microliters of the MF 
filtrate were then ultrafiltered as described above, and the UF filtrate was analyzed for 
radioactivity. The percent Dex-P associated with the SLNs (% SLN associated) was 
calculated using the equation: 
                                  
                
                     
 
This process was repeated following either a 2 or 24 h incubation at 37°C, and 
comparisons were made with SLNs in PBS alone.  
 
6.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent 
measurements. For comparison of two samples, t-tests (paired two sample for means) 
were used. Groups of 3 or more were compared using analysis of variance (ANOVA) 
one-way test with SigmaStat 3.5 software (Systat Inc., San Jose, CA). Differences were 
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considered statistically significant when P<0.05, and the Holm-Sidak method was used to 
perform pairwise multiple comparisons on significant effects and interactions. 
 
6.3. RESULTS AND DISCUSSION** 
6.3.1. SLN Stability – Physiological Temperature and pH. The initial studies in this 
section were focused on evaluating the stability of the SLNs. Although the Dex-P release 
study discussed in the previous chapter indicated that SLNs likely remained intact in the 
presence of physiological temperature and pHs, further studies were conducted to 
evaluate size and shape changes. SLNs prepared in PBS were initially monitored for 
time- and temperature-dependent changes in size and shape. As determined by DLS, 
SLNs incubated at 37°C were shown to increase in size by approximately 40 nm within a 
24 h time period, whereas the particle size of SLNs stored at 4°C remained approximately 
the same (Figure 6.4).  
 
Figure 6.4. Time- and temperature-dependent growth of SLNs (n=3) 
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SLNs stored at either 4°C or 37°C for 24 h were also analyzed by TEM. Visually, the 
SLNs appeared to be similar in shape, and there was no significant difference (P>0.05) in 
the calculated aspect ratios. Particle size results obtained using this method were 
consistent with the DLS results, again showing a difference of approximately 40 nm 
between SLNs at 4°C and 37°C (Figure 6.5, Table 6.1). As in the previous chapter, the 
actual values obtained using TEM were slightly larger than those obtained with DLS. 
This may be attributable to the assumption of spherical particles inherent in the DLS 
calculations. Overall, no evidence for disassociation of the SLNs was observed, and the 
particles remained within the size range (<200 nm) deemed suitable for tumor-targeting 
via the EPR effect [29]. 
 
Figure 6.5. TEM images of SLNs stored for 24 h at either 4°C (left) or 37°C (right) 
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Table 6.1. Particle size, PSD, and aspect ratio of SLNs stored at either 4°C or 37°C 
for 24 h as calculated from analysis of TEM images (n=3) 
 
Temperature (°C) Particle Size (nm) PSD (nm) Aspect Ratio 
4 92.9±3.7 16.4 1.30±0.02 
37 131.8±5.0 43.7 1.29±0.02 
 
 
Additional studies were focused on elucidating the mechanism of particle size growth. As 
an initial test, SLNs were returned to 4°C following a 24 h incubation at 37°C and 
monitored for size changes. Over a seven day period, SLNs did not exhibit any size 
recovery, indicating that growth was not attributable to any temperature-dependent 
swelling process (Figure 6.6).  
 
Figure 6.6. Particle size of SLNs stored at 4°C following a 24 h incubation at 37°C 
(n=3) 
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been used to explain growth of SLNs [33]. The driving force is the higher surface energy 
and correspondingly higher solubility of the smaller particles in comparison to larger 
particles, as described by the Kelvin equation [211].  Small particles dissolve, generating 
a supersaturated solution with respect to the large particles, and the dissolved species then 
redeposit on the surfaces of larger particles. To test this theory, the data was fit using 
appropriate equations describing Ostwald ripening. The process can be divided into two 
steps: 1) diffusion of the solute molecules and 2) interface-controlled growth 
(detachment/attachment of the solute molecules to and from the particle surface) [212]. 
Interface-controlled growth can occur through continuous growth, surface nucleation, or 
spiral growth. The process can be rate-limited by either step. In the case of diffusion-
controlled growth or interface-controlled growth occurring through continuous or spinal 
growth, the data can be fit using  
     
     
where d is the average diameter at time t, d0 is the average diameter at time t=0, and k is 
the growth rate. For diffusion- and spiral growth-controlled processes, the exponent n is 
3, whereas for continous growth processes, the exponent n is 2 [213, 214]. In the case of 
surface nucleation, growth can best be fit using a logarithmic dependence on time: 
              
 
 
  
where τ is a time constant [213]. For our system, the data was non-linear when plotted 
against the log time (Figure 6.7), confirming that, within this time range, growth is not 
likely controlled by surface nucleation. Plots of the cube and square of the mean diameter 
versus time were both, however, reasonably linear (Figure 6.7), preventing a conclusive 
determination of the growth mechanism.  
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Figure 6.7. SLN 37°C growth profiles plotted as the cube of the mean diameter 
versus time (top left), the square of the mean diameter versus time (top right), and 
the diameter plotted versus the log time (bottom) 
 
 
 
To differentiate between the two, an additional study evaluating the effect of particle 
concentration on growth was performed. Dilution of SLNs led to smaller particle size 
increases when SLNs were incubated at 37°C (Figure 6.8), corresponding with 
dissolution-mediated growth. However, it may be that both processes are involved or that 
the mechanism changes over time. It is also notable that because the various components 
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of the SLNs are characterized by different solubilities, they may also display different 
rates of exchange. This may lead to particles having different compositions following 
growth than they did initially, though it is difficult to prove this experimentally. 
 
 
Figure 6.8. Effect of concentration on particle size growth at 37°C (n=3) 
 
6.3.2. SLN Stability – Human Plasma Proteins. SLNs were next evaluated for their 
stability in the presence of human plasma proteins (excepting CE). Following incubation 
with 10% human plasma in PBS, SLNs were analyzed by DLS and TEM. Unfortunately, 
the presence of the plasma proteins obscured the SLN peak in the DLS data. SLNs 
appeared to remain intact in the presence of the plasma as determined by TEM imaging 
(Figure 6.9), but the background resulting from plasma components prevented a 
conclusive analysis.  
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Figure 6.9. TEM images of 10% human plasma with (left) and without (right) SLNs 
 
For this reason, further studies were conducted with HSA as representative of human 
plasma. The particle size growth profiles of SLNs incubated with and without 10% HSA 
were similar across a 24 h study (Figure 6.10), indicating that particles were remaining 
intact without aggregation in the presence of the protein. Only a slight increase in the 
particle size of SLNs incubated with the protein over that of SLNs alone was observed at 
the final time point, which may be attributable to some protein adsorption on the particle 
surface.  
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Figure 6.10. Particle size of SLNs incubated at 37°C with or without 10% HSA as a 
function of time (n=3) 
 
 
 
The turbidity of SLN suspensions was assessed as a second measure of stability. Large 
turbidity increases would be expected with particle aggregation or disassociation (due to 
the insolubility of the lipid phase). Instead, both SLNs incubated with and without 10% 
HSA displayed only minor increases in turbidity over the time period of the study (Figure 
6.11), which could be attributed to the normal particle size growth. Finally, SLNs of a 
similar formulation were incubated with HSA and analyzed by SEC. SLNs were eluted at 
11.2 min, while HSA came off the column later at 15.5 min (dimer) and 17.5 min 
(monomer). Following the initial mixing of SLNs with HSA, the two components eluted 
similarly to their individual SEC profiles (Figure 6.12). After a 2 h incubation at 37°C, 
the SLN peak area was increased slightly from that observed before incubation (P<0.05). 
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with SLNs was so low that no HSA loss was identified on the basis of the HSA peak size. 
Overall, no evidence was seen for SLN instability in the presence of the representative 
plasma protein.   
 
 
Figure 6.11. Turbidity of SLNs (as measured by the absorbance at 350 nm) 
incubated at 37°C with or without 10% HSA as a function of time (n=3) 
 
 
Figure 6.12. SEC profiles for HSA, SLNs, and a mixture of SLNs with HSA before 
and after a 2 h incubation at 37°C (left). Direct overlay of the mixture profiles at 0 
and 2 h (right). Adapted from [197]** 
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6.3.3. Stability of Dex-P Association with SLNs. The final studies in this section were 
focused on confirming the stability of the association of Dex-P with SLNs in the presence 
of human plasma proteins. The drug release studies discussed in the previous chapter 
were conducted under sink conditions, and as such, should represent the drug release that 
would occur in the circulation. However, in addition to this study, other methods were 
considered to specifically evaluate drug partitioning onto plasma proteins. Centrifugation 
at 40,000g for 4 h failed to sediment the SLNs due to the low average density of the 
SLNs (1.05 g/cm
3
). While SEC can be effectively used with individual proteins or 
possibly mixtures of a few proteins, it can be difficult to use with a complex plasma 
sample. As an alternative, a stepwise filtration method was used to determine the stability 
of Dex-P association with SLNs.  
 
It was hypothesized that Dex-P would exist in three forms following incubation with 
human plasma: 1) Dex-P associated with SLNs, 2) Dex-P solubilized in plasma 
(including protein-bound drug), and 3) drug aggregates (unsolubilized drug). The SLN- 
and protein-associated Dex-P would be expected to pass through a 0.2 μm filter, but 
unsolubilized drug would not. Using ultrafiltration (MWCO 10 kD), free drug could then 
be separated from that bound to proteins or associated with SLNs. As the ratio of bound 
to unbound drug is constant when protein concentration is greater than drug 
concentration, determination of the free drug will allow for the calculation of protein 
bound and correspondingly SLN-associated Dex-P.  
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Dex-P was shown to be highly protein-bound (64%) under the conditions used in this 
study; sequential ultrafiltrations led to a loss of approximately 2% of the drug. Using 
these corrections, it was shown that greater than 96% of Dex-P remained associated with 
the SLNs in PBS following a 24 h incubation. When incubated in 50% human plasma, 
this value was reduced to 85.5% due to an increased presence of drug aggregates as well 
as free drug (Table 6.2). Thus, while drug release from the SLNs was slightly accelerated 
in the presence of plasma proteins, Dex-P remained predominantly associated with the 
nanoparticles.  
 
 
Table 6.2. Association of Dex-P with SLNs during a 24 h incubation in PBS or 50% 
human plasma (n=3). Adapted from [197]** 
 
Sample  
Incubation  
time (h)  
Unaggregated  
DEX-P(%) 
a
  
Released  
 DEX-P (%)
 b
  
SLN-associated  
DEX-P (%)
 c
  
SLN in 
PBS  
0  98.4 ± 0.5  0.8 ± 0.5  97.6 ± 0.6  
2  97.8 ± 1.4  1.2 ± 0.2  96.6 ± 1.3  
24  97.8 ± 1.5  1.6 ± 0.1  96.2 ± 1.6  
SLN in 
plasma  
0  98.1 ± 2.3  3.0 ± 0.2  95.2 ± 2.2  
2  98.1 ± 3.0  4.2 ± 0.5  93.9 ± 2.7  
24  93.2 ± 1.2  7.7 ± 0.6  85.5 ± 1.8
*
  
 
a 
calculated from the recovery of DEX-P after microfiltration using a 0.2 µm syringe filter  
b
 calculated from the percentage of DEX-P in the filtrate of ultrafiltration (MWCO: 10 
kDa) and corrected based on 98% membrane recovery and 64% protein binding  
c 
calculated from the following equation, SLN-associated DEX-P (%) = a-b  
* 
Significantly different from 0 and 2 h time points of this sample  
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6.4. CONCLUSIONS 
 
The studies described in this section were designed to confirm the stability of SLNs and 
the retention of Dex-P with the SLNs under conditions mimicking those found in human 
plasma (specifically the absence of CE activity). Although SLNs increased in size by 
approximately 40 nm when incubated for 24 h at physiological temperature, they 
appeared to retain their ellipsoidal shape. This growth may be attributable to Ostwald 
ripening and is unlikely to affect the ability of SLNs to achieve tumor targeting. Analysis 
of SLNs incubated with 10% HSA by DLS, UV/Visible spectroscopy, and SEC indicated 
the possibility of minor protein adsorption on the particles, but no evidence of particle 
disassociation or aggregation was observed. Further, using a multi-step filtration process, 
Dex-P was shown to remain predominantly associated with the SLNs (85.5%) during a 
24 h incubation in the presence of 50% human plasma.  
 
 
 
 
*Portions of the introduction, Figure 6.1, and Figure 6.2 reprinted with kind permission 
from Springer Science+Business Media: AAPS Journal, Nanoparticles Containing Anti-
inflammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug 
Release, 11(1), 2009, 120-122, X. Lu, M.D. Howard, D.R. Talbert, J.J. Rinehart, P.M. 
Potter, M. Jay, M. Leggas, Copyright © 2009 Springer Science+Business Media, LLC.  
 
**Portions of the results and discussion section, Table 6.2, and Figure 6.12 containing 
data from M.D. Howard reproduced with permission from Kim, J-K; Howard, M.D.; 
Dziubla, T.D.; Rinehart, J.J.; Jay, M.; Lu, X., Uniformity of Drug Payload and Its Effect 
on Stability of Solid Lipid Nanoparticles Containing an Ester Prodrug. ACS Nano 2010, 
5, (1), 209-216. Copyright ©2011 American Chemical Society.  
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Chapter 7 
 
Carboxylesterase-Triggered Hydrolysis of Nanoparticle PEGylating Agents 
 
7.1. INTRODUCTION 
The discovery that poly(ethylene glycol) (PEG) can be used as a surface coating to 
increase the circulation lifetime of nanoparticles has unquestionably contributed to the 
growth of research on nanocarrier drug delivery systems [215]. Today, PEG is considered 
a primary component of nearly all nanoparticle drug delivery systems with surfaces being 
coated through a variety of adsorption, grafting, or entrapment techniques [63]. This 
hydrophilic, flexible polymer acts to reduce opsonin adsorption and macrophage uptake, 
delaying removal of the nanoparticles by the RES [71, 85]. The extended circulation in 
turn provides a greater opportunity for the nanoparticles to reach the site of action, most 
notably tumors [216, 217].  
 
Much research has been conducted on how to achieve optimum in vivo results, including 
studying the ideal amount, packing density, molecular weight, and structure of PEG on 
the surface of nanoparticles [63]. However, the other component of achieving optimal in 
vivo results that has been considered less frequently is the stability of the PEG coating. 
The nanoparticle drug delivery systems must not only be appropriately PEGylated upon 
injection, but the PEG coating must remain stably attached to the nanoparticle while in 
the circulation. The paucity of reports in this area may be due in part to the difficulty in 
characterizing PEG itself. PEG lacks a chromophore for UV detection, limiting 
quantitative measurements by traditional methods [218, 219]. Alternatively, as PEG is 
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used to provide stealthiness to nanocarriers, it may be assumed that the PEG cloud 
surrounding the nanoparticle will sufficiently prevent interactions with proteins and 
enzymes that may affect its own stability. 
 
However, recent studies may refute this assumption. PEG has been shown to desorb from 
nanoparticle surfaces in the presence of proteins [114, 220]. Further, the development of 
bioresponsive systems based on sheddable PEG coatings has led to concern over the 
stability of PEG derivatives against hydrolysis. These systems are designed such that 
upon loss of the PEG coating, nanoparticles become destabilized, accelerating drug 
release [221]. While hydrolysis has been triggered by stimuli such as an acidic pH [222] 
and a reducing environment [223, 224], PEG derivatives have also been designed for 
enzymatic cleavage [23, 225]. These are of the greatest concern because they indicate 
that the PEG cloud may not be as impenetrable to proteins as expected, at least in some 
cases, and warrant the study of PEG coatings previously assumed to be stable.   
 
PEG coatings secured by ester linkages are one such example. Many PEGylating agents 
are linked to a lipid moiety through an ester bond; the lipid moiety is inserted into the 
core of the nanoparticle while PEG resides on the surface of the particle. Two of the 
PEGylating agents used in the SLNs under consideration – PS60 and PEG6000MS – are 
a case in point, and it is of interest to know if these SLN components are susceptible to 
hydrolysis in the presence of CE for several reasons (Figure 7.1). On a system-specific 
level, enzymatic degradation of these compounds may help explain the drug release 
results previously obtained. Previous studies have shown that release of ester prodrugs 
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incorporated into the SLNs was dependent on CE activity [37], and while this may be 
attributable to the structure of the specific ester prodrug, hydrolysis of one or both of 
these SLN components may have contributed to the accessibility, and subsequent release, 
of the drug by CE. On a broader level, this knowledge may be used to design systems 
capable of achieving tumor-targeted drug delivery in humans by taking advantage of the 
negligible blood CE activity [208] in comparison to the higher tumor CE activity [37, 
209]. Unfortunately, enzymatic degradation of PEGylating agents may also prevent the 
use of normal animal models for in vivo testing. Mice and rats both have significantly 
higher blood CE levels than humans [208, 226, 227], and studies performed in these 
animals may fail to give results representative of what would be seen in humans. 
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Figure 7.1. CE-catalyzed ester hydrolysis of PS60 (top) and PEG6000MS (bottom)  
 
 
 
7.2. MATERIALS AND METHODS 
 
7.2.1. Materials. SA was obtained from Spectrum Chemicals and Laboratory Products 
(Gardena, CA). PS60 and Brij
®
 78 were from Uniqema (Chicago, IL). PEG6000MS was 
a gift from Stepan (Northfield, IL). PBS was purchased from Invitrogen (San Diego, 
CA). NaOH was obtained from Fisher Scientific (Pittsburgh, PA). NaCl, BNPP, and CE 
(porcine liver esterase, 3.2 M (NH4)2SO4 suspension, 36 mg/ml, 154 units/mg) were 
obtained from Sigma-Aldrich (St. Louis, MO).  Water was used from a Millipore Milli-Q 
Synthesis ultrapure water system (Billerica, MA).  
 
7.2.2. SLN Preparation. SLNs were prepared using NET as previously described [131]. 
In brief, the process consists of three steps: 1) melting an appropriate mixture of lipids 
and surfactants, 2) adding an aqueous phase to generate an oil-in-water microemulsion, 
and 3) cooling the microemulsion to form a suspension of SLNs. For this study, materials 
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were melted at 70°C and cooled to room temperature. The aqueous phase consisted of 
0.9% NaCl or PBS, as appropriate. The primary formulation (formulation 2 SLNs) 
consisted of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij
®
 78, and 3.0 mg/mL 
PEG6000MS; unless specifically noted otherwise, the term “SLN” refers to this 
formulation. Formulation 1 SLNs comprised of 1.6 mg/mL SA, 0.4 mg/mL PS60, and 3.5 
mg/mL Brij
®
 78 were also used in the pH-stat experiments. PS60 (0.4 mg/mL) and 
PEG6000MS (3.0 mg/mL) micelles were prepared using the same process but without the 
addition of a lipid phase.  
 
7.2.3. Turbidity and DLS analysis. As a measure of turbidity, UV absorbance 
measurements were taken at 380 nm using a Beckman DU 7500i Spectrophotometer 
(Beckman Coulter Inc., Brea, CA). Five samples (n=3) were incubated at 37°C in PBS 
with shaking at 100 rpm over a period of 48 h: SLNs, SLNs with CE, SLNs with CE and 
BNPP, CE, and CE with BNPP.  Concentrations of CE (1.86 Units/ml, equivalent of 10% 
mouse plasma [208]) and BNPP (1mM, previously shown to inhibit CE [37]) were kept 
constant for all samples.  At each time point (0, 1, 3, 6, 24, and 48 h), 500 μL aliquots 
were removed for turbidity measurements. PBS dilutions were performed as necessary to 
achieve a signal in the range of 0.2-1.0 absorbance units. The background signal 
associated with CE alone or the CE-BNPP combination was subtracted from the 
respective SLN sample for ease of analysis. An additional 30 μL were removed at each 
time point for measurement of the particle size and PI by DLS. These aliquots were 
diluted to 1 mL using 0.2 μm filtered water. Measurements were performed at 25°C on a 
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Delsa™ Nano Zeta Potential and Submicron Particle Size Analyzer (Beckman Coulter 
Inc., Brea, CA).   
 
7.2.4. TEM. SLNs in PBS were incubated with and without CE (1.86 units/ml) at 37°C 
with shaking at 100 rpm. Samples were removed for TEM imaging at 1 and 24 h. Seven 
microliters of each were incubated for 1.5 min on a carbon-coated TEM grid. The grid 
was dried and stained with 0.2 μm filtered 2% uranyl acetate for an additional 1.5 min 
followed by an additional 5 min of drying. Images were obtained using a Philips Tecnai 
Biotwin 12 equipped with a Gatan ES 1000W CCD digital camera (FEI, Hillsboro, OR) 
and analyzed using the ImageJ processing program [164]. For each sample, five images 
were taken at different locations on the grid and twenty particles were measured per 
image. For each particle, the lengths of both the major and minor axes were obtained 
using the manual analytical tools. The volume of an ellipsoid with these dimensions was 
calculated from these values using the equation for a prolate spheroid (the assumed 
shape): 
       
 
 
             
  
where r is the radius of the relevant axis. This value was used as the volume of an 
equivalent sphere to allow for the calculation of an approximate particle diameter 
according to the following equation:  
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The calculated diameters for the 100 analyzed particles were averaged to provide a mean 
and SD for the particle size.   
 
7.2.5. SEC. Analysis was performed using a Shimadzu Prominence LC series equipped 
with a RID-10A refractive index detector. The mobile phase was 5 mM PBS, run at a rate 
of 0.5 mL/min. Twenty microliter samples were injected to a Shodex Asahipak GF-7M 
HQ column (7.5 mm x 150 mm). Molecular weight calculations were made using a 
calibration curve developed from PEG molecular weight standards. For concentration 
calculations, a calibration curve was prepared using NaOH-treated PEG6000MS. SLNs 
and PEG6000MS micelles were treated with 0.1 N NaOH for 3 days. Aliquots were 
removed and neutralized with 0.1 N HCl. Samples were centrifuged to remove any 
precipitate prior to analysis. To confirm complete release of free PEG, new aliquots were 
removed and analyzed again 24 h later. For the CE hydrolysis study, SLNs and 
PEG6000MS micelles (3 mg/ml) were prepared in PBS and aliquots immediately 
removed for the 0 h time point measurements (n=3). Samples were then treated with CE 
(1.86 units/mL final concentration) or a combination of CE and BNPP (5 mM) and 
incubated at 37°C with shaking at 100 rpm. Five hundred microliter aliquots were 
removed for analysis at 1, 5, 10, 15, 30, and 60 min. The CE-only aliquots were treated 
with BNPP upon removal in order to stop the reaction. Prior to analysis, all samples were 
centrifuged, and the supernatant was collected for injection onto the column. To 
determine the origin of the peak present in the initial samples, PEG6000MS was prepared 
in PBS at various concentrations (1-5 mg/mL) and analyzed without undergoing CE- or 
NaOH-treatment. 
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7.2.6. Measurement of Free Fatty Acid (FFA) Production. In addition to measuring 
the production of free PEG, hydrolysis of ester-containing PEGylating agents can also be 
analyzed by monitoring for production of FFAs. These experiments were performed 
using a pH-stat apparatus (Metrohm Titrando 842, Metrohm USA Inc., Riverview, FL). 
The pH meter was calibrated using pH 2.0, 7.0, and 10.0 standards, and all samples were 
degassed prior to analysis. Twenty-five milliliters of formulation 1 SLNs, formulation 2 
SLNs, or PS60 micelles in 0.9% NaCl were brought to 37°C with stirring. The pH was 
adjusted to 7.4, and the enzyme solution was added (1.86 units/mL final concentration). 
The pH was kept constant by titrating the produced FFAs with a 0.01 N NaOH solution 
using an automated burette; the volume of NaOH added was recorded as a function of 
time. Samples were monitored for 2 h. Control samples for each were pre-treated with 
BNPP (5 mM) prior to CE exposure. Additionally, blank samples in which CE was added 
to 0.9% NaCl alone were analyzed. All samples were analyzed in triplicate. For 
comparison, the amount of NaOH added at 15 min intervals was averaged, and the 
measurements for all three samples were corrected for the addition of enzyme alone using 
their respective BNPP measurements. The SLN measurements were corrected for the 
hydrolysis of PEG6000MS using information (molecular weight and purity) obtained 
from the SEC studies. An additional study was performed in which, following the normal 
study period, samples with and without BNPP were titrated to pH 9.0 in order to confirm 
that all FFAs produced were in the detectable, ionized form. A spiking experiment was 
run to determine if enzyme was being inactivated. PS60 micelles with and without BNPP 
were run as normal; at 1 h, 1 mL of sample was removed and replaced with 1 mL of a 10 
mg/mL PS60 solution. The samples were run for an additional hour.  
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7.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent 
measurements. Comparisons were made using a t-test (paired two sample for means).  
Results are considered statistically significant at a level of p<0.05.  
 
7.3. RESULTS 
7.3.1. Particle Size and Turbidity. It was assumed that hydrolysis of the SLN 
PEGylating agents may lead to instability of the particles, either due to particle 
disassociation or aggregation. If the concentration of surfactants is reduced due to 
degradation of PEG6000MS or PS60, particles may disassociate, leading to the release of 
the lipid phase. Due to the presence of Brij
®
 78, a non-ester-containing surfactant, and 
other unhydrolyzed surfactant molecules, this insoluble material may remain dispersed at 
least temporarily before precipitating. Alternatively, if SLNs remain intact, it is possible 
that they may aggregate due to the lessened concentration of PEG on their surfaces. 
Based on this assumption, we monitored the turbidity of the SLN suspensions; the 
absorbance at 380 nm was chosen as a quantifiable marker of turbidity due to the low 
absorbance of CE and BNPP at this wavelength. SLNs incubated with CE were compared 
to SLNs alone and SLNs pre-treated with BNPP prior to the addition of CE over a 48 h 
period (Figure 7.2). Following correction for the background signal of CE or CE and 
BNPP in combination, the turbidity of SLNs incubated with CE was observed to be 35-
fold greater at the 0.5 h time point as compared to the two controls. Only a minimal 
increase in turbidity was seen with SLNs alone or SLNs incubated with CE and BNPP; 
no significant differences were observed between the two (p>0.05). Interestingly, the 
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absorbance measurements of SLNs incubated with CE showed a decrease between 0.5 
and 6 h followed by a slight increase for the remaining time period.  
Figure 7.2. Turbidity of SLNs incubated at 37°C with CE, with BNPP-inhibited CE, 
or alone. Turbidity is assessed by measuring the sample absorbance at 380 nm. 
Samples were corrected for the background signal of CE or CE and BNPP in 
combination (n=3). 
 
 
 
Throughout the turbidity study, aliquots were removed from the samples for 
measurement of the particle size. Control samples of CE alone or CE with BNPP failed to 
give the intensity necessary for particle size measurement by DLS and, as such, it was 
assumed that all size measurements reported were related to the SLNs themselves. The 
particle sizes of SLNs and SLNs with inhibited CE are similar, while SLNs with CE 
showed smaller sizes (Figure 7.3). This difference became especially noticeable at later 
time points with SLNs incubated with CE showing an average size of nearly 40 nm 
smaller than SLNs pre-treated with BNPP prior to exposure to CE at 48 h. SLNs with and 
without exposure to CE exhibited similar morphologies and homogeneities based on 
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TEM images taken at the 1 and 24 h time points (Figure 7.4) though analysis of the 
particle size using the ImageJ processing program revealed a similar trend as was 
observed by DLS (Table 7.1).  
 
Figure 7.3. Particle size of SLNs incubated at 37°C with CE, with BNPP-inhibited 
CE, or alone as a function of time (n=3) 
 
 
Figure 7.4. TEM images of SLNs incubated at 37°C with or without CE for 1 (left) 
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Table 7.1. Representative particle size distribution data obtained from SLNs 
incubated at 37°C with and without CE for either 1 or 24 h. Both DLS and TEM 
data is shown; analysis of the TEM images was performed using the ImageJ 
processing program. 
 
Sample 
DLS TEM 
Size (nm) PI Size (nm) SD (nm) 
1 h 
-CE 93.3 0.017 98.0 15.1 
+CE 87.5 0.017 90.0 11.8  
24 h 
-CE 146.8 0.035 154.3 52.0 
+CE 127.9 0.101 143.1 43.9 
 
 
7.3.2. SEC. While the low molecular weight of PS60 prevented its analysis by SEC, this 
method was deemed suitable for monitoring the hydrolysis of PEG6000MS. In analyzing 
this material alone, identical peaks were observed for the degradation product of 
PEG6000MS incubated with CE and PEG6000MS exposed to NaOH. Based on a PEG 
molecular weight calibration curve (Figure 7.5), it was determined that this peak was 
associated with a higher molecular weight than was expected (10,376 vs 6,000). As this 
prevented the use of an external standard for quantification, a calibration curve was 
developed using NaOH-treated PEG6000MS; peak height was shown to increase linearly 
with concentration (Figure 7.6). 
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Figure 7.5. SEC molecular weight calibration curve (data from laboratory of Dr. 
Younsoo Bae) 
 
 
Figure 7.6. SEC concentration calibration curve developed from NaOH-treated 
PEG6000MS 
 
 
 
In experiments designed to study the hydrolysis of PEG6000MS by CE, it was observed 
that a peak was present at the expected retention time in the SEC eluent prior to CE 
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exposure. To determine if this was associated with an impurity in the product (PEG6000) 
or to free PEG6000MS, PEG6000MS was analyzed at concentrations ranging from 1-5 
mg/mL. Peak height was again shown to increase linearly with concentration, indicating 
that the initial peak was likely due to a product impurity (Figure 7.7). A peak associated 
with free PEG6000MS would be expected to remain constant above the CMC (appendix 
C). This impurity peak was subtracted from all subsequent analyses of SEC results.  
 
Figure 7.7. Untreated PEG6000MS peak height varies with concentration, 
indicating the presence of an impurity. 
 
 
 
Inclusion in SLNs appears to delay the hydrolysis of PEG6000MS as compared to when 
it is in micellar form (Figure 7.8). However, almost 100% hydrolysis is still reached 
within 15 minutes following exposure of the SLNs to CE. When samples were pre-treated 
with BNPP prior to CE exposure, hydrolysis of PEG6000MS in both SLN and micellar 
form was negligible.   
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Figure 7.8. Hydrolysis of PEG6000MS as determined by SEC with RI detection. 
SLNs (top) and PEG6000MS micelles (bottom) were incubated with CE in the 
presence or absence of BNPP (n=3).  
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7.3.3. Measurement of FFA Production. The pH-stat technique was used to measure 
the change in pH induced by the formation of FFA following hydrolysis of PS60 and 
PEG6000MS by CE. PEG6000MS could not be monitored in its micellar form using this 
technique due to immediate precipitation following CE exposure. However, both SLNs 
and PS60 micelles were monitored for the production of FFA following the introduction 
of CE. To provide a direct comparison between SLNs and micelles, a second SLN 
formulation (formulation 1 SLNs) was analyzed in which PS60 but not PEG6000MS was 
included. Adjustment of pH was not required when BNPP was included in the mixture 
except for that required to correct for the enzyme itself (determined by blank 
measurements).  
 
The average amount of NaOH added at 15 min intervals (n = 3) appears in Figure 7.9, 
having corrected for the amount associated with the addition of enzyme alone by 
subtracting out the amount added in the respective BNPP measurements at each time 
point (n=3). Additionally, SLN measurements were corrected for the hydrolysis of 
PEG6000MS, calculating the μmoles hydrolyzed using the SEC-determined molecular 
weight and accounting for the free material present initially. In each case, a substantial 
input of NaOH was required initially following CE exposure to return the pH to 7.4 
followed by a slower addition over the long-term.  During the initial phase, hydrolysis of 
PS60 appeared slower in SLNs than micelles. The addition of PEG6000MS to the SLNs 
appeared to retard hydrolysis even further. At later time points, the three curves become 
linear. If only the second hour was plotted and fitted with a linear trend line, hydrolysis 
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rates could be obtained: PS60 micelles, 0.0036 μmol/min; formulation 1 SLNs, 0.0087 
μmol/min; formulation 2 SLNs, 0.0080 μmol/min. 
 
 
Figure 7.9. Hydrolysis of PS60 in SLNs and PS60 micelles as determined using the 
pH-stat technique. All three samples were corrected for the addition of enzyme; 
formulation 2 SLNs were also corrected for PEG6000MS hydrolysis (n=3).   
 
 
 
To confirm that all FFAs produced were in the detectable ionized form, samples were 
titrated to pH 9 following a 2 h incubation. There was no difference between samples 
with and without BNPP (data not shown). To determine if enzyme was being inactivated 
over time, PS60 micelle samples with and without BNPP were run as above but spiked 
with additional PS60 at 1 h. Accounting for the general dilution effect using the BNPP 
control, hydrolysis of the spiked PS60 was 75-95% of the initial addition. 
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7.4. DISCUSSION 
Although many PEGylated nanoparticles have been described, relatively little research 
has been conducted on the stability of PEG coatings [114, 220]. Most reports have 
focused on the therapeutic outcome involved with the use of PEGylated nanocarriers 
instead of the mechanism of degradation. However, loss of PEG from the surface of 
nanoparticles may have profound implications for drug release and in vivo behavior.  
 
Ester-containing PEGylating agents have long been used in nanoparticles, some of which 
have achieved long circulation lifetimes and/or desirable therapeutic outcomes [228]. In 
the cases where such results have not been achieved, it has typically been attributed to 
suboptimal PEG surface coverage. However, as recent studies have described 
nanoparticles designed to specifically release PEG in the presence of esterases [23], it is 
possible that this may occur in other systems not specifically designed to do so. Loss of 
surface PEG may explain the sub-optimal results observed for some nanoparticle drug 
delivery systems.  
 
As such, it was considered critical to evaluate the SLNs under study for their stability in 
the presence of CE. Both PS60 and PEG6000MS contain potentially cleavable ester 
bonds, and previous studies have shown that drug release from the SLNs was dependent 
on the CE activity of the surrounding environment [37]. As it was anticipated that 
cleavage of PEG from the surface of SLNs may result in particle instability (either from 
particle breakdown or aggregation), preliminary studies were focused on observing 
changes in particle stability due to the presence of CE. Turbidity studies clearly indicated 
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a difference between SLNs incubated with and without CE. The addition of BNPP-
inhibited CE as a second control showed that the turbidity increase with CE was likely 
due to hydrolysis of the ester bonds and not simply to a general protein effect. The 
minimal increase in turbidity observed with the two control samples was likely a result of 
the observed increase in particle size.  
 
Interestingly, it was noted that the SLNs incubated with CE alone decreased in turbidity 
following a major spike at 0.5 h. Although this could be due to precipitation, the samples 
did not show visible signs of settling at this stage.  This may instead be attributable to the 
formation of other colloidal structures since the SLNs also have a non-ester-containing 
surfactant, Brij
®
 78, which would not be hydrolyzed in the presence of CE. 
 
As a second test of stability, the change in the particle size distributions of SLNs 
incubated with and without CE and SLNs incubated with both CE and BNPP were 
measured. SLNs remained detectable following exposure to CE, although the particle size 
was smaller than the two controls. Based on this, it did not appear that aggregation was 
occurring to a large extent. Instead, the produced FFAs may be released from the SLNs 
or a portion of the SLNs may be disassociating completely. Again, due to the presence of 
Brij
®
 78 and other unhydrolyzed surfactant, alternative colloidal structures may be 
formed that allow for at least temporary solubilization of the free lipid material. 
However, these would likely be dissolved during the dilution step necessary to achieve an 
intensity reading within the instrument‟s range, leaving only intact SLNs. The SLNs may 
then be smaller than the controls because a portion of the PEG has been cleaved from the 
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surface or because the remaining SLNs had less of the ester-containing PEGylating 
agents initially. Preparation of test batches containing SA with Brij
®
 78 only, SA with 
Brij
®
 78 and PS60, and SA with Brij
®
 78, PS60, and free PEG6000 confirmed that 
particles could be detected in all cases, with sizes ranging from 100-200 nm in diameter.  
 
TEM analysis of the SLNs provided confirmation of the DLS results. While a similar 
trend in size growth was seen between DLS and TEM images, the sizes obtained with 
TEM were slightly larger than what was measured by DLS.  This atypical result is 
potentially a result of the non-spherical structure of the particles, which will give a 
slightly larger hydrodynamic radius than a perfectly spherical particle [207]. 
Interestingly, the SLNs remaining following CE exposure appeared to have no major 
morphological differences as compared to those without CE, although their image 
backgrounds appeared slightly different. This may be attributed to the presence of the 
free hydrolyzed materials in the SLN plus CE samples. 
 
Based on these studies, it appeared that changes were occurring to SLNs incubated with 
CE, and further study was warranted. Methods were developed to allow for the 
measurement of the hydrolysis of each of the components separately. In each case, 
hydrolysis of the material in SLNs was compared to hydrolysis of the material in micelle 
form to determine if SLNs provided any protection against enzymatic cleavage. 
 
The degradation of PEG6000MS was monitored using SEC. As no external standard was 
available, a reference was prepared by hydrolyzing PEG6000MS with NaOH. Repeat 
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measurements confirmed the complete hydrolysis of PEG6000MS, and chromatographic 
peaks associated with the CE-hydrolyzed PEG6000MS were shown to appear with the 
same retention time as NaOH-hydrolyzed PEG6000MS. Thus, all data obtained with CE 
is expressed in reference to the NaOH-hydrolyzed PEG6000MS. A clear difference was 
observed between SLNs pre-treated with BNPP prior to CE exposure and those not pre-
treated. Whereas untreated SLNs reached approximately 100% hydrolysis within 15 min, 
the addition of BNPP appeared to completely inhibit hydrolysis of the PEG-ester bonds 
in the SLNs.  
 
In comparing degradation of PEG6000MS in SLNs and in micelles, we expected that 
SLNs may offer some protection against hydrolysis. Previous NMR studies confirmed 
that these nanoparticles exhibited the expected core-shell structure with the majority of 
lipids (from stearyl alcohol as well as the hydrophobic portion of the surfactants and 
PEGylating agents) solidified in the core [207]. Based on the solid nature of the particles, 
it was assumed that CE would have limited access to the PEG6000MS ester bond, which 
likely resides at the interface between the core of the nanoparticles and the PEGylated 
surface. Interestingly, this was observed but only to a limited extent. The increase in free 
PEG was more gradual with SLNs than micelles. For example, nearly 75% of 
PEG6000MS in micellar form was hydrolyzed within 1 min of exposure to CE; this level 
was not reached in SLNs until 10-15 min after exposure. However, the SLN advantage 
was quickly negated, with both samples reaching nearly 100% hydrolysis within 15 min.  
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Unfortunately, the low molecular weight of the PS60 degradation product prevented its 
analysis using the available SEC system. The pH-stat technique, which relies upon the 
analysis of FFAs produced instead of free PEG, was employed as an alternative method. 
As FFAs were produced, a neutralizing basic solution was automatically added to the 
solution in order to maintain a constant pH. The amount of NaOH added was reflective of 
the amount of FFA formed by hydrolysis of PS60.  
 
Again, a clear difference was observed between SLNs exposed to CE with and without 
BNPP pre-treatment, with the NaOH addition being significantly greater in untreated 
samples. There was no difference in the profiles obtained with pre-treated samples and 
blank samples (CE added to 0.9% NaCl), providing a second confirmation that 
PEGylating agents were susceptible to hydrolysis by CE. In order to better compare PS60 
hydrolysis between SLNs and micelles, formulation 1 SLNs (containing PS60 but not 
PEG6000MS) were also analyzed.  
 
Interestingly, within 2 h, the hydrolysis for all samples was less than 40% of the total 
predicted amount. This low amount could not be traced to a pKa issue or to enzyme 
inactivation. Instead, it is assumed that this is attributable to the accessibility of the PS60 
ester bond to attack. The rapid initial NaOH addition may be due to hydrolysis of free or 
easily accessible PS60, of which there appears to be less in SLN samples than micellar 
samples. The slower hydrolysis rates observed later may be associated with the 
hydrolysis of PS60 in micelles or SLNs. During this stage, the hydrolysis of PS60 in the 
SLN samples was more rapid than in micellar samples. This was unexpected and 
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indicates that the PS60 micelles may pack such that the ester bond is protected from 
enzymatic attack. However, the rate in SLNs was still quite slow.  
 
These results were somewhat surprising based on the hydrolysis of PEG6000MS 
discussed previously. Based on their structures, it was expected that PS60 and 
PEG6000MS would align within SLNs in a similar manner, i.e., with the ester bonds of 
both at the interface of the solid core of the SLNs and the PEGylated surface. If this 
indeed were the case, they might be expected to display similar degradation patterns. Yet, 
the hydrolysis of PEG6000MS occurred much more rapidly than the hydrolysis of PS60. 
It is possible that the PS60 ester bond is integrated more extensively into the core of the 
SLNs, providing it with greater protection against attack by CE. The addition of 
PEG6000MS to the SLNs may thus provide another barrier against enzymatic attack, 
explaining why hydrolysis in the SLN formulation containing PEG6000MS is even 
slower than in the SLNs lacking PEG6000MS. CE may have to cleave PEG6000MS from 
the surface of particles prior to attacking the PS60 ester bonds. Further, it was previously 
proposed that the SLNs lacking PEG6000MS may be in a more fluid state at 37°C than 
the SLNs containing PEG6000MS, thereby rendering enzymatic attack easier [207]. 
Alternatively, it may be the structure of PS60 itself that is less favorable to enzymatic 
attack than PEG6000MS. As seen in Figure 7.1, PEG6000MS consists of a single linear 
PEG chain, whereas PS60 is in effect a branched PEG chain. This structure may provide 
more steric hindrance than the linear PEG chain in PEG6000MS.  
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7.5. CONCLUSIONS 
SLNs were evaluated for their stability in the presence of CE, specifically in regard to 
degradation of PS60 and PEG6000MS. Blank SLN suspensions were observed to become 
extremely turbid within the first 30 min following exposure to CE indicating dissociation 
or aggregation of at least a portion of the nanoparticles. The particle size of SLNs 
incubated with CE was smaller than the size of controls at all time points studied, but 
their morphologies appeared similar in TEM images taken following 1 and 24 h 
incubations. Although SLNs offered some protection over micelles, PEG6000MS was 
rapidly degraded within 15 min. In contrast, PS60 hydrolysis was much slower, reaching 
only 36% in 2 h. Based on these results, it appears that the accelerated release of Dex 
observed in the presence of CE may be partially attributable to increased accessibility of 
the prodrug to enzymes following hydrolysis of the ester-containing materials PS60 and 
PEG6000MS. On a broader scale, these studies reveal the importance of confirming the 
stability of PEG surface coatings prior to undertaking in vivo experiments in small animal 
models, which can have considerably higher plasma esterase activity than humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Melissa Howard 2011 
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Chapter 8 
Optimization of the Lyophilization Process for Long-term Stability of Solid Lipid 
Nanoparticles 
 
8.1. INTRODUCTION 
Long-term storage stability can be considered as a final criterion for the development of a 
nanoparticle drug delivery system. However, stability can be limited by a number of 
factors when nanoparticles are stored as aqueous suspensions. Specifically with SLNs, 
lipid crystallization and/or polymorphic transformations can lead to drug expulsion [136-
138]. Particles can grow via Ostwald ripening processes [34], and aggregation can lead to 
gelation [142, 143]. Drug degradation can also occur [155, 229]. 
 
Lyophilization (freeze-drying) is one of the most effective means of improving both the 
physical and chemical stability of SLNs. The process consists of three main steps: 
freezing, primary drying, and secondary drying [230]. During the first step, water freezes 
into ice crystals while excluding particles and any free material (the cryo-concentrated 
phase). Both drying steps are conducted under vacuum. The primary drying step is 
conducted at low temperatures, and it is during this phase that frozen water is removed 
through sublimation. During the secondary drying phase, the temperature is raised to 
remove any unfrozen water through desorption.  
 
Unfortunately, both the freezing and drying steps can generate various stresses that may 
destabilize nanoparticles. For example, the formation of ice crystals can induce 
mechanical stress on the particles [231]. Freezing can lead to crystallization of PEG, 
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reducing its ability to serve as a steric stabilizer and leading to particle fusion [230]. For 
this reason, it is critically important to optimize the lyophilization process in order to 
reduce these stresses. It can also be valuable to add excipients designed to protect the 
nanoparticles from these stresses; such molecules are known as lyoprotectants (LPs). 
Sugars are the most commonly used LPs, though various polymers have been used 
successfully in some situations [230]. 
 
Several possible mechanisms have been proposed for the ability of LPs to prevent 
destabilization of the nanoparticles. The particle isolation hypothesis is based on the 
theory that particle aggregation is prevented simply by LPs spatially separating the 
particles [230]. The water replacement hypothesis is based on the ability of LPs to 
hydrogen bond with the components on the particle surface, effectively replacing water 
as it freezes. This can maintain PEG in a pseudo-hydrated state and prevent chain 
entanglement [230, 232]. The most popular theory, however, is the amorphous glass 
theory. This theory states that the LPs partition into the cryo-concentrated phase during 
the freezing process and then solidify into an amorphous glass around the particles. This 
glassy matrix can subsequently protect the particles from fusion [231, 232].  
 
This section was designed to develop an optimized lyophilization protocol for Dex-P 
loaded SLNs, in terms of both the use of LPs and the lyophilization process itself. 
Lyophilized SLNs will be tested for their redispersibility, which is defined as their ability 
to be returned to their pre-dried state. Upon development of an optimized protocol, SLNs 
will be evaluated for their long-term storage stability. Comparisons will be made between 
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lyophilized SLNs and SLNs stored as aqueous suspensions and between storage at 4°C 
and 25°C/60% RH.  
 
8.2. MATERIALS AND METHODS 
8.2.1. Materials. SA, polyvinyl alcohol (PVA), and poly(vinylpyrrolidone) (Povidone 
K-30, 40K average molecular weight; PVP) were obtained from Spectrum Chemicals and 
Laboratory Products (Gardena, CA). PS60 and Brij
®
 78 were purchased from Uniqema 
(Chicago, IL), and PEG6000MS was a gift from Stepan (Northfield, IL). Dex (USP) was 
a gift from Pfizer (Kalamazoo, MI). ACN and MeOH were purchased from Fisher 
Scientific (Pittsburgh, PA). HYDRANAL
®
-Coulomat AD, NaCl, fructose, glucose, 
maltose, mannose, sucrose, and trehalose were from Sigma-Aldrich (St. Louis, MO). 
Lactose was from Sheffield Bioscience (Norwich, NY, USA). PBS was from Invitrogen 
(San Diego, CA). Water was obtained from a Milli-Q Synthesis ultrapure water system 
(Millipore; Billerica, MA). Centrifugal filter devices (Amicon Ultra-0.5, Ultracel-10 
Membrane, 10 kD) were purchased from Millipore (Billerica, MA).  
 
8.2.2. Synthesis of Dex-P. The procedure to prepare Dex-P has previously been 
reported [35]. Briefly, 300 mg Dex was dissolved in 12 mL pyridine to which 578 mg 
palmitoyl chloride was added in a dropwise manner. The mixture was stirred in the dark 
under nitrogen for 24 h. The solvent was evaporated using a stream of nitrogen, and the 
dried product was dissolved in dichloromethane prior to loading onto a 30 mL silica gel 
column. The purified product was obtained using a dichloromethane to 
dichloromethane:ethyl acetate (6:4 v/v) gradient elution. The reaction progress was 
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monitored using silica gel TLC with a chloroform:ethyl acetate (7:3 v/v) mobile phase. 
Retention factors for Dex and Dex-P were 0.10 and 0.69, respectively.  
 
8.2.3. SLN Preparation. SLNs were prepared using NET as previously described [131]. 
The process consists of three steps: 1) melting an appropriate mixture of lipid, 
surfactants, long-chain PEGylating agents, and drug; 2) adding a pre-heated aqueous 
phase with stirring to generate an o/w microemulsion; and 3) cooling the microemulsion 
to form a suspension of SLNs. For this study, microemulsions were prepared at 70°C in 
order to ensure the melting of all components, and SLNs were cooled in a room 
temperature water bath. The formulation composition was 1.6 mg/mL SA, 0.4 mg/mL 
PS60, 2.8 mg/mL Brij
®
 78, and 3.0 mg/mL PEG6000MS. Where appropriate, Dex-P was 
added at 0.16 mg/mL, or the equivalent of a 10% drug load (w/w comparison with SA). 
SLNs designed for lyophilization were prepared in Milli-Q water, whereas SLNs 
designed to be stored as aqueous suspensions were prepared in 0.9% NaCl. SLNs were 
filtered using a 0.2 μm nylon membrane prior to lyophilization. SLNs were lyophilized 
using an FTS Systems Dura-Dry MP/Dura-Stop MP lyophilizer System (SP Scientific, 
Warminster, PA). Specific lyophilization protocols are described in detail below.  
 
8.2.4. General SLN Characterization Techniques 
8.2.4.1. DLS. Particle size and PI values were obtained using a Delsa™ Nano Zeta 
Potential and Submicron Particle Size Analyzer (Beckman Coulter Inc., Brea, CA). All 
measurements were performed at 25°C following a 1:30 dilution with Milli-Q water. 
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8.2.4.2. Drug Loading and Encapsulation Efficiency. The following HPLC conditions 
were used for determination of the Dex-P concentration: Alltech C18 column (5 μm, 250 
mm×4.6 mm), 95:5 ACN:H2O mobile phase run at 2 mL/min, and UV detection at λ=240 
nm. A standard curve was developed in the range of 10-200 μg/mL using three samples at 
five concentrations (shown in chapter 5). Drug loading and encapsulation efficiency were 
determined using a two-step process. Drug loaded SLNs were first filtered through a 0.2 
μm nylon membrane to remove any unsolubilized drug. Filtered SLNs (termed MF) were 
then ultrafiltered (Amicon YM-10, 10K MWCO) to remove free drug, and the retentate 
was collected. One hundred microliters each of the initial, MF, and retentate samples 
were diluted to 500 μL with MeOH, and 10 μL were injected onto the HPLC column. 
Encapsulation efficiencies were calculated by comparing the amount of drug remaining 
in the retentate to that in the initial sample.  
 
8.2.5. Optimization of the Lyophilization Process 
8.2.5.1. Effect of LP Type and Concentration: Freeze-thaw study. SLNs (1 mL) were 
added to 7 mL vials containing potential LPs. Nine LPs (glucose, fructose, mannose, 
trehalose, maltose, sucrose, lactose, PVA, and PVP) were tested at four concentrations: 
0.5:1, 1:1, 2:1, and 5:1 (LP:SA weight ratio). An additional sample lacking any LP was 
used as a control. Following an overnight freezing at -20°C, samples were thawed at 
room temperature and evaluated for particle size/PI by DLS. 
 
8.2.5.2. Effect of LP Type and Concentration: Lyophilization Study. SLNs (1 mL) 
were added to 7 mL vials containing fructose, mannose, maltose, or sucrose. Four LP:SA 
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ratios were used (5:1, 10:1, 15:1, and 20:1). Three samples were prepared per condition, 
and an additional three control samples were prepared without LP. The following 
lyophilization protocol was used: freezing at -40°C on a pre-cooled shelf for 2 h, primary 
drying at -20°C for 24 h using a vacuum of 100 mTorr, and secondary drying at 20°C for 
16 h using a vacuum of 100 mTorr. SLNs were reconstituted to their original volume 
with Milli-Q water using manual shaking, and the particle size and PI were determined 
by DLS. 
 
8.2.5.3. Effect of SLN Concentration. SLNs were prepared at 1x, 5x, and 10x the 
original concentration, i.e., the 1x, 5x, and 10x samples contain 1.6, 8, and 16 mg/mL 
SA, respectively. Sucrose was added at either a 15:1 sucrose:SA weight ratio or at a fixed 
2.4% w/v concentration (n=3 per condition). Lyophilization and reconstitution were 
conducted as described above, and the particle size and PI were determined by DLS.  
 
8.2.5.4. Effect of Secondary Drying Time. SLNs were lyophilized using a 15:1 
sucrose:SA weight ratio. Lyophilized samples were reconstituted to the original volume 
using Milli-Q water, and DLS was used for measurement of the particle size and PI 
(n=3). The lyophilization protocol was as follows: freezing at -40°C for 2 h on a 
precooled shelf, primary drying at -20°C for 24 h, and secondary drying at 20°C for 
either 0, 8, or 16 h. A vacuum of 100 mTorr was used during both drying steps.  
 
8.2.5.5. Effect of Freezing Temperature and Rate. SLNs were lyophilized using a 15:1 
sucrose:SA weight ratio. Lyophilized samples were reconstituted to the original volume 
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using Milli-Q water, and DLS was used for measurement of the particle size and PI 
(n=3). For the evaluation of the temperature effect, temperatures of -20°C, -40°C, and -
80°C were used in the 2 h freezing period; the rest of the lyophilization protocol was the 
same as described above. In order to compare the rate effect, SLNs were either frozen at -
20°C on a precooled shelf for 2 h (“fast” freeze) or placed on a room temperature shelf, 
cooled to -20°C at a rate of 0.5°C/min, and then allowed to sit at -20°C for an additional 
2 h (“slow” freeze). The primary and secondary drying conditions were the same as 
described above. 
 
8.2.5.6. Effect of Reconstitution Media. SLNs prepared in Milli-Q water were 
lyophilized with a 15:1 sucrose:SA weight ratio. The lyophilization protocol was as 
follows: freezing at -20°C on a precooled shelf for 2 h, primary drying at -20°C for 24 h 
using a vacuum of 100 mTorr, secondary drying at 20°C for 16 h using a vacuum of 100 
mTorr. SLNs were reconstituted to the original volume using either Milli-Q water, 0.9% 
NaCl, or PBS. The effects on particle size and PI were determined by DLS (n=3). 
Osmolality measurements (n=3) were performed using a Fiske 110 Osmometer 
(Advanced Instruments, Inc., Norwood, MA, USA). The instrument was calibrated with 
50, 290, and 850 mOsm/kg standards.  
 
8.2.5.7. Effect of Drug Loading. SLNs loaded with 10% Dex-P and control blank SLNs 
were lyophilized using a 15:1 sucrose:SA weight ratio. The lyophilization protocol was 
as follows: cooling from room temperature to -20°C at 0.5°C/min, a 2 h hold at -20°C, 
primary drying at -20°C for 24 h using a vacuum of 100 mTorr, secondary drying at 20°C 
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for 16 h using a vacuum of 100 mTorr. SLNs were reconstituted to the original volume 
using Milli-Q water, and the particle size and PI were determined using DLS (n=3). 
 
8.2.5.8. Batch-to-Batch Variability. Three batches of SLNs with and without 10% Dex-
P were lyophilized on separate days (n=3/batch). A sucrose:SA weight ratio of 15:1 was 
used, and the lyophilization process was as follows: cooling from room temperature to -
20°C at 0.5°C/min, a 2 h hold at -20°C, primary drying at -20°C for 24 h using a vacuum 
of 100 mTorr, secondary drying at 20°C for 16 h using a vacuum of 100 mTorr. SLNs 
were reconstituted to the original volume with Milli-Q water, and the particle size and PI 
were measured by DLS. 
 
8.2.5.9. Evaluation of the Optimized Lyophilized Product. Prior to reconstitution, the 
lyophilizate was evaluated for water content using a Metrohm 684 Karl Fischer 
coulometer equipped with a Metrohm 703 titration stand. Lyophilized SLNs (1-3 mg) 
were dissolved in MeOH, and approximately 100 μL were added to the Karl Fischer 
reagent (HYDRANAL®-Coulumat AD). Corrections were made for the presence of 
water in the MeOH used to dissolve the samples.  Following reconstitution, SLNs were 
evaluated for the presence of large aggregates using a SALD-7101 Laser Diffraction 
Particle Size Analyzer (Shimadzu Scientific Instruments, Columbia, MD, USA). To 
achieve an appropriate signal intensity, SLNs were diluted 2x with Milli-Q H2O. 
Reconstituted SLNs were also analyzed by TEM. Images were obtained using a Philips 
Tecnai Biotwin 12 equipped with a Gatan ES 1000W CCD digital camera (FEI, 
Hillsboro, OR). A drop of sample (7 µL) was incubated for 1.5 min on a carbon coated 
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TEM grid. The grid was then dried and stained with 0.2 μm filtered 2% uranyl acetate for 
an additional 1.5 min. Excess stain was removed, and the grid was allowed to dry for 5 
min prior to imaging. Drug loaded SLNs were also evaluated for encapsulation efficiency 
using the methods described above. 
 
8.2.6. Stability Study. A 3 month stability study was conducted comparing 10% Dex-P 
loaded SLNs lyophilized prior to storage with those stored as aqueous suspensions. 
Lyophilization was conducted as follows: cooling from room temperature to -20°C at 
0.5°C/min, a 2 h hold at -20°C, primary drying at -20°C for 24 h using a vacuum of 100 
mTorr, secondary drying at 20°C for 16 h using a vacuum of 100 mTorr. A 15:1 
sucrose:SA weight ratio was used. All vials were stoppered and crimped for storage. 
SLNs were stored under two conditions: 4°C or 25°C/60% relative humidity (RH). A 
saturated sodium bromide solution was used to control the RH [233]. At select time 
points [days 0, 1, 3, 7, 14, 28 (1 mo), 59 (2 mo), and 89 (3 mo)], SLNs were removed 
from storage for analysis (3 vials/condition). Lyophilized SLNs were reconstituted to 
their original volume (1 mL) with 0.9% NaCl, and all samples were tested for changes in 
the particle size/PI and encapsulation efficiency. These experiments were conducted as 
described above, with the exception that for samples that showed a particle size > 200 
nm, one of the three replicates was filtered with a 0.45 μm nylon filter instead of a 0.2 μm 
nylon filter. This was done in an attempt to differentiate between drug loss due to the 
filtration of large particles and drug loss due to removal of unsolubilized drug. However, 
no differences were observed between the two filtration methods, and as such, data from 
all three samples were used in calculating average values. 
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8.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent 
measurements. For comparison of only two data sets, a t-test (paired two sample for 
means) was utilized. For comparison of 3 or more data sets, an analysis of variance 
(ANOVA, single factor) was performed. Results are considered statistically significant at 
a level of p<0.05.  
 
8.3. RESULTS AND DISCUSSION 
8.3.1.  Optimization of the Lyophilization Process 
8.3.1.1. Effect of LP Type and Concentration. In order to avoid numerous time-
consuming lyophilization procedures, possible LPs were first evaluated by a freeze-thaw 
study. If the tested excipients are unable to provide protection against aggregation during 
the first step of the lyophilization protocol, i.e., freezing, they are unlikely to be suitable 
LPs. Based on previous literature reports [230], nine excipients were chosen for study: 3 
monosaccharides (glucose, fructose, and mannose), 4 disaccharides (trehalose, maltose, 
sucrose, and lactose), and 2 polymers (PVA and PVP). Each excipient was tested at four 
different concentrations, all expressed as LP:SA weight ratios: 0.5:1, 1:1, 2:1, and 5:1. 
Following freezing at -20°C overnight, SLNs were thawed and evaluated for changes in 
the particle size and PI (Figure 8.1). In general, higher concentrations of excipient led to 
smaller increases in the particle size. It was observed that the two polymers were clearly 
the least effective in maintaining the particle size. Even at the highest concentrations, 
particles increased from approximately 95 nm to over 130 nm. Performance was better 
with the sugars, although there was no clear difference between the mono- and 
disaccharides. PI values followed a similar trend. As such, the two best performers from 
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each sugar category were chosen for a full lyophilization study: fructose and mannose for 
the monosaccharides and sucrose and maltose for the disaccharides. At the highest 
concentrations, particle size increases were <10 nm and changes in the PI were negligible 
with these excipients.  
 
 
Figure 8.1. The effect of various LPs on the change in particle size (top) and PI 
(bottom) following an overnight freezing at -20°C and subsequent thawing. 
Excipients include 3 monosaccharides (glucose, fructose, and mannose), 4 
disaccharides (trehalose, maltose, sucrose, and lactose), and 2 polymers (PVA and 
PVP). Each excipient was tested at four concentrations, all expressed in reference to 
SA (LP:SA weight ratio): 0.5:1, 1:1, 2:1, and 5:1. The bottom dotted line represents 
the original SLN condition: 95.5 nm and a PI of 0.047. The top dotted line 
represents the condition of SLNs frozen without any LP: 142.1 nm and a PI of 0.167.  
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Based on the trend of decreasing particle size with increasing LP concentration observed 
in the freeze-thaw study, higher concentrations were chosen for the lyophilization study. 
LP:SA ratios began at the 5:1 ratio used in the previous study and were raised to 10:1, 
15:1, and 20:1. A basic lyophilization protocol was chosen for use: freezing at -40°C for 
2 h on a precooled shelf, primary drying at -20°C/100 mTorr for 24 h, and secondary 
drying at 20°C/100 mTorr for 16 h.  In this study, disaccharides were shown to better 
maintain the particle size and PI values of SLNs than monosaccharides (Figure 8.2). 
Specifically with fructose, particle size increases were large and variable. PI values were 
also higher (>0.2) than disaccharide samples (0.1-0.2). This is consistent with previous 
studies in which the use of disaccharides has been shown to be advantageous [146, 234]. 
It is thought that this is due to the ability of the disaccharides to solidify in an amorphous 
state while the monosaccharides crystallize upon freezing. Crystallization may decrease 
the ability of the excipient to interact with the SLNs and limit its ability to prevent 
aggregation.  
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Figure 8.2. The effect of various LPs on the change in particle size (top) and PI 
(bottom) following lyophilization. Excipients included 2 monosaccharides (mannose 
and fructose) and 2 disaccharides (sucrose and maltose). Each excipient was tested 
at four LP:SA weight ratios: 5:1, 10:1, 15:1, and 20:1 (n=3). The bottom dashed line 
represents the initial SLN condition: 96.2 nm and a PI of 0.092. The top dashed line 
represents the condition of SLNs lyophilized without LP: 207.0 nm and a PI of 
0.212. 
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Interestingly, increases in the LP concentration were not as clearly advantageous in the 
lyophilization study as they were in the freeze-thaw study. Sucrose was the only LP that 
showed a smaller particle size increase with higher concentration, and the reduction upon 
going from the 15:1 ratio to the 20:1 ratio was minimal. With all other LPs, there 
appeared to be a destabilization of the particles with higher LP concentrations (15:1 with 
fructose and maltose and 20:1 with mannose). This was somewhat surprising as most 
studies have reported that increasing the excipient concentration improves the 
maintenance of particle size [216, 235, 236]. However, there have been at least some 
reports of destabilization with higher LP concentrations [237, 238]. Unfortunately, there 
is currently a lack of understanding regarding what controls this. As has been reported, 
the most important parameter is the concentration of LP in the cryo-concentrated phase, 
which is determined by a competition between the diffusion rate of LP molecules and the 
freezing rate [231]. If diffusion of the LP molecules is limited (for example, because of 
high viscosity), the LP may be retained in the bulk frozen state as opposed to entering the 
cryo-concentrated phase. It may be that there is a certain critical LP concentration at 
which the freezing rate becomes faster than the diffusion step, and particle aggregation 
results. Alternatively, it has been proposed that the sugar molecules hydrogen bond with 
the PEGylated surfaces of nanoparticles [230], and it is possible that at high 
concentrations, this could lead to particle bridging.  
 
Based on these studies, sucrose at a LP:SA ratio of 15:1 was chosen as the optimal LP 
concentration. This equates to 2.4% w/v and is a considerably lower LP concentration 
than has been used with numerous other nanoparticle systems [232, 239]. Under these 
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conditions, particles increased in size by <17% and remained within a size range 
appropriate to take advantage of the EPR effect [29]. Although the particle size 
distribution broadened, it also remained within the range of PI values (PI<0.3) considered 
acceptably monodisperse [240, 241]. Additional studies were aimed at optimizing the 
lyophilization protocol in order to potentially limit changes to an even greater degree.  
 
8.3.1.2. Effect of SLN Concentration. It has previously been observed with polymeric 
nanoparticles that a higher nanoparticle concentration can lead to improved 
redispersibility following reconstitution [242]. To determine whether this was the case 
with the SLN system under consideration, nanoparticles were prepared at 1x, 5x, and 10x 
the original concentration, lyophilized, and evaluated for particle size changes. Results 
are shown in Table 8.1. Surprisingly, only the 1x SLN sample could be easily 
reconstituted. All other samples remained cloudy, despite showing relatively small 
particle sizes. This may be partially attributed to the dilution step required for particle 
size measurement, during which large aggregates may dissolve.  For comparison, the 5x 
and 10x samples were diluted to the 1x concentration and re-analyzed, but the results 
were not improved. Finally, to determine if it was the overall sucrose concentration and 
not the LP:SA ratio that led to good redispersibility, SLNs prepared at 5x and 10x were 
lyophilized in the presence of 2.4% w/v sucrose and evaluated for particle size changes. 
In this case, the samples were very cloudy following reconstitution, and the particle size 
increases were larger. The higher SLN concentrations may prevent the formation of the 
protective amorphous shell around the nanoparticles, possibly for similar reasons to those 
described earlier with higher LP concentrations. Results may be improved by using lower 
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SLN concentrations, but this would be undesirable for achieving a sufficiently high drug 
dose.  
 
Table 8.1. Effect of SLN concentration on redispersibility 
SLN 
Concentration 
Initial 15:1 LP:SA Ratio 
15:1 LP:SA Ratio + 
Dilution 
2.4% LP 
Particle 
size (nm) 
Visual 
Appearance 
Particle  
size (nm) 
Visual 
Appearance 
Particle 
 size (nm) 
Visual 
Appearance 
Particle  
size (nm) 
Visual 
Appearance 
1x 97.8 clear 116.4±1.6 clear N/A N/A N/A N/A 
5x 98.4 clear 125.6±2.7 cloudy 123.5±4.6 cloudy 180.1±17.0 very cloudy 
10x 102.3 clear 154.5±10.3 cloudy 161.1±17.1 cloudy 424.7±108.1 very cloudy 
 
 
 
8.3.1.3. Effect of Secondary Drying Time. The effects of the secondary drying time on 
the particle size and PI of the SLNs are shown in Figure 8.3. No clear trend was evident, 
with the 8 h drying time resulting in slightly higher (though not statistically significant, 
P>0.05) particle size increases and PI values than that of either the 0 h or 16 h drying 
time. The smallest average values were obtained for the 16 h drying time.  Based on this 
data and a desire to ensure the least residual moisture content, a 16 h secondary drying 
time was chosen for further studies.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. The effect of secondary drying time on the particle size and PI of SLNs  
following lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3) 
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8.3.1.4. Effect of Freezing Temperature and Rate. The effects of freezing temperature 
and rate were evaluated together because they are inherently related. Lower freezing 
temperatures lead to faster freezing rates. However, to attempt to separate the two effects, 
three different temperatures were tested initially, and then direct comparisons were made 
between two different freezing methods at the “optimal” temperature. A clear trend in the 
redispersibility of the SLNs was observed with freezing temperature when the fast freeze 
method was employed (Figure 8.4). As the temperature decreased, both the particle size 
and PI increases became larger. With a -20°C freeze, the particle size increased by only 
12.4±2.0%, and the average PI was 0.177±0.025. For comparison, samples were then 
frozen to -20°C using a slow freeze and evaluated for redispersibility (Figure 8.5). 
Although the fast freeze samples trended toward a smaller particle size, the difference 
was not statistically significant (p>0.05). On the other hand, the slow freeze samples 
exhibited a statistically significant smaller PI value (p<0.05).  
 
Figure 8.4. The effect of freezing temperature on the particle size and PI of SLNs  
following lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3) 
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Figure 8.5. The effect of freezing rate (-20°C freeze) on the particle size and PI of 
SLNs following lyophilization in the presence of a sucrose:SA 15:1 weight ratio 
(n=3) 
 
These results were again somewhat surprising in light of other literature reports. Most 
studies have reported an improvement in redispersibility with lower temperatures and 
faster freezing rates [231, 232, 242, 243]. This is primarily because a faster freezing rate 
should result in smaller ice crystals that result in less mechanical stress on the particles. 
However, if the freezing rate is too fast to allow partitioning of the LP molecules into the 
cryo-concentrated phase, this benefit may be negated, as it apparently is with these SLNs. 
Overall, it appeared clear that better redispersibility could be obtained with a -20°C 
freezing temperature, and that although a slower freezing rate at that temperature did not 
significantly affect the particle size change, it may reduce the change in the particle size 
distribution (PI of 0.117±0.043 for slow freeze vs PI of 0.177±0.025 for fast freeze). 
 
8.3.1.5. Effect of Reconstitution Media. Although SLNs could be reconstituted with 
water, it may be preferable to use alternative solutions for reconstitution, either for 
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certain lab situations or to satisfy clinical requirements. For example, a 2.4% w/v sucrose 
solution would be considered hypo-osmotic and may be unsuitable for injection. For this 
reason, SLNs reconstituted in H2O, 0.9% NaCl (used commonly for reconstitution in 
clinical situations), and PBS (used commonly in lab situations to mimic physiological 
conditions) were compared (Table 8.2). No difference was observed among the particle 
size and PI values for the three solutions as determined by ANOVA, indicating that a 
variety of solutions could be used for reconstitution without significantly impacting the 
properties of the SLNs. Specifically, samples reconstituted with 0.9% NaCl were slightly 
hyperosmotic but remained within a clinically relevant range [244].  
 
Table 8.2. Effect of the reconstitution media on SLN properties 
Reconstitution 
Media 
Size (nm) PI 
Osmolality 
(mOsm/kg) 
H2O 101.6±1.8 0.177±0.025 74.8±1.1 
0.9% NaCl 104.2±4.3 0.171±0.027 350.9±2.2 
PBS 102.0±2.3 0.223±0.020 382.8±4.0 
 
  
8.3.1.6. Effect of Drug Loading. Drug loading has been shown to significantly impact 
nanoparticle redispersibility in some situations [239] but not in others [245]. The 
difference was primarily attributed to the presence of free drug in solution. As Dex-P 
loaded SLNs typically display very high encapsulation efficiencies (only 1-2% free drug 
following 0.2 μm filtration), this was not expected to be a limiting factor. However, in 
experiments designed to test this, it was observed that SLNs loaded with 10% Dex-P w/w 
SA showed slightly larger particle size increases and slightly higher PI values than blank 
SLNS (Figure 8.6). This may be a result of the small amount of free drug present in 
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solution or to a difference in the surface properties of the SLNs with drug loading. Either 
way, the changes with drug loading are not expected to impair the ability of the SLNs to 
function as a drug delivery system. With the 22.50% increase in particle size, the particle 
size increased only to 123.2±0.8 nm, which is well within the 200 nm size limit 
considered appropriate for taking advantage of the EPR effect [29]. The PI also remained 
within a range considered suitably monodisperse [240, 241].  
 
Figure 8.6. The effect of drug loading on the particle size and PI of SLNs following  
lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3) 
 
 
 
8.3.1.7. Batch-to-Batch Variability. Although intra-batch variability was minimal as 
evidenced by the standard deviations given above, it was important to evaluate batch-to-
batch variability. As shown in Table 8.3, batches of both blank and 10% Dex-P loaded 
SLNs prepared on different days using the same protocol appeared to be of similar 
quality. ANOVA tests revealed no statistically significant differences in either the 
particle size or PI of SLNs prepared on different days (p>0.05).  
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Table 8.3. Batch-to-Batch variability 
Day 
Particle Size Increase (%) PI 
Blank 10% Dex-P Blank 10% Dex-P 
1 15.22±1.61% 22.50±0.81% 0.133±0.012 0.181±0.023 
2 15.16±4.18% 24.22±1.80% 0.117±0.043 0.161±0.009 
3 14.91±1.39% 27.50±0.83% 0.171±0.027 0.152±0.046 
 
8.3.1.8. Evaluation of the Optimized Lyophilized Product. Lyophilized products were 
shown to have a low water content of 1.09±0.12%, a value considered acceptable for 
lyophilized pharmaceuticals [246]. Following reconstitution, SLNs were evaluated for the 
presence of large aggregates by laser diffractometry (LD) and for shape changes by TEM. 
Although DLS is preferable for analyzing particles in the nanometer range, it has a 
limited range of analysis for particles in the micrometer or millimeter range. For 
example, the Delsa™ Nano instrument used in these studies has an analytical range of 0.6 
nm-7 μm. LD can be used as a complementary technique for evaluation of larger 
particles; the Shimadzu SALD-7101 instrument used in these studies was designed to 
study particles in the range of 0.01-300 μm. Both blank and drug-loaded SLNs appeared 
monodisperse with median diameters (D50%) of 247 and 257 nm, respectively.  
Representative particle size distributions are shown in Figure 8.7. The different particle 
sizes obtained from the two techniques can be explained by the different measurement 
principles. Of relevance for this study is that large aggregates did not appear to be present 
to any significant extent. Analysis of the reconstituted SLNs by TEM further indicated 
that the particle shape was maintained throughout the lyophilization and reconstitution 
process (Figure 8.8).  
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Figure 8.7. Representative particle size distributions obtained by laser 
diffractometry of SLNs following lyophilization and reconstitution (Blank SLNs, 
top; 10% Dex-P loaded SLNs, bottom)  
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Figure 8.8. Representative TEM images of blank (left) and 10% Dex-P loaded SLNs 
(right) following lyophilization and reconstitution  
 
 
 
Finally, drug loaded SLNs were evaluated for encapsulation efficiency. A number of 
studies have shown drug loss upon lyophilization as a result of lipid crystallization or 
phase transitions [235, 247]. However, this was not observed to any significant extent 
with the Dex-P loaded SLNs. Drug was shown to remain predominately associated with 
SLNs (97.98±1.83% retention), confirming that SLNs could be lyophilized using this 
protocol with minimal changes to the physicochemical properties of the nanoparticles.  
 
8.3.2. Stability Study. Once the lyophilization protocol was optimized to minimize 
changes in the physicochemical properties of the SLNs, lyophilized SLNs were evaluated 
for stability over a 3 month time period. Two possible storage conditions were tested 
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(4°C and 25°C/60% RH), and comparisons were made with SLNs stored as aqueous 
suspensions. Particle size and PI data are shown in Figures 8.9 and 8.10. The most 
significant particle size growth was observed with the aqueous suspensions stored at 
25°C/60% RH. With the particle size reaching nearly 500 nm within 3 months, the 
system would be considered unacceptable for use as a tumor-targeted drug delivery 
system in most cases. SLN suspensions stored at 4°C also showed growth, but it was 
much less than that observed at 25°C/60% RH. The particle size increased <40 nm, 
remaining well within the recommended 200 nm limit [29]. On the contrary, lyophilized 
SLNs showed greater consistency in their particle size measurements. The particle size of 
lyophilized SLNs stored at 4°C was maintained across the entire time period of the study. 
Lyophilized SLNs stored at 25°C/60% RH were stable up to 1 month prior to showing a 
slight increase in the particle size. In terms of PI values, all remained <0.3, generally 
considered the acceptable limit of monodispersity [240, 241]. However, increases were 
also observed over the 3 month time period with all conditions. Although the lowest 
absolute values were obtained with the aqueous suspension stored at 4°C, the increase 
over the time period of the study was smallest with the lyophilized SLNs stored at 4°C. 
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Figure 8.9. Changes in the particle size and PI of lyophilized SLNs stored at either 
4°C or 25°C/60% RH over a 3 month time period (n=3) 
 
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0 20 40 60 80 100
P
I
P
a
rt
ic
le
 S
iz
e 
(n
m
)
Time (d)
Lyophilized 4°C
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0 20 40 60 80 100
P
I
P
a
rt
ic
le
 S
iz
e 
(n
m
)
Time (d)
Lyophilized 25°C/60% RH
169 
 
 
 
 
Figure 8.10. Changes in the particle size and PI of SLNs stored as aqueous 
suspensions at either 4°C or 25°C/60% RH over a 3 month time period (n=3) 
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In analyzing the drug loading, the first step was to confirm that the drug concentration in 
the samples remained stable across the time period of the study (Figure 8.11). Comparing 
drug concentrations of each sample to the day 0 sample, it appeared that virtually 100% 
of the drug remained in the Dex-P form with no noticeable hydrolysis. Following this 
confirmation, it was then necessary to determine how much Dex-P remained associated 
with the SLNs. A two-step process was used in which any unsolubilized drug is removed 
by 0.2 μm (or 0.45 μm) filtration and free drug is removed by ultrafiltration. Figures 8.12 
and 8.13 provide information regarding the drug retention following each step. The data 
generally echoed that observed with the particle size changes. SLNs stored as aqueous 
suspensions at 25°C/60% RH exhibited the most significant drug loss. This drug loss was 
consistent across the entire time period, with the exception of the final time point. 
Interestingly, the other three samples seemed to exhibit a “plateau” encapsulation 
efficiency in the range of 75-80%. However, they differed in how long it took to achieve 
this plateau, how long the plateau was maintained, and whether the drug loss was 
primarily associated with the 0.2 μm filtration step or the ultrafiltration step. Aqueous 
suspensions stored at 4°C showed decreasing encapsulation efficiency up to 2 weeks and 
then remained approximately consistent at 75%. Lyophilized SLNs stored at 4°C showed 
a drop in encapsulation efficiency at the 3 day mark but then remained at approximately 
80% encapsulation efficiency. Results with the lyophilized SLNs stored at 25°C/60% RH 
were similar but could not be maintained. As the particle size began to increase following 
1 month of storage, drug loss was also accelerated. With both sets of lyophilized samples, 
drug loss due to the 0.2 μm filtration step was fairly consistent and less than that lost 
during the ultrafiltration step. The trend was opposite with the samples stored as aqueous 
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suspensions with the drug loss being predominantly controlled by the 0.2 μm filtration 
step. The difference may be associated with Dex-P exhibiting varying solubility in the 
presence and absence of sucrose, as has been observed with other compounds [248]. 
 
 
Figure 8.11. Stability of drug concentration in SLN samples over a 3 month time 
period (n=3) 
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Figure 8.12. Changes in the drug encapsulation efficiency of lyophilized SLNs stored 
at either 4°C or 25°C/60% RH over a 3 month time period (n=3). Data is expressed 
as % drug retention and is separated into the Dex-P concentration found in the 0.2 
μm filtrate (MF) and the retentate collected following ultrafiltration.  
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Figure 8.13. Changes in the drug encapsulation efficiency of SLNs stored as aqueous 
suspensions at either 4°C or 25°C/60% RH over a 3 month time period (n=3). Data 
is expressed as % drug retention and is separated into the Dex-P concentration 
found in the 0.2 μm filtrate (MF) and the retentate collected following 
ultrafiltration.  
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Overall, lyophilized SLNs stored at 4°C seemed to exhibit the greatest stability. Based on 
the slight decrease in encapsulation efficiency, there appeared to be some restructuring of 
the particle. However, this did not affect the particle size, and once it was complete, the 
encapsulation efficiency remained constant throughout the rest of the study. Further, with 
a size of approximately 130 nm and an encapsulation efficiency of around 80%, SLNs 
stored under these conditions could be considered suitable for use as tumor-targeted drug 
delivery system.  
 
8.4. CONCLUSIONS 
In this section, an optimized protocol for lyophilization of SLNs was developed, and 
comparisons were made between the long-term stability of aqueous and lyophilized 
SLNs. Of nine possible lyoprotectants tested, sucrose was shown to provide the best 
particle redispersibility. Specifically, a 15:1 sucrose:SA weight ratio was chosen based on 
the minimal increase in particle size and PI observed with this condition. A series of 
experiments also showed that better redispersibility could be obtained using lower SLN 
concentrations, higher freezing temperatures, slower freezing rates, and longer secondary 
drying times. The choice of reconstitution media was shown to have a negligible effect 
on the particle redispersibility. Larger particle size and PI increases following 
lyophilization were observed with drug loaded SLNs, but both parameters remained 
within an acceptable range for a tumor-targeted nanoparticle drug delivery system. 
Encapsulation efficiency and particle shape were maintained following lyophilization, 
and no large aggregates could be detected. Lyophilized SLNs stored at 4°C exhibited the 
greatest stability during the 3 month study. Particle size was maintained across the entire 
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time period. A slight reduction in encapsulation efficiency was observed within the first 3 
days of storage but then remained consistent at approximately 80%.  
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Chapter 9 
Summary and Conclusions 
 
The guiding hypothesis for this dissertation was that the interactions among the 
components of SLNs decrease the crystallinity of nanoparticle lipids resulting in 
enhanced drug loading and decreased nanoparticle stability. To this end, the following 
specific aims were identified: 1) to fully characterize nanotemplate engineered SLNs for 
their physicochemical properties including particle size, shape, structure, and changes in 
the extent or type of crystallinity from the starting materials due to interactions among the 
nanoparticle components, 2) to assess the degree of loading of Dex-P into nanotemplate 
engineered SLNs compared to other compounds of similar structure or lipophilicity, 3) to 
evaluate the stability of nanotemplate engineered SLNs in conditions mimicking those of 
human plasma as a function of time, 4) to determine if the PEGylating agents 
incorporated into SLNs are affected by the CE activity of the surrounding environment, 
and 5) to determine if the storage stability of drug loaded SLNs is enhanced when using 
lyophilization protocols that minimize changes in the physicochemical properties of the 
nanoparticles. 
 
Based on early work from this laboratory, two formulations were chosen for evaluation. 
SA was used as the lipid phase with Brij
®
 78 and PS60 as surfactants in both 
formulations; the second formulation differed by the inclusion of a long-chain 
PEGylating agent, PEG6000MS. Both formulations exhibited a particle size of <100 nm, 
an ellipsoidal shape, and low polydispersity.
 
SLNs were shown to have the expected solid 
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core structure and PEGylated surface based on 
1
H-NMR spectroscopy. Analysis of the 
bulk materials indicated that a number of complex interactions are present among the 
SLN components, including a eutectic between SA and Brij
®
 78. Unfortunately, the low 
melting point of the eutectic was shown to limit the physiological stability of the SLNs, 
specifically in the formulation lacking PEG6000MS. For this reason, formulation 2 SLNs 
in which PEG6000MS was included, were chosen for further studies.  
 
Following this choice of formulation, SLNs loaded with Dex-P were prepared and 
evaluated for changes in their physicochemical properties. High drug loadings of up to 
30% w/w SA could be obtained while maintaining drug encapsulation efficiencies >85%. 
The core-shell structure of the particles was maintained at all drug loadings, and although 
particle size was shown to increase with drug concentration, it remained within the size 
range considered suitable for tumor-targeting by the EPR effect.  Interestingly, a 
transition from ellipsoidal- to rod-shaped particles was observed at the 30% drug loading. 
Analysis of the drug-matrix interactions by DSC indicated that Dex-P likely resided at 
the core-shell interface with the palmitate chain serving to anchor the drug within the 
solid SA and Dex interacting with the SA-Brij
®
 78 phase. A small burst release of Dex-P 
(<20%) was observed within the first 3 h of incubation at 37°C followed by a slower 
release over the remaining time period. For comparison, AP and curcumin were also 
evaluated for their extent and mechanism of drug loading as well as for their effects on 
SLN properties. AP interacted more favorably with the SA-PEG6000MS phase than with 
the SA-Brij
®
 78 eutectic but seemed to adopt a similar conformation to Dex-P, allowing 
for high drug loadings. The drug loading of curcumin was more limited, and its release 
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from the SLNs was faster than Dex-P. This difference was attributed to the lack of 
interaction between curcumin and the solid SA phase of the particle. From this data, it 
appears that these SLNs have a great potential for high drug loading based on the 
decreased crystallinity of SA described above. However, this potential is modulated by 
the ability of the drug to interact with the SLN components, which may be correlated 
with its structure. 
 
Previous studies indicated that drug release from the SLNs was dependent on the CE 
activity of the surrounding environment. However, additional studies were required to 
evaluate the stability of the nanoparticles in both the presence and absence of CE activity. 
When incubated at 37°C in the absence of protein, SLNs increased in diameter by 
approximately 40 nm within a 24 h time period but appeared to retain their ellipsoidal 
shape. Analysis of SLNs incubated with 10% HSA by DLS, UV/Visible spectroscopy, 
and SEC indicated the possibility of minor protein adsorption on the particles, but no 
evidence of particle disassociation or aggregation was observed. Although Dex-P 
association with SLNs was slightly lower in the presence of 50% human plasma than in 
PBS alone (85.5%<96.2% at 24 h), it appeared that the majority of enzymatic drug 
release was taking place at the surface of the SLNs.  
 
Interestingly, even in the absence of Dex-P, SLNs demonstrated some instability in the 
presence of CE that could be attributed to hydrolysis of the PEG-ester compounds. Blank 
SLN suspensions became extremely turbid within the first 30 min following exposure to 
CE indicating dissociation or aggregation of at least a portion of the nanoparticles. The 
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particle size of SLNs incubated with CE was smaller than the size of controls at all time 
points studied, although particle shape appeared similar as determined by TEM images 
taken following 1 and 24 h incubations. Although SLNs offered some protection over 
micelles, PEG6000MS was rapidly degraded within 15 min. PS60 hydrolysis was much 
slower, reaching only 36% in 2 h. These results indicated that the accelerated release of 
Dex observed in the presence of CE may be partially attributable to increased 
accessibility of the prodrug to enzymes following hydrolysis of the ester-containing 
materials PS60 and PEG6000MS.  
 
During the last stage of this project, a lyophilization protocol designed to minimize 
changes in the physicochemical properties of the SLNs was developed, and the long-term 
storage stability of SLNs was evaluated. Sucrose was shown to provide the best particle 
redispersibility among the nine lyoprotectants that were evaluated. Specifically, a 15:1 
weight ration of sucrose:SA was chosen based on the minimal increase in particle size 
and PI observed with this condition. Lower SLN concentrations, higher freezing 
temperatures, slower freezing rates, and longer secondary drying times were also shown 
to contribute to better redispersibility. A variety of both lab and clinically relevant 
solutions could be used to reconstitute the SLNs with negligible effects on the 
physicochemical properties of the particles. Larger particle size and PI increases 
following lyophilization were observed with drug loading, but both parameters remained 
within an acceptable range for a tumor-targeted nanoparticle drug delivery system. 
Changes in the encapsulation efficiency and particle shape following lyophilization were 
minimal. Also, no large aggregates were produced during the process. During the 3 
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month stability study, comparisons were made between lyophilized SLNs and SLNs 
stored as aqueous suspensions and between SLNs stored at either 4°C or 25°C/60% RH. 
The greatest stability was observed with lyophilized SLNs stored at 4°C. Particle size 
was maintained across the entire time period, and encapsulation efficiency was shown to 
be consistent at 80% following a reduction to this value within the first 3 days of storage.  
 
The results of these studies support the proposed hypothesis. The interactions among the 
SLN components were shown to result in decreased crystallinity of the lipid phase. This 
was advantageous in terms of achieving a high drug load but did have negative 
ramifications in terms of the stability of the particles. However, for practical 
considerations, the stability of the SLNs could be improved by adjustments to the 
formulation (e.g., the addition of PEG6000MS and the reduction in the Brij
®
 78 
concentration) and storage conditions (e.g., lyophilization). Further, instability in the 
presence of CE likely contributed to the accelerated drug release observed in CE-
containing media and may be used as a trigger for achieving bioresponsive drug release. 
 
In conclusion, this work yielded valuable information in regard to both the drug delivery 
system under study and nanoparticles in general. Several observations were reported with 
the nanotemplate engineered SLNs that may be of relevance to other nanoparticle 
systems. For instance, the in-depth crystallinity analysis led to the discovery of complex 
interactions among the SLN components that have a major effect on the particle behavior. 
This points to the importance of analyzing bulk materials in order to identify potential 
issues that may arise with the nanoparticles (e.g., physiological stability) prior to 
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performing expensive and time-consuming in vitro or in vivo studies. It is also possible 
that these interactions may be utilized advantageously in other systems. The drug loading 
analysis provided information regarding the mechanism of drug packing within SLNs and 
outlined some tools that may be utilized to predict how and to what extent drugs can be 
loaded into SLNs. As another example, evidence of instability of the ester-containing 
PEG compounds in the presence of CE may provide an explanation for the poor in vivo 
results observed with other PEG-coated nanoparticle systems. It also provides 
justification for evaluating such stability prior to undertaking animal studies. 
 
 In terms of the drug delivery system itself, SLNs could be prepared using formulation 2 
with desirable physicochemical properties and sufficient stability to warrant further 
development. Future studies must be aimed at determining the biodistribution and 
therapeutic efficacy of these SLNs in vivo. Due to the hydrolysis of Dex-P as well as the 
ester-containing PEGylating agents in the presence of CE, alternative animal models 
must be employed for these studies. Currently, the most feasible option seems to be the 
carboxylesterase-deficient Es1e(-/-)/SCID mouse model. Although drug was still released 
to a greater extent in the plasma from these animals than from human plasma, it is likely 
to be the most closely representative situation of the small animal models. Further, if 
results could be shown to be improved using this animal model as compared to normal 
mice or rats, it would provide validation for the CE-triggered drug release and give 
confidence that results in humans would be improved to an even greater extent.  
  
 
Copyright © Melissa Howard 2011 
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Appendices 
 
 
This section contains the following additional information: 
 
 Appendix A: Abbreviations 
 Appendix B: Analytical Techniques 
 Appendix C: Surfactant Micelle Evaluation 
Appendix D: Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable 
Release of Dexamethasone 
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Appendix A 
 
Abbreviations 
 
Throughout this dissertation, abbreviations are given following the first use of a word or 
phrase. However, for convenience, Table A.1 includes an alphabetical list of the 
commonly used abbreviations. 
 
Table A.1. Abbreviations   
AA Ascorbic acid 
ACN Acetonitrile 
AP Ascorbyl palmitate 
BNPP Bis(4-nitrophenyl) phosphate 
CE Carboxylesterase 
CHCl3/CDCl3 Chloroform/Deuterated chloroform 
Dex Dexamethasone 
Dex-P Dexamethasone palmitate 
DLS Dynamic light scattering 
DSC Differential scanning calorimetry 
EPR Enhanced permeability and retention 
FFA Free fatty acid 
H2O/D2O Water/Deuterated water 
HPH High pressure homogenization 
HPLC High performance liquid chromatography 
HSA Human serum albumin 
IFP Interstitial fluid pressure 
LD Laser diffractometry 
LP Lyoprotectant 
MDR Multidrug resistance 
MeOH Methanol 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NET Nanotemplate engineering technology 
NF-κB Nuclear factor kappa B 
NMR Nuclear magnetic resonance 
P-gp P-glycoprotein 
PBS Phosphate buffered saline 
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Table A.1. Abbreviations (continued)  
PEG Poly(ethylene glycol) 
PEG6000MS PEG6000 monostearate 
PI Polydispersity index 
PS60 Polysorbate 60 
PSD Pooled standard deviation 
PVA Polyvinyl alcohol 
PVP Poly(vinylpyrrolidone) 
RES Reticuloendothelial system 
RH Relative humidity 
RI Refractive index 
SA Stearyl alcohol 
SD Standard deviation 
SEC Size exclusion chromatography 
SLN Solid lipid nanoparticle 
TEM Transmission electron microscopy 
TLC Thin layer chromatography 
UV Ultraviolet 
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Appendix B 
Analytical Techniques 
 
This section is intended to provide an explanation of the analytical techniques used 
throughout this dissertation as well as to provide information regarding their application 
as appropriate.   
 
B.1. PARTICLE SIZING TECHNIQUES 
B.1.1. Dynamic Light Scattering (DLS) 
Both DLS and laser diffractometry (LD, described in detail below) make use of the light 
scattering property of particles in determining the particle size distribution. As light 
waves strike the particle, the electron orbits of the included molecules are perturbed with 
the same frequency as the electric field of the incident wave. This generates an induced 
dipole within the molecule, which manifests itself as a source of electromagnetic 
radiation, resulting in scattered light. Basically, the end result is that the direction and 
intensity of the light appears changed though its wavelength/energy remain the same 
[249]. This scattering primarily results from diffraction, refraction, and reflection of the 
light (Figure B.1). 
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Figure B.1. Mechanisms of light scattering 
 
 
DLS is a technique primarily used to determine the size of sub-micron particles 
suspended in a liquid [250]. It is based on the measurement of the Brownian motion of 
the particles, which is their random movement due to the bombardment by solvent 
molecules that surround them. By accounting for the viscous forces and thermal energy 
that affect particle movement, the particle size can be inversely correlated with particle 
velocity. This relationship is known as the Stokes-Einstein equation: 
   
  
    
 
where d is the diameter of the particle, k is the Boltzmann‟s constant (1.38 x 10-23 J/K), T 
is the temperature in kelvins,   is the viscosity, and D is the translational diffusion 
coefficient. It is important to recognize that the diameter measured by this technique is 
the hydrodynamic diameter of the particle and can be affected by the particle‟s surface 
properties as well as the concentration and type of ions in the surrounding environment 
(Figure B.2). 
Diffraction 
Refraction 
Reflection 
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Figure B.2. The measured hydrodynamic diameter of a particle 
 
 
The instrument is set up so that a laser is focused on the sample of interest. As the light 
passes through the dispersion, it is scattered by the particles, and the scattered light is 
detected. Because the particles are in motion, the intensity of the scattered light 
fluctuates; the rate at which these intensity fluctuations occur will depend on the size of 
the particles. A representative diagram of a DLS instrument set-up is shown in Figure 
B.3. 
Hydrodynamic Diameter 
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Figure B.3. Schematic diagram of a dynamic light scattering instrument 
 
 
 
Following detection, intensity signals are compared using a correlator with the goal of 
generating an autocorrelation function (Figure B.4) [251]. Basically, the correlator 
compares the intensity, I, at time t with that at time t + τ.  Similar intensities are said to 
exhibit high correlation. Normalization of the intensity function by average intensities 
allows the correlation to be expressed within a range of 0-1: 
     τ   
          τ  
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where g
(2)
(t) is the normalized intensity autocorrelation function, I(t) is the intensity 
detected at time t, τ is the delay time,         is the normalization factor, and brackets 
(<>) indicate a time average. For small particles, in which intensity fluctuations are rapid, 
there is little similarity between the signals at different time points and the correlation 
decays quickly. For larger particles with slower intensity fluctuations, the correlation may 
persist for a long time.  
 
Figure B.4. Representative intensity versus time graphs (left) for small (top) and 
large (bottom) particles with their corresponding autocorrelation functions (right) 
 
 
 
For particles that exhibit Brownian motion, the normalized intensity autocorrelation 
function will be an exponential function or a sum of exponentials. Using the Siegert 
relationship, the intensity autocorrelation function can be converted to the autocorrelation 
function of the electric field of the scattered light,      τ :  
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     τ        τ    + 1 
If the particles are monodisperse,      τ  will be a single exponential: 
      τ      τ 
where B is a constant dependent on instrument parameters and   is a decay constant 
proportional to the diffusion coefficient: 
 = Dq2 
In this equation, D is the diffusion coefficient and q is the magnitude of the scattering 
vector: 
  
       θ   
λ
 
where n is the refractive index of the media, λ is the wavelength of the incident light, and 
θ is the scattering angle. In the case of polydisperse particles,      τ  will be the sum of 
exponentials with differing decay constants: 
     τ       
 
    τ  
where Ai is the relative intensity of light scattered by a particle with decay constant  i and 
is related to the amount of such particles.  
 
As the final step in the analysis, the correlation function is fit using various algorithms to 
determine the particle size. The most commonly applied analysis is the cumulants 
analysis. However, it is most appropriately applied only when samples are monodisperse. 
In this analysis, the logarithm of      τ  is fit to a polynomial in τ to determine the 
coefficients, Km: 
        τ        τ 
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The first order coefficient [or the slope of          τ    is the average decay constant < > 
from which the diffusion coefficient and particle size (z-average diameter) can be 
determined. The second order coefficient (< -< >)2 divided by < >2 is the PI, which is 
an estimate of the width of the particle size distribution.   
 
In the case of multiple particle populations, a multiple exponential can be fit to the 
correlation function using algorithms, such as CONTIN, Marquardt, and non-negative 
least squares (NNLS). The NNLS technique is the simplest, solving the matrix so that 
only positive values for Ai are obtained. The CONTIN method also uses an NNLS 
technique but in combination with an eigenfunction analysis. The Marquardt method uses 
repeated iterations from an initial guess to fit the data.  
 
B.1.2. Laser Diffractometry (LD) 
LD is the second light scattering technique used in these studies to determine the particle 
size. However, it relies on different principles than DLS and is most commonly used for 
particle populations in the micron range (though the exact range depends on the 
properties of the instrument chosen). This technique is based on the fact that particles 
scatter light at angles that are related to their size [252]. There is a logarithmic increase in 
the scattering angle with a decrease in the particle size as well as a decrease in the 
scattering intensity. Basically, larger particles scatter light at narrow angles with high 
intensity while smaller particles scatter at wider angles but with less intensity. A 
representative instrument set-up is shown in Figure B.5.  
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Figure B.5. Representative set-up of a laser diffractometer 
 
 
 
Two models are used in analyzing LD data: the Fraunhofer Approximation and the Mie 
Theory [252]. Though the Fraunhofer Approximation was used with early LD 
instruments, it has since been shown to be in error when measuring particles <50 μm in 
size. For this reason, the Mie theory was introduced. It is based on Maxwell‟s 
electromagnetic field equations and can predict the particle size of a much wider range of 
particles. The calculations involved with Mie Theory are complex and will not be 
discussed here, but the premise is that the particle size can be calculated based on the 
scattering response of the particles.  
 
B.1.3. Transmission Electron Microscopy (TEM) 
TEM is a microscopic technique commonly used for the analysis of materials on the 
nanoscale. Because it uses electrons, which have a shorter wavelength than light, it is 
capable of achieving resolution a thousand times better than can be achieved with a light 
microscope [253]. Instruments consist of three main parts: 1) the electron gun that 
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produces the electron beam (usually a tungsten filament coupled to a high voltage source) 
and the electromagnetic condenser lens that focuses it on the sample, 2) the image-
producing system (consisting of the sample stage along with the electromagnetic 
objective, intermediate, and projector lenses that focus the electrons passing through the 
sample to form a highly magnified image), and 3) the image-recording system (consisting 
of a fluorescent screen for viewing the image and a digital camera for recording the 
image). A representative instrument set-up is shown in Figure B.6. Although not shown, 
all instruments are also equipped with a vacuum system. Samples must be analyzed under 
vacuum in order to minimize the collision frequency of electrons with gas atoms. 
 
 
Figure B.6. Schematic diagram of a transmission electron microscope. Adapted 
from [253]. Reproduced with permission from Transmission Electron Microscope 
(TEM). Encyclopedia Britannica. Encyclopedia Britannica Online. Encyclopedia 
Britannica, 2011. 
<http://www.britannica.com/EBchecked/topic/602949/transmission-electron-
microscope>. Copyright © 2008 Encyclopedia Britannica, Inc. 
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Sample preparation for nanoparticles typically consists of applying the suspended 
nanoparticles to a grid formed from a conductive metal and coated with carbon and 
allowing them to dry. The use of the conductive metal disperses the electron beam and 
prevents damage to the sample, while the carbon coating improves interactions with the 
samples. Depending on the thickness of the sample in comparison to the wavelength of 
the electrons, some electrons pass through the specimen while others are scattered, 
generating the specimen image. However, due to the insufficient contrast for most 
samples, stains are commonly required. In order to not obscure details of the samples, 
negative staining is used more frequently than positive staining. This results in staining of 
the background while the samples are left unstained. The most popular negative stains are 
salts of heavy metals known to be good electron scatterers. Their application results in 
the images having a dark background while the samples appear lighter.  
 
B.2. NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY 
B.2.1. 
1
H-NMR Spectroscopy 
1
H-NMR spectroscopy is the most commonly used analytical technique for the evaluation 
of molecular structures [254]. It is based on the proton having a nuclear spin of ½, which 
causes it to behave as a magnet. When this small “magnet” is placed within a larger 
magnetic field, the proton can align either with (α, lower energy state) or against (β, 
higher energy state) the magnetic field (Figure B.7). The energy difference between the 
two spin states is proportional to the strength of the magnetic field: 
    
 
  
  , 
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where ΔE is the energy difference between the two spin states, h is Planck‟s constant 
(6.626 × 10
-34
 J∙s), B0 is the strength of the external magnetic field, and γ is the 
gyromagnetic ratio (26,753 sec
-1 
gauss
-1
 for a proton). Following treatment with 
electromagnetic radiation in the radiofrequency (RF) range, nuclei may absorb the 
necessary photon of energy for promotion from the lower energy state to the higher 
energy state. It is this absorption of energy that is detected by the NMR spectrometer. 
Differences in the nuclei arise from the shielding of surrounding electrons, which allows 
for the determination of chemical structures.  
 
Figure B.7. (a) Nuclear spins align either with (α) or against (β) the applied 
magnetic field, (b) leading to an energy difference that is dependent on the strength 
of the external magnetic field, B0. 
 
 
 
B.2.2. Relaxation Time Measurements 
Following the promotion of a nucleus to a higher energy state, the energy must 
subsequently be given off in order for the nucleus to return to the lower energy state. This 
is referred to as relaxation. Nuclear relaxation can be broken into two components: 
longitudinal or spin-lattice (T1) and transverse or spin-spin (T2). This is based on the fact 
b) a) 
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that when a magnetic field (B1) is applied perpendicularly to the static magnetic field 
(B0), the nuclear spin experiences a different effective magnetic field (Beff) (Figure B.8) 
[255]. The magnetization vector is correspondingly tipped from the longitudinal plane 
into the transverse plane, and relaxation must take place in both directions. Obtaining 
information on the time necessary for the relaxation process can provide valuable 
information regarding the environment of the molecule in question. Specifically, T1/T2 
ratios much greater than 1 are indicative that a molecule (or portion of a molecule) is 
highly constrained with little flexibility, whereas T1/T2 ratios close to 1 indicate that a 
molecule (or portion of a molecule) is free in solution.  
  
Figure B.8. Nuclei precess around the longitudinal magnetic field, B0, with a 
magnetization vector, M (a). Application of a transverse magnetic field, B1, causes 
the nuclear spin to experience a different effective magnetic field, Beff, and a 
corresponding change in M (b).  
 
a 
a) 
b) 
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Longitudinal relaxation involves an exchange of energy between the excited spins and the 
surrounding molecules (the lattice) as thermal motion or heat. A number of processes can 
be involved, including dipolar coupling, quadrapolar coupling, paramagnetic interactions, 
scalar coupling, chemical shift anisotropy, and spin rotation [256]. The most commonly 
applied experiment used for the determination of T1 values is an inversion recovery 
sequence (Figure B.9). A 180° pulse is applied to invert the longitudinal magnetization 
(while not applying any transverse magnetization). This is followed by a delay (t) and a 
90° pulse prior to detection. The sample undergoes longitudinal relaxation during the 
delay but does not necessarily reach equilibrium, giving a signal that is only a fraction of 
that obtained with the sample in its original state. The experiment is repeated numerous 
times with various delay periods, allowing for the generation of a curve comparing the 
signal intensity with the time delay. Fitting of this curve allows for the calculation of the 
longitudinal relaxation time (T1), which is considered the time necessary to reduce the 
difference between the longitudinal magnetization and its equilibrium value by a factor of 
e (Figure B.10). 
 
Figure B.9. Inversion recovery experiment used for the determination of T1 
relaxation times 
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Figure B.10. The spin-lattice relaxation time, T1, is defined as the time necessary to 
reduce the difference between the longitudinal magnetization (MZ) and its 
equilibrium value by a factor of e. 
 
 
 
Transverse relaxation involves excited spins exchanging energy with each other and is a 
shorter process than longitudinal relaxation. Relaxation mechanisms may be similar to 
those seen with longitudinal relaxation but may also involve spins interacting through J 
coupling [256]. Although in theory, T2 values could be determined from the linewidths 
obtained following a 90° pulse, these can be skewed based on magnetic field 
inhomogeneity (resulting values are given the term T2*). To account for this, the Carr 
Purcell Meiboom Gill sequence is typically employed for determination of T2 values 
(Figure B.11).  This sequence begins with a 90° pulse to shift the magnetization vector 
out of the longitudinal plane into the transverse plane. Following a delay (t), a 180° pulse 
is applied to flip the magnetization in the y direction. A delay of “2t” is allotted, followed 
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by a second 180° pulse and a final delay of “t” time. The signal is then detected, and 
again, a curve can be prepared comparing the delay time with the signal. The time needed 
to reduce the transverse magnetization by a factor of e is then considered the actual T2 
relaxation time (Figure B.12). 
 
Figure B.11. The Carr Purcell Meiboom Gill sequence applied for the determination 
of T2 relaxation times 
 
 
Figure B.12. The spin-spin relaxation time (T2) is defined as the time necessary to 
reduce the transverse magnetization by a factor of e.  
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B.3. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
DSC is an analytical technique based on comparing the difference in the amount of heat 
required to increase the temperature of a sample in comparison with a reference at the 
same rate [257]. A representative instrument set-up is shown in Figure B.13. Larger 
amounts of heat are required to keep the sample increasing in temperature at the same 
rate as the reference. First, the sample will have a higher heat capacity than the reference. 
Secondly, the sample may undergo thermal transitions (melting, recrystallization, glass 
transition, etc) that require large inputs of heat at certain temperatures. By plotting the 
heat input required versus temperature, information regarding both heat capacity and 
phase transitions can be obtained.  
 
Figure B.13. Schematic of a differential scanning calorimeter 
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B.4. POWDER X-RAY DIFFRACTION (PXRD) 
PXRD is an analytical technique primarily used for phase identification of crystalline 
materials; additional information may be gained on crystal structure as well [258]. It is 
based on the fact that as X-rays hit atoms, they are diffracted. In the absence of atomic 
order, the diffracted waves will be random and will interfere destructively. However, in 
the presence of crystalline material, there will be constructive interference in some 
directions (Figure B.14). This can be described by Bragg‟s law: 
         
where λ is the X-ray wavelength, d is the distance between crystalline planes, and θ is the 
angle between the incident ray and the scattering planes. Because the wavelength is fixed 
by the instrument, the X-ray tube and/or the detector must move in order to achieve the 
necessary θ angles for constructive interference (Figure B.15). The result is that each 
type of crystal generates a distinctive diffraction pattern.  
 
Figure B.14. Schematic depicting Bragg’s Law 
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Figure B.15. Schematic of a powder X-ray diffractometer 
 
 
 
B.5. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
As with all chromatography techniques, HPLC is an analytical technique designed to 
separate mixtures [259]. It involves the flow of solvent (mobile phase) through a column 
(stationary phase) at high pressures. Samples are injected onto the column, and molecules 
within the sample are separated based on their properties. In this dissertation, reversed 
phase HPLC is employed in which the stationary phase is non-polar and the mobile phase 
is more polar.  Separation is based on the hydrophobicity of the molecules with more 
polar compounds coming off the column more quickly. Detection techniques can be 
chosen as appropriate.  
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B.6. SIZE EXCLUSION CHROMATOGRAPHY (SEC) 
SEC is a chromatographic technique designed to separate materials (molecules, 
macromolecules, colloids) based on their size [260]. Similarly to HPLC, samples are 
added to a column through which mobile phase is flowing. Mobile phase can be pumped 
through the column or run through using gravity flow. Larger materials fail to enter the 
pores of the column and pass through the column quickly, whereas smaller materials 
enter the pores of the column and are retained for a longer period of time. When an 
aqueous solution is used as the mobile phase, SEC is referred to as gel filtration 
chromatography (GFC). When an organic solvent is employed, SEC is termed gel 
permeation chromatography (GPC). Detection techniques can be chosen as appropriate. 
 
B.7. KARL FISCHER COULOMETRIC TITRATION 
The Karl Fischer titration is a commonly used titrimetric method for the determination of 
trace amounts of water in a sample [261]. The titration is based on two reactions. In the 
first, an alcohol (ROH), sulfur dioxide (SO2), and a base (R‟N) react to form an 
alkylsulfite intermediate: 
ROH + SO2 + R‟N ↔ [R‟NH]SO3R 
During the second reaction, this intermediate reacts with iodine (I2) and water from the 
sample: 
[R‟NH]SO3R + I2 + H2O + 2R‟N ↔ [R‟NH]SO4R + 2[R‟NH]I 
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Because water and iodine are consumed in equimolar amounts during the second 
reaction, the consumption of iodine can be monitored to provide information on the 
presence of water in the sample. In the volumetric method, iodine is included with the 
reagents. However, with the coulometric method, which is used in this study, iodine is 
generated at an electrode. 
 
The extent of reaction is monitored bipotentiometrically, meaning that electrical 
conductivity changes of the reaction solution are measured.  As sulfur is oxidized in the 
second reaction, two electrons are produced that react with iodine: 
I2 + 2e
- → 2I- 
This changes the electrical potential of the system, and the change is detected by an 
electrode. 
 
Practically speaking, the alcohol generally used for the reaction solution is methanol. 
Substitutions have been made in the case of sample insolubility in methanol or side 
reactions with methanol. Pyridine was originally used as the base but has been replaced 
by imidazole (Figure B.16). As a stronger base, imidazole serves to shift the balance of 
reaction 1 to the right. Further, it lacks the unpleasant odor and toxicity associated with 
pyridine. 
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Figure B.16. Structures of bases used in Karl Fischer Titration: Pyridine (left) and 
Imidazole (right) 
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Appendix C 
 
Surfactant Micelle Evaluation 
 
 
 
C.1. INTRODUCTION 
A careful evaluation of the uniformity of any drug delivery system is important, 
specifically in the case of SLNs where the low molecular weight surfactants used for 
stabilization are known to form other structures, such as micelles [34]. As such, it was 
deemed important to gain background information on the potential self-assembly of all 
components used in the formation of the SLNs under study.  
 
C.2. PYRENE CMC ASSAY 
C.2.1.  Background 
Pyrene is a polynuclear aromatic compound with a strong fluorescence spectrum (Figure 
C.1). Due to its different, non-planar structure in its excited state as compared to its 
ground state, certain emission bands in its fluorescence emission spectrum are very 
sensitive to the solvent‟s polarity [262].  This makes it a valuable probe molecule for 
CMC determination because, as micelles form, they entrap pyrene, causing it to 
experience a more hydrophobic environment than when it is free in the aqueous solution. 
This results in a corresponding change in its emission spectrum [263].  
 
Figure C.1. Structure of pyrene 
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C.2.2. Experimental Method 
The assay consisted of adding pyrene (67.6 μL of a 0.1 mg/mL acetone solution) to clean 
7 mL vials and allowing it to evaporate. Five milliliter surfactant samples prepared in 
Milli-Q water at relevant concentrations were then added to the vials and allowed to 
shake overnight at 100 rpm in the dark. Two milliliters of each sample were then added 
to a quartz cuvette and analyzed by a Varian Cary Eclipse Fluorescence 
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The following 
conditions were used: excitation wavelength, 335 nm; emission spectra, 350-500 nm; 
excitation slit width, 5 nm; emission slit width, 1.5 nm; slow setting. Before the first 
sample was loaded into the quartz cuvette and between every sample, the cuvette was 
washed with acetone to eliminate any pyrene residue and then subsequently washed with 
deionized water to remove any remaining acetone.  Samples were analyzed to retrieve the 
peak intensities using the Cary Eclipse software.  The ratio of the first (I1 ~ 372 nm) and 
third (I3 ~ 383nm) peak intensities was plotted against the surfactant concentration.  
Concentration is expressed in mM values for comparison with the literature. 
Manufacturer reported molecular weight values were used for Brij
®
 78 (1151.56 g/mol) 
and PS60 (1311.67 g/mol). A value of 10,643 g/mol was used for PEG6000MS based on 
the SEC-determined molecular weight of free PEG (chapter 7). Two different methods 
were used for computing the CMC [264]. For the tangent method, the curve was fit using 
two linear equations (one for the rapidly varying part and one for the nearly horizontal 
part), and the point of intersection was defined as the CMC. For the inflection method, 
the OriginPro8.5 program was used to fit the curve using a Boltzmann-type sigmoid, and 
the inflection point was used as the CMC. Each experiment was repeated twice to provide 
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an average and standard deviation. Experimentally determined values were compared to 
literature values where available.  
 
C.2.3. Results and Discussion 
Representative curves for Brij
®
 78, PS60, and PEG6000MS are shown in Figure C.2. 
Experimentally determined CMC values are given in Table C.1. The results from the 
inflection and tangent methods are shown. Both have been used in the literature, though 
the inflection method is more commonly applied for nonionic surfactants with low CMC 
values (<1 mM) [264]. In this case, the PS60 literature values agreed better with the 
CMCtangent value, whereas the Brij
®
 78 literature value agreed more closely with the 
CMCinflection method. No literature data was available for PEG6000MS. Of greatest 
importance for this study was the observation that the three surfactants can all form 
micelles at the concentrations used in SLN preparation [PS60, 0.4 mg/ml≈0.3050 mM (> 
12 times the CMC); Brij
®
 78, 2.8 mg/ml≈2.4315 mM (> 180 times the CMC); 
PEG6000MS, 3.0 mg/ml≈0.2819 mM (>10 times the CMC)]. Preparations of SA and 
Dex-P were also analyzed, but I1/I3 ratios were consistent across the entire concentration 
range. 
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Figure C.2. Representative plots of the variation in the I1/I3 ratio of pyrene peak 
intensities (I1 ~ 372 nm, I3 ~ 383nm) with concentration for Brij
®
 78, PS60, and 
PEG6000MS  
 
Table C.1. CMC values of Brij
®
 78, PS60, and PEG6000MS 
 
Sample 
Experimental Values Literature 
CMCinflection 
(mM) 
CMCtangent 
(mM) 
CMC (mM) Method 
Brij
®
 78 0.0092±0.0023 0.0135 ± 0.0006 0.0050 [265] Surface tension 
PS60 0.0135±0.0006 0.0240 ± 0.0005 
0.0206 [266] Surface tension 
0.0209 [266] 
Iodine 
absorbance 
PEG6000MS 0.0178±0.0007 0.0271 ± 0.0001 Previously unreported 
 
 
 
C.3. TEM 
DLS is one technique that can be used in analyzing nanoparticle suspensions for the 
presence of micelles. The SLNs under study appear monodisperse (Figure C.3) and are 
characterized by low PI values (<0.1). Representative formulation 1 SLNs were 
characterized by a D10% of 45.4 nm, a D50% of 58.4 nm, and a D90% of 75.3 nm. 
Representative formulation 2 SLNs exhibited a D10% of 67.8 nm, a D50% of 85.6 nm, 
1
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and a D90% of 109.9 nm. However, in this case, a dilution step was required to bring the 
SLN sample intensity within the range appropriate for the instrument, which would dilute 
PS60 and PEG6000MS micelles below their CMC values. This makes it difficult to 
conclude the absence of micelles from the DLS analysis.  
 
Figure C.3. Representative DLS intensity distributions for formulation 1 (left) and 
formulation 2 (right) SLNs 
 
 
 
TEM was chosen as an alternative technique for analysis. Brij
®
 78, PS60, and 
PEG6000MS were prepared at the concentrations used in SLN preparation and imaged 
using the same protocol as described in chapter 4 (Figure C.4). Brij
®
 78 and PS60 had a 
dense population of small dots. When analyzed using ImageJ, the sizes were determined 
to be 13.3±4.2 nm and 23.1±3.4 nm (mean ± SD of 10 micelles), respectively. 
PEG6000MS micelles appeared larger at a size of 37.7±8.8 nm. In the majority of SLN 
images (e.g., those in chapter 4), particles in this size range cannot be observed, 
indicating the absence of micelles. In some SLN images, there were some dots 
intermediate within this size range (17.3±2.1 nm), but these could be traced to the 
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background associated with the stain itself (18.5±4.4 nm). Overall, it appeared likely that 
micelles were not present to any great extent within SLN suspensions.  
 
 
 
Figure C.4. TEM images of formulation 2 SLNs without background dots (a), 
formulation 2 SLNs with background dots (b), uranyl acetate stain (c), Brij
®
 78 
micelles (d), PS60 micelles (e), and PEG6000MS micelles (f) 
 
 
 
Copyright © Melissa Howard 2011 
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Appendix D 
Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable Release of 
Dexamethasone* 
 
 
 
D.1. INTRODUCTION 
Polymer micelles are polymer nanoassemblies with a distinctive core-shell structure. 
They have been touted as promising drug carriers because they can protect drug payloads 
from the in vivo environment by entrapping drugs in a hydrophobic core enveloped by a 
hydrophilic shell [267].  Several preclinical and clinical studies have shown that polymer 
micelles improve the bioavailability and tumor-targeted delivery of various therapeutic 
agents while allowing chemical modifications to the core and shell for multifunctional 
applications [268].  
 
Furthermore, these systems can be designed so that drugs are released in tumors in 
response to a biological stimulus [269-271]. For example, in a process known as the 
Warburg effect, cancer cells consume glucose inefficiently and produce a large amount of 
lactic acid that acidifies tumor tissues [272]. Drug conjugation through acid-sensitive 
hydrazone bonds may then lead to accelerated drug release at the tumor site [273]. In 
addition to providing a second method for tumor-targeting, this technique also provides 
opportunities for tuning drug release to achieve an appropriate profile. By modifying the 
chemistry surrounding the drug linker, drug release can be modulated so that tumors are 
treated with the appropriate drug concentration and schedule [274].  
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For these reasons, pH-sensitive polymer micelles were investigated as an alternative 
delivery system for Dex. Poly(ethylene glycol)-poly(amino acid) block copolymers were 
chosen because they have been shown to be a versatile drug delivery platform to design 
multifunctional drug carriers [275]. Dex was entrapped using hydrazone-ester dual 
linkers to achieve pH-controlled drug release in a tunable manner (Figure D.1A). The 
dual linkers consist of acid-labile hydrazone (a) and enzymatically degradable ester (b) 
linkages while spacers (X) modulate Dex release patterns and stability of the micelles. 
The dual linker micelles can achieve tunable release of Dex in tumors (Figure D.1B), 
reducing the IFP that limits tumor accumulation of other drugs (Figure D.1C). Micelles 
with single hydrazone or ester linkers were also tested for acid-sensitive Dex release. The 
physicochemical properties of the micelles, including particle size and Dex release 
patterns, were characterized at different pH values corresponding to the normal 
physiological condition (pH 7.4) and the acidic tumor tissues (pH 5.0). Stability of Dex 
loaded micelles was also tested in the presence of CE. In addition to providing 
information on a possible Dex delivery system, our characterization of these polymer 
micelles provides valuable insight into the design of drug-binding linkers and drug 
carriers for tunable release. 
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Figure D.1. Mechanism of tumor-preferential tunable release of Dex from polymer 
micelles. Polymer micelles entrap Dex through hydrazone-ester dual linkers (A).  
The dual linkers consist of acid-labile hydrazone linkages (a) and enzymatically 
degradable ester linkages (b) while spacers (X) modulate Dex release patterns and 
stability of the micelles. The dual linker micelles can achieve tunable release of Dex 
in tumors (B), reducing the IFP that limits tumor accumulation of other drugs (C).  
 
 
 
D.2. MATERIALS AND METHODS 
D.2.1. Materials. α-Methoxy-ω-amino poly(ethylene glycol) (PEG-NH2, MW=12,266) 
was purchased from NOF Corporation (Shibuya-ku, Tokyo, Japan). L-aspartic acid β-
benzyl ester, triphosgene, 4,4-diphenyl-cyclohexa-2,5-dienone, 2-hydroxy-1-(1-
hydroxycyclohexyl)ethanone, 4-acetylbutyric acid (ABA), 6-oxoheptanoic acid (OHA), 
7-oxooctanoic acid (OOA), Dex, prednisolone, N,N‟-diisopropylcarbodiimide (DIC), 4-
(dimethylamino)pyridine (DMAP), ACN, benzene, N,N-dimethylformamide, anhydrous 
N,N-dimethylformamide (DMF), anhydrous dimethyl sulfoxide (DMSO), DMSO-d6, 
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D2O, anhydrous ethyl ether, anhydrous hexane, anhydrous hydrazine, anhydrous 
tetrahydrofuran (THF), acetate buffer solution, and phosphate buffer solution were 
purchased from Sigma-Aldrich (St. Louis, MO). Regenerated cellulose dialysis bags with 
molecular weight cut off (MWCO 6-8,000 Da) and Slide-A-Lyzer G2 dialysis cassettes 
with MWCO 10,000 were purchased from Fisher Scientific (Pittsburgh, PA). Amicon-
Ultra centrifugal ultrafiltration devices with MWCO 10,000 were purchased from 
Millipore (Billerica, MA). 
 
D.2.2. PEG-PBLA Block Copolymer Synthesis. Our synthesis protocol is shown in 
Figure D.2. β-Benzyl-L-aspartate N-carboxy anhydride (BLA-NCA, 2) was prepared 
using the Fuchs-Farthing method as described elsewhere [276]. Triphosgene (2.88 g, 9.7 
mmol) and β-benzyl-L-aspartate (5.0 g, 22.4 mmol) were mixed in dry THF (100 mL). 
The reaction was conducted in N2 at 45°C until the solution turned clear. Anhydrous 
hexane was slowly added to the reaction solution for recrystallization of BLA-NCA in -
20C. Purified BLA-NCA was polymerized in anhydrous DMSO at 45C for 2 days by 
using amino-terminated PEG as a macroinitiator. The amount of BLA-NCA was adjusted 
with respect to PEG to prepare PEG-PBLA block copolymers with 35 units of aspartic 
acid, 3. The reaction solution was precipitated in anhydrous ethyl ether. White PEG-
PBLA was collected by freeze-drying from benzene.  
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Figure D.2. (A) Synthesis of block copolymers. PEG-PBLA, 3, was prepared from 12 
kDa PEG, 1, and 35 units of BLA-NCA, 2. PEG-pAsp, 4, was produced by complete 
deprotection of 3 in 0.1 N NaOH. Dex was conjugated to 4 through an ester linkage 
by an esterification reaction between the hydroxyl group at the C21 moiety of DEX 
and carboxyl groups of 4 to give 7. Dex was conjugated at its C3 and C20 positions 
to PEG-p(Asp-Hyd), 5, through ketone linkages to produce 8 and 9, respectively. 
Reactions between 5 and various ketonic acids (ABA, OHA, and OOA) produced 6 
in which the ketonic acids served as spacers. Dex was conjugated to 6 through an 
esterification reaction to give three polymer compositions with hydrazone-ester dual 
linkers (10, 11, and 12). (B) Structure of Dex with relevant conjugate sites numbered  
 
D.2.3. PEG-p(Asp-Est-Dex) Synthesis. PEG-PBLA was dissolved in 0.1 N NaOH to 
deprotect benzyl ester groups. The solution was dialyzed against deionized water using 
MWCO 6-8,000 Da until NaOH was removed completely. PEG-poly(aspartate) [PEG-
p(Asp), 4] was collected by freeze drying. Dex was conjugated to PEG-p(Asp) through 
an ester bond in DMSO at room temperature. DIC and DMAP were used for the 
esterification reaction. The reaction solution was precipitated in anhydrous ethyl ether. 
The product was freeze dried from benzene to collect PEG-poly(aspartate ester 
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Dexamethasone) [PEG-p(Asp-Est-Dex), 7]. Sample aliquots were filled with nitrogen to 
minimize hydrolytic degradation. 
 
D.2.4. PEG-p(Asp-Hyd-Dex) Synthesis. Hydrazide groups were introduced to PEG-
PBLA through aminolysis reactions as previously reported [273]. PEG-PBLA and 
anhydrous hydrazine were reacted in DMSO at 45C for 1 h (50-100 mg polymer/mL 
DMSO) to prepare PEG-poly(aspartate hydrazide) [PEG-p(Asp-Hyd), 5]. PEG-p(Asp-
Hyd) was precipitated in anhydrous ethyl ether and freeze dried from benzene. Dex and 
PEG-p(Asp-Hyd) were mixed in DMSO at 40C for 72 h. The reaction solution was 
precipitated in anhydrous ethyl ether repeatedly. The precipitates were collected from 
benzene to provide PEG-poly(aspartate hydrazone Dexamethasone) [PEG-p(Asp-Hyd-
Dex), 8 and 9]. 
 
D.2.5. PEG-p(Asp-Hyd-X-Est-Dex) Synthesis (‘X’ indicates ketonic acids as 
spacers). PEG-p(Asp-Hyd) block copolymers were reacted with three ketonic acids 
(ABA, OHA and OOA) separately in DMSO at 40C for 3 days. Reaction solutions were 
precipitated in anhydrous ethyl ether, followed by freeze drying from benzene. Each 
PEG-p(Asp-Hyd) modified with ketonic acids, 6, was reacted with Dex in DMSO at 
room temperature by adding DIC and DMAP. The reactions were conducted for 24 h, 
followed by precipitation in anhydrous ethyl ether and freeze drying from benzene. The 
ketonic acids provided spacers of 3, 4 and 5 methylene groups („X‟) between PEG-
p(Asp-Hyd) and Dex in the final products [PEG-p(Asp-Hyd-X-Est-Dex), 10, 11 and 12].  
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D.2.6. Polymer Micelle Preparation. Polymer micelles were prepared from 7, 8, 9, 10, 
11 and 12. Either reconstitution or freeze drying methods were used to prepare the 
micelles. The reconstitution method was conducted by dissolving drug-conjugated 
polymer powders directly in aqueous solutions and sonicating the solution. For the freeze 
drying method, block copolymers were dissolved in ACN first and diluted with deionized 
water, adjusting the final ACN content to 20%. The block copolymer solutions were 
freeze dried, following dry ice freezing. Freeze-dried micelle powders were reconstituted 
in aqueous solutions. All micelles were filtered through 0.2 m filters prior to further 
experiments. Polymer micelles from Dex-conjugated block copolymers are abbreviated 
according to the drug-binding linkers used, which include hydrazone (HYD-M), ester 
(EST-M), hydrazone-ABA-ester (ABA-M), hydrazone-OHA-ester (OHA-M) and 
hydrazone-OOA-ester (OOA-M). 
 
D.2.7. Analytical Methods. Particle size of polymer micelles in water was determined 
by DLS measurements using a Zetasizer Nano-ZS (Malvern; Worcestershire, UK). The 
instrument was equipped with a He-Ne laser (4 mW, 633 nm) and set up to collect 173° 
angle scattered light. Number distributions are presented as the mean particle size. 
1
H-
NMR experiments were performed on a Varian 500 MHz NMR (Varian Inc., Palo Alto, 
CA) at 25°C. Products were dissolved in DMSO-d6 and analyzed following each step in 
the synthetic pathway. NMR spectra were also obtained for freeze-dried micelles 
reconstituted in D2O. Where appropriate, SEC was additionally used to confirm the 
success of reactions. The system was a Shimadzu Prominence HPLC series equipped 
with a Shodex Asahipack GF-7M HQ column and an RID-10A refractive index detector. 
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The mobile phase was 5 mM PBS run at 0.5 mL/min; the column temperature was held at 
35°C. Molecular weight was calculated through comparison with a calibration curve 
based on PEG standards. The PI was calculated by dividing the weight average molecular 
weight by the number average molecular weight. Dex loading was confirmed by 
1
H-
NMR spectroscopy and quantified by HPLC. Ester-containing micelles were prepared at 
2 mg/mL in either acetate buffer (10 mm pH 5.0, n=3) or phosphate buffer (10 mM pH 
7.4, n=3).  One hundred microliters of each sample were combined with 100 µL 
prednisolone (0.1 mg/mL) as an internal standard and 10 µL NaOH (0.1 N). The mixed 
solutions were incubated at 37°C overnight with shaking at 100 rpm. Samples were 
neutralized with 10 µL HCl (0.1 N). One hundred microliters of the neutralized samples 
were mixed with ACN (45% ACN/55% H2O) and ultrafiltered. Filtrates were analyzed 
by HPLC according to the following conditions. The system was a Shimadzu Prominence 
HPLC series equipped with a SPD-M20A Photodiode Array Detector. Five microliter 
samples were injected to an Eclipse XDB-C18 (4.6 mm×150 mm, 5 micron, Agilent 
Technologies) column at 40°C. The mobile phase (45% ACN/55% H2O) was run at a 
flow rate of 1 mL/min. Concentrations were calculated based on peak area calibration 
curves prepared for Dex and Prednisolone at 254 nm from 1 to 500 μg/mL. 
 
D.2.8. pH-Dependent Drug Release Study. Drug release studies were conducted in 
acetate (10 mM, pH 5.0) and phosphate (10 mM, pH 7.4) buffers under sink conditions. 
Samples were removed at 0 h from initial preparations. Dialysis cassettes were loaded 
with 400 μL of 2 mg/mL micelle solutions and placed into 5 L of buffer solutions at 
37°C. At each time point (1, 3, 6, and 24 h), the entire internal solution was collected 
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from three dialysis cassettes and stored at room temperature until all samples had been 
collected. Samples were treated as described above to determine drug loading by HPLC 
analysis. Data are presented as percent drug remaining, using 0 hr concentrations as the 
standard. The area under the curve (AUC0-t: where „t‟ represents a time point) was 
determined by using the trapezoidal rule for % Dex released (% Dex released = 100 - % 
DEX remaining) with respect to time. AUC values were compared for the early (0-3 h) 
and late (3-24 h) periods.  
 
D.2.9. CE-Dependent Drug Release Study. Polymer micelles (2 mg/mL) were 
incubated under non-sink conditions at 37°C/pH 7.4 in media with varying levels of CE 
activity: 1) RPMI cell culture medium; 2) RPMI with 10% fetal serum bovine (FBS); 3) 
RPMI with 10% mouse plasma (MP); 4) RPMI with 10% human plasma (HP); 5) RPMI 
with 10% FBS and 10% MP; and 6) RPMI with 10% FBS and 10% HP. Mouse plasma is 
known to have higher levels of CE activity than human plasma (46). RPMI was used as a 
control to determine the effects of ions and small molecules (vitamins and amino acids) 
on micelle stability. FBS was used as a control for general protein effects on micelle 
stability. All combinations were prepared on a volume basis. Plasma samples contained 
sodium heparin as the anti-coagulant. One hundred microliter aliquots (n=3) were 
collected at 0 and 24 h, followed by ultrafiltration and HPLC analysis as described above. 
Drug release patterns were determined by quantifying cleaved Dex and Dex-ketonic acid 
conjugates. 
 
221 
 
D.2.10. Statistical Analysis. Statistical analyses were performed using ANOVA (single 
factor) at the 5% significance level.  Data were recorded as mean ± SD. All experiments 
were done in triplicate as specified in the results section. Data analyses were performed 
using Microsoft Excel (2007). 
 
D.3. RESULTS 
D.3.1. Block Copolymer Synthesis. Figure D.2 summarizes the synthetic pathways for 
all materials used in the research. Using the PEG peak as a reference, 
1
H-NMR indicated 
that the polymerization reaction between 12 kDa PEG, 1, and BLA-NCA, 2, had 
proceeded to give PEG-PBLA, 3, with 35 units of aspartic acid. GPC further showed 
neither unreacted PEG nor PBLA homopolymers after purification. Molecular weight 
distribution of the block copolymers was homogeneous with a polydispersity index 
smaller than 1.3. The results were consistent with what we observed previously. PEG-
p(Asp), 4, was produced by complete deprotection of 3 in 0.1 N NaOH. Dex was 
conjugated to 4 through an ester linkage by an esterification reaction between the 
hydroxyl group at the C21 moiety of Dex and carboxyl groups of 4 to give 7. Dex loading 
was 8.67±0.86 wt% (n=6). Dex was conjugated at its C3 and C20 positions to PEG-
p(Asp-Hyd), 5, through ketone linkages to produce 8 and 9, respectively. Drug loading 
for these two products together appeared low by 
1
H-NMR and could not be quantified by 
HPLC due to difficulties in cleaving the drug from the polymer. Reactions between 5 and 
various ketonic acids (ABA, OHA, and OOA) produced 6 in which the ketonic acids 
served as spacers containing 3, 4 and 5 methylene groups. Dex was subsequently 
conjugated to 6 through esterification to give three polymer compositions with 
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hydrazone-ester dual linkers, 10, 11, and 12. Dex loadings were 4.63±0.75, 5.57±0.61, 
and 4.50±0.28 wt% for 10, 11, and 12, respectively (n=6). 
 
D.3.2. Polymer Micelle Preparation. All Dex-conjugated block copolymers formed 
polymer micelles irrespective of the composition. Freeze-dried micelles were readily 
reconstituted in aqueous solutions at concentrations >2 mg/mL; no precipitate was 
observed. Prepared micelles were smaller than 100 nm: EST-M (85.74 nm), ABA-M 
(61.50 nm), OHA-M (43.82 nm), and OOA-M (37.84 nm). 
1
H-NMR spectra of the 
micelles in DMSO-d6 (Figure D.3) showed the characteristic peaks of Dex [dienone (7.3, 
6.2 and 6.0 ppm) and hydroxyethanone (5.2 ppm)] and PEG (3.6 ppm). A complete 
reduction of Dex peaks was seen in the micellar spectra in D2O while the PEG peak 
remained, indicating that Dex is primarily entrapped within the micelles.  
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Figure D.3. 
1
H-NMR spectra of polymer micelles in DMSO-d6 and D2O. 
1
H-NMR 
spectra of the micelles in DMSO-d6 showed the characteristics peaks of Dex 
[dieneone (7.3, 6.2 and 6.0 ppm) and hydroxyethanone (5.2 ppm)] and PEG (3.6 
ppm). A complete reduction of Dex peaks was seen in the micellar spectra in D2O 
while the PEG peak remained, indicating that Dex was entrapped within the 
micelles. 
 
HYD-M, a mixture of 8 and 9, did not form homogeneous polymer micelles. We were 
unable to determine the particle size of HYD-M because it varied between batches (4.50 - 
2187.20 nm).  Our preliminary experiments showed that drug release from HYD-M (8 
and 9) was negligible even under strongly acidic conditions (pH<2) and at elevated 
temperatures (>60C). To elucidate the mechanism, PEG-p(Asp-Hyd) was reacted with 
two model ketone compounds, 4,4-diphenyl-cyclohexa-2,5-dienone and 2-hydroxy-1-(1-
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hydroxycyclohexyl)ethanone, which represent the C3 and C20 moieties of Dex, 
respectively. HPLC analysis revealed that hydrazone formation at the C3 ketone of Dex 
is favorable and highly stable compared to the hydrazone at the C20 ketone of Dex. 
Based on these results, we concluded that direct conjugation of Dex to PEG-p(Asp) 
through the hydrazone would be inappropriate to design our polymer micelles for the 
delivery and pH-sensitive release of Dex in tumors. We did not pursue further 
experiments with HYD-M accordingly. 
 
D.3.3. pH-Dependent Dex Release from the Micelles. Drug release patterns showed 
that EST-M was unstable at pH 7.4 while it was more stable at pH 5.0 (Figure D.4). 
51.39% and 32.37% of Dex were released from EST-M in 6 h at pH 7.4 and pH 5.0, 
respectively. Polymer micelles with hydrazone-ester dual linkers showed the opposite 
drug release patterns. In all cases (ABA-M, OHA-M, and OOA-M), Dex release from the 
micelles was suppressed at pH 7.4 and accelerated at pH 5.0. The results suggest that 
polymer micelles with hydrazone-ester dual linkers may remain stable in blood and 
release more Dex in acidic tumor tissues. Dex release was reduced at pH 5.0 as the chain 
length of the spacer increased. Interestingly, Dex release was less dependent on the 
spacer at pH 7.4. To suppress Dex release at pH 7.4, we also attempted to test ketonic 
acids longer than OOA, but the block copolymers precipitated forming no micelles (data 
not shown).  
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Figure D.4. Time- and pH-dependent release of Dex from polymer micelles at 37°C. 
EST-M was unstable at pH 7.4 while it was more stable at pH 5.0. Polymer micelles 
with hydrazone-ester dual linkers showed the opposite drug release patterns with 
drug release being accelerated at pH 5.0 and suppressed at pH 7.4. Dex release was 
reduced at pH 5.0 as the chain length of the spacer increased but was less dependent 
on the spacer at pH 7.4.  
 
 
 
Dex release profiles were compared by calculating the AUC values of Dex released at 
different pH conditions. Data were analyzed by separating the AUC values for the early 
(0-3 hr) and late (3-24 hr) time periods (Table D.1). The AUC0-3 showed that ABA-M 
suppressed drug release at pH 7.4 effectively with respect to EST-M. OHA-M and OOA-
M released slightly more drugs than EST-M in the same time period. At pH 5.0 (0-3 h), 
all micelles released Dex in a pH-dependent manner. At later time periods (AUC3-24), 
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Dex release at pH 7.4 was slower and more sustained in all micelles with dual linkers 
compared to EST-M. The AUC3-24 at pH 5.0 showed that ABA-M released more Dex 
than either OHA-M or OOA-M. It is intriguing that OOA-M, containing longer and more 
hydrophobic spacers, released more Dex than OHA-M. Among the micelles with dual 
linkers, ABA-M released the least amount of Dex at pH 7.4 and the greatest amount of 
drug at pH 5.0 during the early time period (0-3 h). In the later time period (3-24 h), all 
micelles showed similar Dex release patterns at pH 7.4. However, ABA-M still released 
more Dex than OHA-M and OOA-M at pH 5.0. Based on the pH-dependent drug release 
studies, ABA-M was chosen as the lead composition for further studies. 
 
Table D.1. Accumulated Dex release from polymer micelles 
pH Micelles 
AUC 
a
 
% Dex released  hour b Micelles/EST-M c Micelles/ABA-M c 
0-3 hr 3-24 hr 0-3 hr 3-24 hr 0-3 hr 3-24 hr 
7.4 
EST-M 59.62 1162.83 1 1 - - 
ABA-M 45.20 893.03 0.76 0.77 1 1 
OHA-M 70.02 893.24 1.17 0.77 1.55 1.00 
OOA-M 83.86 983.39 1.41 0.85 1.86 1.10 
5.0 
EST-M 30.29 540.59 1 1 - - 
ABA-M 105.38 1536.74 3.48 2.84 1 1 
OHA-M 76.27 1106.28 2.52 2.05 0.72 0.72 
OOA-M 97.17 1254.63 3.21 2.32 0.92 0.82 
a
 AUC denotes the area under the curve of Dex released from the micelles. 
b
 The unit for AUC is defined as % Dex released  hour. 
c
 The ratios show Dex released from each micelle with respect to either EST-M or ABA-
M. 
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D.3.4. CE-Dependent Drug Release. In addition to pH, we tested stability of ABA-M 
in the presence of CE to confirm that polymer micelles can protect Dex and the ester 
linkers from enzymatic degradation. The micelles were incubated at 37°C under six 
different conditions as described in the Materials and Methods section. Total Dex 
released from ABA-M is summarized in Figure D.5. No dissociation of micelles was seen 
in all incubation conditions at 0 h. Dex release was minimal (<5%) at the initial time 
point. An ANOVA analysis indicated no significant differences among the six samples at 
0 h (p>0.05). It is noticeable that ABA-M remained stable in RPMI, FBS, MP and HP 
alone or in combination, suggesting that the micelles protected Dex and the dual linkers 
in the solutions that contain various additives such as ions, small molecules, amino acids, 
proteins and digestive enzymes. Following 24 h incubations, Dex release was slightly 
higher (10 - 15%) in samples containing mouse plasma compared to the samples lacking 
CE activity (p<0.05). A slight difference in release was also observed between drug 
release in this study and the pH-dependent study described above, which may be 
attributable to the non-sink versus sink conditions employed.  
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Figure D.5. Stability of polymer micelles (ABA-M) in cell culture medium (RPMI), 
10% fetal bovine serum (FBS), 10% mouse plasma (MP), 10% human plasma (HP), 
and in combinations of these. Drug release was low at the initial time point, 
indicating that polymer micelles are stable in the presence of biological media. Drug 
release was slightly elevated in media containing CE at 24 h as compared to media 
lacking CE.  
 
 
D.4. DISCUSSION 
D.4.1. Polymer Synthesis and Dex Conjugation. Dex was conjugated to PEG-p(Asp) 
block copolymers through hydrazone-ester dual linkers to prepare polymer micelles that 
can release the drug preferentially in acidic tumor tissues (pH<7.0). We initially tested 
Dex conjugation to PEG-pAsp block copolymers using single hydrazone and ester 
linkers. While Dex could be conjugated to block copolymers directly through a 
hydrazone linker, the drug loading was low and the hydrazone bond appeared too stable 
to release the drug in a physiologically relevant time period. Further, micelles from this 
composition were not homogenous in size, which may result from both 8 and 9 being 
present or from the polymers having an insufficiently hydrophobic section due to the low 
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drug load. The results also indicated that Dex conjugation through ester linkers had 
limited stability. Polymer micelles entrapping Dex through an ester linkage would be 
unsuitable for drug delivery to tumors because more drug would be released in blood (pH 
7.4) than in acidic tumor tissues (<pH 6.5). In spite of these apparent failures at achieving 
pH-dependent Dex release, each linkage still showed successful reaction yields 
(hydrazone formation) and high drug conjugation (ester formation) between Dex and 
block copolymers. To take advantage of these possibilities, Dex was conjugated to the 
block copolymers using a hydrazone-ester dual linker with ketonic acids of varying 
carbon chain lengths introduced as spacers. Dex loading (4.50 - 5.57 wt%) was high 
enough to prepare polymer micelles that can carry the drug at concentrations even greater 
than the effective dose (<1 mg/kg) [277] for future in vivo applications.  
 
D.4.2. Preparation of Dex Loaded Micelles. Block copolymers with hydrazone-ester 
dual linkers formed polymer micelles smaller than 100 nm, which is clinically relevant 
for tumor-preferential drug delivery by the EPR effect [278]. Interestingly, particle size 
of the micelles with dual linkers decreased as hydrophobicity of ketonic acids increased 
in comparison to EST-M. This may be attributable to how the different polymer 
compositions assemble into micelles with differences in hydrophobicity leading to a 
change in the micellar aggregation number. 
1
H-NMR analysis in DMSO-d6 confirmed 
Dex conjugation to polymers (Figure D.3). The NMR spectra of the micelles in D2O 
showed a complete reduction of peaks from free Dex and the core-forming segment of 
PEG-p(Asp) block copolymers. Only the PEG peak was observed in all micelle 
compositions. These results indicate that micelles exhibited the expected core-shell 
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structures with PEG on the surface and the hydrophobic portion of the polymers forming 
the core to which Dex was entrapped with limited molecular mobility. It is noted that 
polymer micelles were readily prepared by reconstituting freeze-dried powders, which 
would facilitate the pharmaceutical development of Dex loaded polymer micelles.  
 
D.4.3. pH-Dependent Dex Release from the Micelles. Polymer micelles with 
hydrazone or ester single linkers were unsuitable to achieve Dex release in the acidic 
environment of tumors. The hydrazone linker was too stable to release Dex in both pH 
7.4 and 5.0 solutions likely as a result of the multiple double bonds present around the 
hydrolytic site when Dex is conjugated at the C3 position. Dex release from HYD-M was 
negligible in 72 h. Ester linkers caused undesirable Dex release from the micelles at pH 
7.4 while suppressing drug release at pH 5.0. In vivo applications of our polymer micelles 
with single linkers appeared unlikely for parenteral delivery of Dex. Ester linker micelles 
may alternatively be suitable for oral delivery of Dex as they may remain stable in acidic 
gastric fluids until they reach the small intestine.  
 
Polymer micelles with hydrazone-ester dual linkers achieved Dex release suitable for 
tumor-preferential delivery of Dex. As Dex is conjugated to these polymers following the 
insertion of a spacer, the hydrazone linker regains its susceptibility to pH-dependent 
hydrolysis that was lost in the HYD-M composition. In comparison to EST-M, the dual 
linker micelles suppressed Dex release at pH 7.4 while accelerating Dex release at pH 
5.0. Similarly to the hydrazone linker, the difference in ester stability between the single 
and dual linkers can be attributed to the surrounding chemical structure. Importantly, the 
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results suggest that polymer micelles with dual linkers will remain stable in blood and 
release more Dex in acidic tumor tissues. Dex release at pH 5.0 was dependent on the 
chain length of ketonic acid spacers for the dual linker micelles. Dex remaining in OHA-
M and OOA-M at 24 h were greater than ABA-M. The suppressed drug release at pH 5.0 
with longer ketonic acids may be attributed to the increased hydrophobicity stabilizing 
the micelle core. The difference in Dex release between OHA-M and OOA-M was not 
significant. There was no difference in Dex release at pH 7.4, irrespective of the spacer 
length. These results suggest that the hydrazone is responsible for drug release at pH 5.0 
while ester hydrolysis contributes to Dex release at pH 7.4.  
 
It is unknown why polymer micelles did not prevent linkers from hydrolysis at pH 7.4. 
Our initial expectation was that more hydrophobic spacers would make the micelle cores 
more stable, and thus suppress drug release further. However, even though Dex 
molecules are tightly entrapped in the micelle core (as seen in the 
1
H-NMR analysis), the 
polymer micelle cores may be porous enough to allow water molecules to penetrate and 
attack both bonds. Previous results have shown that hydrolysis of small molecule 
prodrugs with ester linkages can be suppressed as the chain length of tail groups is 
extended [279]. In contrast, our results showed that the chain length of spacers did not 
seem to affect the stability of ester linkages in the micelle core. The difference may be 
attributable to the fact that the mobility of spacers is restricted in the micelle core, 
offsetting the effects of chain extension, whereas tail groups of prodrugs can move freely 
in solutions, leading to extended degradation half-lives of ester bonds. It is also possible 
that the surrounding micelle environment, including the hydrophilic PEG shell, might 
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have attracted water molecules close to the ester linkages in polymer cores, and therefore, 
hydrolysis reactions took place.  
 
D.4.4. Tunable Dex Release from the Micelles. We analyzed the AUC of Dex release 
patterns to confirm tunable drug release from the micelles. Tunable drug release is 
important to control Dex distribution in tumors at different time points after the injection 
of polymer micelles. Tumor accumulation of polymer micelles was previously shown to 
reach its maximum level after 3 hours post-injection [280]. For this reason, the AUC 
values were analyzed both in the early (0-3 h) and late (3-24 h) stages of the drug release 
study (Figure D.4). Table D.1 summarizes the results.  
 
The AUC0-3 showed that ABA-M (45.20) effectively suppressed drug release at pH 7.4 
with respect to EST-M (59.62). OHA-M (70.02) and OOA-M (83.86) released slightly 
more Dex than EST-M in the same period. At pH 5.0 (0-3 h), all micelles released Dex in 
a pH-dependent manner [ABA-M (105.38), OHA-M (76.27) and OOA-M (97.17)] 
compared to EST-M (30.29). At later time periods (AUC3-24), Dex release at pH 7.4 was 
slower and more sustained in all dual linker micelles compared to EST-M (1162.83): 
ABA-M (893.03), OHA-M (893.24), and OOA-M (983.39). The AUC3-24 at pH 5.0 
showed that ABA-M (1536.74) released more Dex than either OHA-M (1106.28) or 
OOA-M (1254.63). It is interesting that OOA-M, containing longer and more 
hydrophobic spacers, released more DEX than OHA-M. Among the dual linker micelles, 
ABA-M released the least drugs at pH 7.4 and the most drugs at pH 5.0 during the early 
time period (0-3 h). Using Dex release from ABA-M (100%) as the reference, release 
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from OHA-M (155%) and OOA-M (186%) was greater at pH 7.4 between 0-3 h. OHA-M 
(72%) and OOA-M (92%) suppressed DEX release at pH 5.0 in the early period 
compared to ABA-M (100%). In the later time period (3-24 h), Dex release patterns at 
pH 7.4 were similar in all micelles [ABA-M (100%), OHA-M (100.0%) and OOA-M 
(110%)]. At pH 5.0, however, ABA-M (100%) still released more Dex than OHA-M 
(72%) and OOA-M (82%).  
 
These multi-step drug release profiles are desirable for achieving the necessary Dex 
concentrations at the tumor site. In the early stages following micelle accumulation in 
tumors, micelles are expected to exhibit a prompt drug release, bringing Dex 
concentrations up to the required level rapidly. The slower drug release at later time 
points will allow for Dex concentration levels to be maintained over an extended period 
of time, reducing the need for multiple doses. It remains challenging for OHA-M and 
OOA-M to suppress Dex release at pH 7.4 while achieving tunable DEX release in acidic 
tumor environment. Based on these results, we considered ABA-M the optimal 
composition that would remain stable in blood and release Dex quickly in tumor tissues. 
 
D.4.5. Enzymatic Stability of Dex Loaded Micelles. Ester linkers can undergo 
enzymatic degradation in addition to hydrolysis. We tested stability of ABA-M in the 
presence of CE, a digestive enzyme of esters. We also investigated the influence of ions, 
small molecules (glucose, vitamins and amino acids), and proteins by testing stability of 
micelles in cell culture medium (RPMI) and FBS. Such investigation is of importance 
because the micelles will be exposed to various materials in the blood following 
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injection. Instability in the presence of CE is critically important to be aware of because 
the CE activity of mouse plasma is significantly higher than human plasma, and studies 
performed in these animals may not give results representative of what would be 
observed in humans. Total drug release patterns (free Dex plus Dex-ABA) were 
compared at 0 and 24 h (Figure D.5). We observed no significant differences among the 
samples at the initial time point (p>0.05). However, the micelles in mouse plasma 
containing CE showed a slight increase in Dex release at 24 h as compared to the RPMI 
control. Human plasma lacking CE activity caused no increase in Dex release. As 
1
H-
NMR of the micelles indicated that Dex was entrapped in the micelle core, it seemed 
unlikely that a 60-70 kDa CE enzyme could penetrate the micelle to this extent. However, 
this possibility cannot be excluded completely because no general protein destabilization 
effects on our polymer micelles were observed. Despite this, it is still reasonable to 
surmise that this minimal increase in Dex release (10 - 15% at 24 h) may not significantly 
impact the outcome of future in vivo studies using ABA-M. This apparent stability of 
polymer micelles in the presence of CE indicates that Dex-ABA should be primarily 
released in a pH-dependent manner at the tumor site followed by CE-associated 
regeneration of free Dex.  
 
D.5. CONCLUSIONS 
In exploring polymer micelles as a second possible tumor-targeted drug delivery system, 
Dex was conjugated to poly(ethylene glycol)-poly(aspartate) block copolymers using 
hydrazone, ester, or hydrazone-ester dual linkers. Ketonic acids containing 3, 4, and 5 
methylene groups were used as spacers to separate the dual linkers. DLS measurements 
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and 
1
H-NMR analysis confirmed that all Dex loaded micelles were <100 nm with a core-
shell structure. Single linker micelles appeared unsuitable to release Dex preferentially in 
acidic tumor tissues. Hydrazone linkages between Dex and polymers were non-
degradable at both pH 7.4 and 5.0. Ester linkages that were stable at pH 5.0 were unstable 
at pH 7.4. Hydrazone-ester dual linkers suppressed Dex release at pH 7.4, while 
accelerating drug release at pH 5.0. Dex release decreased at pH 5.0 as the length of the 
ketonic acid increased but was independent of spacer length at pH 7.4. The dual linker 
micelles were also stable in the presence of CEs, suggesting that Dex release was 
primarily due to pH-dependent hydrolysis. Overall, it appears that PEG-poly(aspartate) 
block copolymer micelles with hydrazone-ester dual linkers are a promising drug 
delivery platform for tunable release of Dex in tumors. In comparison to single hydrazone 
or ester linkers, hydrazone-ester dual linkers using ketonic acid spacers are convenient 
and effective in changing the hydrophobicity of the micelle cores, chemical stability of 
drug conjugation linkages, and drug release patterns. Such dual linkers may also be 
useful for other drug delivery platforms to achieve pH-dependent tunable drug release, 
especially for prodrugs that have been developed based only on ester chemistry. Tunable 
drug release using hydrazone-ester dual linkers may bring a variety of options for 
combination chemotherapy and mixed drug delivery using polymer drug carriers in the 
pharmaceutical research area.  
 
*Reproduced with kind permission from Springer Science+Business Media: 
Pharmaceutical Research, Polymer Micelles with Hydrazone-Ester Dual Linkers for 
Tunable Release of Dexamethasone, DOI 10.1007/s11095-011-0470-1, M.D. Howard, A. 
Ponta, A. Eckman, M. Jay, Y. Bae, Copyright © 2011 Springer Science+Business Media, 
LLC. 
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